benzimidazoles - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	benzimidazoles	go back to main search page
Accession:	CHEBI:22715	browse the term
Definition:	An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
Synonyms:	alt_id:	MESH:D001562
	xref_mesh:	MESH:D001562

show annotations for term's descendants Sort by:
Rat (1195) Mouse (1182) Human (1187) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (1182)

benzimidazoles

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

dopamine receptor D2

affects binding

Benzimidazoles analog binds to DRD2 protein

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

G

5-hydroxytryptamine (serotonin) receptor 2A

affects binding

Benzimidazoles analog binds to HTR2A protein

NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934

G

insulin-like growth factor 2

multiple interactions
decreases response to substance

Benzimidazoles inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]
Benzimidazoles results in decreased susceptibility to IGF2 protein

NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553

G

potassium voltage-gated channel, subfamily Q, member 2

multiple interactions

[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; [Benzimidazoles analog results in increased activity of KCNQ2 protein] which results in increased import of Thallium; Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]

NCBI chr 2:180,717,372...180,777,368
Ensembl chr 2:180,717,372...180,777,093

G

potassium voltage-gated channel, subfamily Q, member 3

multiple interactions

[Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]] which results in increased import of Thallium; Benzimidazoles analog results in increased activity of [KCNQ3 protein binds to KCNQ2 protein]

NCBI chr15:65,858,223...66,158,485
Ensembl chr15:65,858,236...66,158,491

G

5-methyltetrahydrofolate-homocysteine methyltransferase

decreases activity

Benzimidazoles results in decreased activity of MTR protein

NCBI chr13:12,196,217...12,273,090
Ensembl chr13:12,197,598...12,272,999

G

steroid sulfatase

multiple interactions

Benzimidazoles inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]

NCBI chr X:168,856,332...169,015,037
Ensembl chr X:168,909,030...169,014,924

G

topoisomerase (DNA) II alpha

decreases activity

Benzimidazoles results in decreased activity of TOP2A protein

NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015

1H-benzimidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

endothelial PAS domain protein 1

increases stability

benzimidazole results in increased stability of EPAS1 protein

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

benzimidazole analog inhibits the reaction [Capsaicin results in increased activity of TRPV1 protein]; benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [benzimidazole analog inhibits the reaction [Protons results in increased activity of TRPV1 protein]]

NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068

1H-benzo[d]imidazole-2-thiol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

2-mercaptobenzimidazole analog results in increased expression of CYP1A1 protein; 2-mercaptobenzimidazole results in increased expression of CYP1A1 protein

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

multiple interactions
decreases activity

bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

multiple interactions
increases transport

[zosuquidar trihydrochloride results in decreased activity of ABCB1 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; abamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]
ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride
abamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride]

PMID:25865432 PMID:34896433

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family C member 1

multiple interactions
increases transport

abamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; emamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Ivermectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

ATP binding cassette subfamily G member 2 (Junior blood group)

decreases abundance
decreases export
decreases activity
multiple interactions
increases export
increases transport

ABCG2 protein results in decreased abundance of bisbenzimide ethoxide trihydrochloride
ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride
bisbenzimide ethoxide trihydrochloride results in decreased activity of ABCG2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; [3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester results in decreased activity of ABCG2 protein] which results in decreased export of bisbenzimide ethoxide trihydrochloride; [bisphenol A results in decreased activity of ABCG2 protein] which results in decreased transport of bisbenzimide ethoxide trihydrochloride; [MLN 8237 affects the activity of ABCG2 protein] which affects the export of bisbenzimide ethoxide trihydrochloride; [MYC protein results in increased expression of ABCG2 protein] which results in increased export of bisbenzimide ethoxide trihydrochloride; Cimetidine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Cyclosporine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; danofloxacin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Genistein promotes the reaction [ABCG2 protein polymorphism results in decreased export of bisbenzimide ethoxide trihydrochloride]; Methotrexate inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Porphyrins inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; Reserpine inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]; Tobacco Smoke Pollution inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; tryptoquivaline inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; verlukast inhibits the reaction [ABCG2 protein results in increased transport of bisbenzimide ethoxide trihydrochloride]

PMID:12869632 PMID:19239227 PMID:26850786 PMID:26907376 PMID:27450509 More...

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

kelch-like ECH-associated protein 1

decreases export

KEAP1 protein results in decreased export of bisbenzimide ethoxide trihydrochloride

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

myelocytomatosis oncogene

multiple interactions

[MYC protein results in increased expression of ABCG2 protein] which results in increased export of bisbenzimide ethoxide trihydrochloride

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

2-aminobenzimidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

2-aminobenzimidazole results in increased expression of CYP1A1 protein

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

5'-hydroxyomeprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

5-hydroxymethylomeprazole results in increased expression of CYP1A1 protein

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 2. subfamily c, polypeptide 37

multiple interactions

[CYP2C37 protein results in increased metabolism of Omeprazole] which results in increased chemical synthesis of 5-hydroxymethylomeprazole

NCBI chr19:39,980,868...40,000,687
Ensembl chr19:39,980,868...40,000,687

5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [mangiferin results in increased expression of ABCB1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [sodium arsenite results in increased expression of ABCB1 protein]

PMID:16121039 PMID:20513373

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

c-abl oncogene 1, non-receptor tyrosine kinase

multiple interactions
decreases expression

Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein]

NCBI chr 2:31,578,256...31,697,105
Ensembl chr 2:31,578,388...31,694,239

G

aryl-hydrocarbon receptor

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

BCL2-like 1

increases expression
multiple interactions

Dichlororibofuranosylbenzimidazole results in increased expression of BCL2L1 protein
Dexamethasone inhibits the reaction [Dichlororibofuranosylbenzimidazole results in increased expression of BCL2L1 protein]

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

caspase 3

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]

PMID:17295206 PMID:18636177

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

cyclin dependent kinase inhibitor 1A

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

carboxylesterase 2H

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Methoxsalen results in increased expression of CES2 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]

NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [sodium arsenite results in decreased expression of CFTR protein]

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

collagen, type I, alpha 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA]

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

colony stimulating factor 1 (macrophage)

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]

PMID:17295206 PMID:18636177

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 protein]]

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily a, polypeptide 5

multiple interactions
increases stability

Dichlororibofuranosylbenzimidazole affects the reaction [HNRNPA1 protein binds to CYP2A5 mRNA]
Dichlororibofuranosylbenzimidazole results in increased stability of CYP2A5 mRNA

NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973

G

fibrillarin

affects localization

Dichlororibofuranosylbenzimidazole analog affects the localization of FBL protein

NCBI chr 7:27,868,293...27,878,701
Ensembl chr 7:27,869,135...27,878,694

G

hypoxia inducible factor 1, alpha subunit

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [TNF protein results in increased expression of HIF1A protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

heme oxygenase 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heterogeneous nuclear ribonucleoprotein A1

affects localization
multiple interactions

Dichlororibofuranosylbenzimidazole affects the localization of HNRNPA1 protein
Dichlororibofuranosylbenzimidazole affects the reaction [HNRNPA1 protein binds to CYP2A5 mRNA]

NCBI chr15:103,148,840...103,155,119
Ensembl chr15:103,148,859...103,155,119

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Glycine results in increased expression of HNRNPK mRNA]

NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157

G

interferon induced protein with tetratricpeptide repeats 1B like 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]

NCBI chr19:34,570,288...34,640,382
Ensembl chr19:34,570,291...34,579,356

G

interferon beta 1, fibroblast

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]

NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011

G

interleukin 6

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]

PMID:11295263 PMID:12185005

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

ISG15 ubiquitin-like modifier

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]

NCBI chr 4:156,283,881...156,285,275
Ensembl chr 4:156,283,912...156,285,253

G

metallothionein 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Cadmium Chloride results in increased expression of MT1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of MT1 mRNA]

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

MX dynamin-like GTPase 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]

NCBI chr16:97,248,235...97,264,106
Ensembl chr16:97,248,235...97,264,107

G

negative elongation factor complex member A, Whsc2

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]

NCBI chr 5:34,055,263...34,093,615
Ensembl chr 5:34,055,260...34,093,757

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions

[Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

polymerase (RNA) II (DNA directed) polypeptide A

decreases phosphorylation
multiple interactions

Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein
Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]; sodium arsenite inhibits the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein]

PMID:8126066 PMID:15039284 PMID:24102143

NCBI chr11:69,624,823...69,649,459
Ensembl chr11:69,624,823...69,649,463

G

regucalcin

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA]

NCBI chr X:20,413,980...20,428,328
Ensembl chr X:20,416,026...20,428,328

G

runt related transcription factor 2

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]

PMID:15962303 PMID:18327666

NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684

G

solute carrier family 30 (zinc transporter), member 1

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]

NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359

G

solute carrier family 38, member 2

affects expression

Dichlororibofuranosylbenzimidazole affects the expression of SLC38A2 protein

NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611

G

tumor necrosis factor

multiple interactions

Dichlororibofuranosylbenzimidazole affects the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]
Dichlororibofuranosylbenzimidazole inhibits the reaction [TNF protein results in increased expression of HIF1A protein]
Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of CYP1B1 protein]]

PMID:11295263 PMID:12185005 PMID:12479793 PMID:25233930

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor (ligand) superfamily, member 11

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA]

PMID:17295206 PMID:18327666 PMID:18636177

NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483

G

transformation related protein 53

increases phosphorylation

Dichlororibofuranosylbenzimidazole results in increased phosphorylation of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thymidylate synthase

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Fluorouracil results in increased expression of TYMS protein]

NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615

G

xanthine dehydrogenase

multiple interactions

Dichlororibofuranosylbenzimidazole inhibits the reaction [Oxygen deficiency results in increased phosphorylation of and results in increased activity of XDH protein]

NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191

5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

increases expression

Omeprazole results in increased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family B member 11

decreases activity

Omeprazole results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

affects expression
multiple interactions

Omeprazole affects the expression of ABCB1A mRNA
Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein]
Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein]

PMID:19483382 PMID:30452898

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 4

decreases expression

Omeprazole results in decreased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family member 2

multiple interactions

[Omeprazole results in increased susceptibility to Cisplatin] which results in decreased expression of ABCC2 protein

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

increases expression

Omeprazole results in increased expression of ABCC3 mRNA

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 6

affects expression

Omeprazole affects the expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP binding cassette subfamily G member 2 (Junior blood group)

increases expression
multiple interactions

Omeprazole results in increased expression of ABCG2 mRNA alternative form; Omeprazole results in increased expression of ABCG2 protein
Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow]

PMID:20804740 PMID:31348918

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

ATP binding cassette subfamily G member 5

affects expression

Omeprazole affects the expression of ABCG5 mRNA

NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439

G

abhydrolase domain containing 1

affects expression

Omeprazole affects the expression of ABHD1 mRNA

NCBI chr 5:31,107,410...31,112,439
Ensembl chr 5:31,107,410...31,112,435

G

abhydrolase domain containing 14b

affects expression

Omeprazole affects the expression of ABHD14B mRNA

NCBI chr 9:106,324,936...106,330,122
Ensembl chr 9:106,324,658...106,330,122

G

abhydrolase domain containing 17A

affects expression

Omeprazole affects the expression of ABHD17A mRNA

NCBI chr10:80,419,483...80,426,199
Ensembl chr10:80,419,488...80,426,175

G

acetyl-Coenzyme A carboxylase alpha

affects expression

Omeprazole affects the expression of ACACA mRNA

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A dehydrogenase, long-chain

affects expression

Omeprazole affects the expression of ACADL mRNA

NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436

G

angiotensin converting enzyme 2

decreases expression

Omeprazole results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

aconitase 1

affects expression

Omeprazole affects the expression of ACO1 mRNA

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

aconitase 2, mitochondrial

affects expression

Omeprazole affects the expression of ACO2 mRNA

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

G

acyl-CoA thioesterase 12

affects expression

Omeprazole affects the expression of ACOT12 mRNA

NCBI chr13:91,889,635...91,934,271
Ensembl chr13:91,889,631...91,934,267

G

acyl-CoA thioesterase 4

affects expression

Omeprazole affects the expression of ACOT4 mRNA

NCBI chr12:84,084,028...84,091,497
Ensembl chr12:84,085,153...84,095,375

G

ADAM metallopeptidase domain 15

affects expression

Omeprazole affects the expression of ADAM15 mRNA

NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303

G

adducin 1

affects expression

Omeprazole affects the expression of ADD1 mRNA

NCBI chr 5:34,731,008...34,789,652
Ensembl chr 5:34,731,008...34,789,652

G

alcohol dehydrogenase 1 (class I)

decreases expression

Omeprazole results in decreased expression of ADH1C mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

alcohol dehydrogenase 4 (class II), pi polypeptide

affects expression

Omeprazole affects the expression of ADH4 mRNA

NCBI chr 3:138,121,217...138,138,444
Ensembl chr 3:138,121,227...138,136,653

G

androgen dependent TFPI regulating protein

affects expression

Omeprazole affects the expression of ADTRP mRNA

NCBI chr13:41,916,621...42,001,092
Ensembl chr13:41,916,624...42,001,160

G

afamin

affects expression

Omeprazole affects the expression of AFM mRNA

NCBI chr 5:90,666,808...90,701,403
Ensembl chr 5:90,666,791...90,701,402

G

angiotensinogen

affects expression

Omeprazole affects the expression of AGT mRNA

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

affects expression

Omeprazole affects the expression of AGTR1A mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

aryl-hydrocarbon receptor

multiple interactions
decreases activity
increases activity
increases expression
decreases expression
affects localization
increases response to substance

AG-879 inhibits the reaction [Omeprazole results in increased activity of AHR protein]; AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of AHR mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]; Omeprazole binds to and results in increased activity of AHR protein; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; Puromycin inhibits the reaction [Omeprazole results in increased expression of AHR protein]
Omeprazole results in decreased activity of AHR protein
Omeprazole affects the localization of AHR protein
AHR protein results in increased susceptibility to Omeprazole
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]

PMID:9139728 PMID:9395520 PMID:14742684 PMID:16109480 PMID:20171196 More...

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aldo-keto reductase family 1, member A1

affects expression

Omeprazole affects the expression of AKR1A1 mRNA

NCBI chr 4:116,493,707...116,508,871
Ensembl chr 4:116,493,707...116,508,877

G

aldo-keto reductase family 7, member A5

affects expression

Omeprazole affects the expression of AKR7A2 mRNA

NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737

G

aldehyde dehydrogenase family 1, subfamily A1

affects expression
multiple interactions

Omeprazole affects the expression of ALDH1A1 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ALDH1A1 mRNA

PMID:19483382 PMID:22687989

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A3

increases expression

Omeprazole results in increased expression of ALDH1A3 mRNA

NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265

G

aldehyde dehydrogenase 2, mitochondrial

affects expression

Omeprazole affects the expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase family 3, subfamily A1

increases expression

Omeprazole results in increased expression of ALDH3A1 mRNA

NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247

G

alkB homolog 7

affects expression

Omeprazole affects the expression of ALKBH7 mRNA

NCBI chr17:57,304,339...57,306,340
Ensembl chr17:57,304,339...57,306,322

G

ankyrin repeat domain 40

increases expression

Omeprazole results in increased expression of TMPRSS2 mRNA

NCBI chr11:94,218,827...94,232,673
Ensembl chr11:94,218,827...94,232,667

G

adaptor-related protein complex 2, mu 1 subunit

affects expression

Omeprazole affects the expression of AP2M1 mRNA

NCBI chr16:20,354,230...20,363,659
Ensembl chr16:20,354,228...20,363,659

G

amyloid P component, serum

affects expression

Omeprazole affects the expression of APCS mRNA

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

apolipoprotein A-IV

affects expression

Omeprazole affects the expression of APOA4 mRNA

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein H

affects expression

Omeprazole affects the expression of APOH mRNA

NCBI chr11:108,286,123...108,305,222
Ensembl chr11:108,234,180...108,305,222

G

apolipoprotein O-like

affects expression

Omeprazole affects the expression of APOOL mRNA

NCBI chr X:111,221,049...111,282,452
Ensembl chr X:111,221,031...111,282,452

G

arginase, liver

affects expression

Omeprazole affects the expression of ARG1 mRNA

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

ADP-ribosylation factor-like 6 interacting protein 1

affects expression

Omeprazole affects the expression of ARL6IP1 mRNA

NCBI chr 7:117,718,113...117,728,848
Ensembl chr 7:117,718,114...117,728,885

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions
affects localization

Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]
Omeprazole affects the localization of ARNT protein
Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]

PMID:9395520 PMID:21703235 PMID:25826687

NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551

G

asialoglycoprotein receptor 2

affects expression

Omeprazole affects the expression of ASGR2 mRNA

NCBI chr11:69,983,470...69,997,013
Ensembl chr11:69,983,470...69,997,013

G

activating transcription factor 5

affects expression

Omeprazole affects the expression of ATF5 mRNA

NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082

G

ATP synthase F1 subunit epsilon

affects expression

Omeprazole affects the expression of ATP5F1E mRNA

NCBI chr 2:174,302,868...174,305,894
Ensembl chr 2:174,302,865...174,305,898

G

ATPase, H+ transporting, lysosomal accessory protein 2

affects expression

Omeprazole affects the expression of ATP6AP2 mRNA

NCBI chr X:12,453,998...12,483,290
Ensembl chr X:12,454,040...12,483,288

G

ATPase, H+ transporting, lysosomal V1 subunit A

affects expression

Omeprazole affects the expression of ATP6V1A mRNA

NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068

G

ATPase, H+ transporting, lysosomal V1 subunit F

affects expression

Omeprazole affects the expression of ATP6V1F mRNA

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

ATPase, copper transporting, alpha polypeptide

multiple interactions

Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein]
Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein]

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

bile acid-Coenzyme A: amino acid N-acyltransferase

affects expression

Omeprazole affects the expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BCL2-associated X protein

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell CLL/lymphoma 6, member B

affects expression

Omeprazole affects the expression of BCL6B mRNA

NCBI chr11:70,114,953...70,120,624
Ensembl chr11:70,114,954...70,120,624

G

bridge-like lipid transfer protein family member 3B

affects expression

Omeprazole affects the expression of BLTP3B mRNA

NCBI chr10:89,580,830...89,655,753
Ensembl chr10:89,580,853...89,655,733

G

BCL2 modifying factor

affects expression

Omeprazole affects the expression of BMF mRNA

NCBI chr 2:118,359,238...118,385,240
Ensembl chr 2:118,359,238...118,380,168

G

BMX non-receptor tyrosine kinase

multiple interactions

BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]

NCBI chr X:162,975,838...163,041,189
Ensembl chr X:162,975,838...163,041,189

G

BCL2/adenovirus E1B interacting protein 3

affects expression

Omeprazole affects the expression of BNIP3 mRNA

NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248

G

basic transcription factor 3

affects expression

Omeprazole affects the expression of BTF3 mRNA

NCBI chr13:98,446,405...98,453,514
Ensembl chr13:98,446,404...98,453,514

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

Omeprazole results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent binding protein

affects expression

Omeprazole affects the expression of C1QBP mRNA

NCBI chr11:70,868,672...70,873,852
Ensembl chr11:70,868,662...70,873,852

G

complement component 1, q subcomponent, C chain

decreases expression

Omeprazole results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

complement component 1, s subcomponent 1

affects expression

Omeprazole affects the expression of C1S mRNA

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

C2 calcium-dependent domain containing 2

affects expression

Omeprazole affects the expression of C2CD2 mRNA

NCBI chr16:97,656,409...97,727,248
Ensembl chr16:97,656,409...97,763,798

G

complement component 7

affects expression

Omeprazole affects the expression of C7 mRNA

NCBI chr15:5,017,232...5,093,230
Ensembl chr15:5,018,244...5,093,222

G

complement component 8, beta polypeptide

affects expression

Omeprazole affects the expression of C8B mRNA

NCBI chr 4:104,623,514...104,661,745
Ensembl chr 4:104,623,514...104,661,745

G

Ca2+-dependent activator protein for secretion 2

affects expression

Omeprazole affects the expression of CADPS2 mRNA

NCBI chr 6:23,262,765...23,840,662
Ensembl chr 6:23,262,772...23,839,420

G

cell cycle associated protein 1

affects expression

Omeprazole affects the expression of CAPRIN1 mRNA

NCBI chr 2:103,593,292...103,627,946
Ensembl chr 2:103,593,286...103,627,994

G

carbonic anhydrase 2

affects expression

Omeprazole affects the expression of CA2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

carbonic anhydrase 3

affects expression

Omeprazole affects the expression of CAR3 mRNA

NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583

G

caspase 3

increases activity
multiple interactions
affects expression
increases cleavage

Omeprazole analog results in increased activity of CASP3 protein; Omeprazole results in increased activity of CASP3 protein
Omeprazole inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
Omeprazole inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]
Omeprazole affects the expression of CASP3 mRNA
Omeprazole results in increased cleavage of CASP3 protein

PMID:15461867 PMID:18336733 PMID:19251492 PMID:19483382 PMID:25637687 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases cleavage

Omeprazole analog results in increased cleavage of CASP8 protein

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

increases activity
multiple interactions

Omeprazole results in increased activity of CAT protein
Omeprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]
Omeprazole inhibits the reaction [Acetic Acid results in increased activity of CAT protein]

PMID:18547560 PMID:28849987 PMID:33245926

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

carbonyl reductase 1

affects expression

Omeprazole affects the expression of CBR1 mRNA

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

cholecystokinin B receptor

multiple interactions

[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

cyclin D1

decreases expression

Omeprazole results in decreased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin dependent kinase inhibitor 1A

increases expression

Omeprazole results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cysteine dioxygenase 1, cytosolic

affects expression

Omeprazole affects the expression of CDO1 mRNA

NCBI chr18:46,846,260...46,861,569
Ensembl chr18:46,846,260...46,861,462

G

choline/ethanolaminephosphotransferase 1

affects expression

Omeprazole affects the expression of CEPT1 mRNA

NCBI chr 3:106,409,576...106,455,118
Ensembl chr 3:106,409,576...106,455,118

G

carboxylesterase 2H

affects expression

Omeprazole affects the expression of CES2 mRNA

NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810

G

complement component factor i

affects expression
decreases expression

Omeprazole affects the expression of CFI mRNA
Omeprazole results in decreased expression of CFI mRNA

PMID:19483382 PMID:25626140

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

cystic fibrosis transmembrane conductance regulator

affects metabolic processing

CFTR protein affects the metabolism of Omeprazole

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

calcineurin-like EF hand protein 1

affects expression

Omeprazole affects the expression of CHP1 mRNA

NCBI chr 2:119,378,172...119,417,505
Ensembl chr 2:119,378,178...119,417,508

G

CDGSH iron sulfur domain 1

affects expression

Omeprazole affects the expression of CISD1 mRNA

NCBI chr10:71,166,324...71,180,679
Ensembl chr10:71,166,310...71,180,784

G

chloride channel, voltage-sensitive 4

affects expression

Omeprazole affects the expression of CLCN4 mRNA

NCBI chr 7:7,285,308...7,303,837
Ensembl chr 7:7,285,308...7,303,850

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

affects expression

Omeprazole affects the expression of CLPP mRNA

NCBI chr17:57,297,264...57,303,371
Ensembl chr17:57,297,305...57,303,188

G

CLPTM1-like

affects expression

Omeprazole affects the expression of CLPTM1L mRNA

NCBI chr13:73,752,121...73,768,758
Ensembl chr13:73,752,125...73,768,724

G

carboxymethylenebutenolidase homolog

affects expression

Omeprazole affects the expression of CMBL mRNA

NCBI chr15:31,565,314...31,590,266
Ensembl chr15:31,565,535...31,590,265

G

cytidine/uridine monophosphate kinase 1

affects expression

Omeprazole affects the expression of CMPK1 mRNA

NCBI chr 4:114,817,810...114,844,425
Ensembl chr 4:114,816,533...114,844,438

G

coatomer protein complex, subunit gamma 1

affects expression

Omeprazole affects the expression of COPG1 mRNA

NCBI chr 6:87,864,801...87,890,577
Ensembl chr 6:87,864,796...87,890,577

G

COP9 signalosome subunit 4

affects expression

Omeprazole affects the expression of COPS4 mRNA

NCBI chr 5:100,666,223...100,695,668
Ensembl chr 5:100,666,175...100,695,669

G

coenzyme Q3 methyltransferase

affects expression

Omeprazole affects the expression of COQ3 mRNA

NCBI chr 4:21,879,646...21,912,163
Ensembl chr 4:21,879,673...21,912,162

G

cytochrome c oxidase subunit 4I1

affects expression

Omeprazole affects the expression of COX4I1 mRNA

NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946

G

carboxypeptidase N, polypeptide 1

affects expression

Omeprazole affects the expression of CPN1 mRNA

NCBI chr19:43,944,746...43,974,990
Ensembl chr19:43,944,746...43,974,995

G

carboxypeptidase Q

affects expression

Omeprazole affects the expression of CPQ mRNA

NCBI chr15:33,083,275...33,594,698
Ensembl chr15:33,083,275...33,594,698

G

cAMP responsive element modulator

affects expression

Omeprazole affects the expression of CREM mRNA

NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748

G

casein kinase 2, beta polypeptide

affects expression

Omeprazole affects the expression of CSNK2B mRNA

NCBI chr17:35,335,171...35,341,029
Ensembl chr17:35,335,172...35,341,029

G

cysteine and glycine-rich protein 1

affects expression

Omeprazole affects the expression of CSRP1 mRNA

NCBI chr 1:135,614,650...135,679,970
Ensembl chr 1:135,647,799...135,679,970

G

catenin alpha 1

affects expression

Omeprazole affects the expression of CTNNA1 mRNA

NCBI chr18:35,251,955...35,387,829
Ensembl chr18:35,251,912...35,387,832

G

cathepsin B

decreases activity

Omeprazole results in decreased activity of CTSB protein

NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372

G

cathepsin D

multiple interactions

Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

cathepsin E

decreases expression

Omeprazole results in decreased expression of CTSE

NCBI chr 1:131,566,052...131,603,245
Ensembl chr 1:131,566,044...131,603,243

G

C-X-C motif chemokine receptor 4

decreases expression
multiple interactions

Omeprazole results in decreased expression of CXCR4 mRNA
AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]

NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
multiple interactions
increases expression
decreases activity

Omeprazole results in increased activity of CYP1A1 promoter
Omeprazole inhibits the reaction [Oxygen results in increased expression of CYP1A1 protein]; Omeprazole promotes the reaction [Oxygen results in decreased expression of CYP1A1 mRNA]
Omeprazole results in increased expression of CYP1A1 mRNA; Omeprazole results in increased expression of CYP1A1 protein
AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]
Omeprazole results in increased activity of CYP1A1 protein
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; lavendustin A inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]
Omeprazole results in decreased activity of CYP1A1 protein

PMID:8647108 PMID:8900397 PMID:9041675 PMID:9139728 PMID:9152597 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
multiple interactions
increases expression
increases activity

Omeprazole results in decreased activity of CYP1A2 protein
[Omeprazole results in increased expression of CYP1A2 protein] which results in decreased alkylation of Phenacetin; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; Omeprazole results in increased expression of and results in increased activity of CYP1A2 protein
Omeprazole results in increased expression of CYP1A2 mRNA; Omeprazole results in increased expression of CYP1A2 protein
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA
Omeprazole results in increased activity of CYP1A2 promoter; Omeprazole results in increased activity of CYP1A2 protein

PMID:9152597 PMID:9744552 PMID:12040753 PMID:12623754 PMID:12841937 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
affects expression
increases expression
decreases activity

Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]
Omeprazole affects the expression of CYP1B1 mRNA
Omeprazole results in increased expression of CYP1B1 mRNA
Omeprazole results in decreased activity of CYP1B1 protein

PMID:12040753 PMID:12623754 PMID:18420780 PMID:21703235 PMID:25826687

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily a, polypeptide 22

affects expression

Omeprazole affects the expression of CYP2A1 mRNA

NCBI chr 7:26,631,564...26,638,838
Ensembl chr 7:26,631,056...26,638,809

G

cytochrome P450, family 2, subfamily b, polypeptide 10

decreases activity
affects expression
increases expression
increases activity

Omeprazole results in decreased activity of CYP2B10 protein
Omeprazole affects the expression of CYP2B3 mRNA
Omeprazole results in increased expression of CYP2B6 mRNA
Omeprazole results in increased activity of CYP2B6 protein

PMID:17954527 PMID:18420780 PMID:19118567 PMID:19483382 PMID:22524704

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

affects expression
increases expression

Omeprazole affects the expression of CYP2B2 mRNA
Omeprazole results in increased expression of CYP2B2 protein

PMID:9152597 PMID:19483382

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2. subfamily c, polypeptide 37

increases metabolic processing
multiple interactions

CYP2C37 protein results in increased metabolism of Omeprazole
[CYP2C37 protein results in increased metabolism of Omeprazole] which results in increased chemical synthesis of 5-hydroxymethylomeprazole

NCBI chr19:39,980,868...40,000,687
Ensembl chr19:39,980,868...40,000,687

G

cytochrome P450, family 2, subfamily c, polypeptide 38

affects metabolic processing
multiple interactions
decreases activity
increases metabolic processing
increases hydroxylation
decreases metabolic processing

CYP2C19 protein affects the metabolism of Omeprazole
[5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]; Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of Clopidogrel]
CYP2C19 protein results in increased metabolism of Omeprazole
CYP2C19 protein results in increased hydroxylation of Omeprazole
CYP2C19 gene alternative form results in decreased metabolism of Omeprazole

PMID:8930576 PMID:9600717 PMID:11752104 PMID:12464242 PMID:12467917 More...

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions
decreases activity

Omeprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]
Omeprazole results in decreased activity of CYP2C9 protein

PMID:15258107 PMID:18420780

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily d, polypeptide 22

affects expression
decreases activity

Omeprazole affects the expression of CYP2D4 mRNA
Omeprazole results in decreased activity of CYP2D6 protein

PMID:18420780 PMID:19483382

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Omeprazole results in increased expression of and results in increased activity of CYP2E1 protein

PMID:15802389 PMID:36243147

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily f, polypeptide 2

affects expression

Omeprazole affects the expression of CYP2F4 mRNA

NCBI chr 7:26,819,380...26,833,085
Ensembl chr 7:26,819,334...26,833,085

G

cytochrome P450, family 2, subfamily j, polypeptide 9

affects expression

Omeprazole affects the expression of CYP2J4 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 3, subfamily a, polypeptide 11

decreases activity

Omeprazole results in decreased activity of CYP3A11 protein

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

affects expression
increases expression

Omeprazole affects the expression of CYP3A9 mRNA
Omeprazole results in increased expression of CYP3A5 mRNA

PMID:19118567 PMID:19483382

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 44

decreases activity

Omeprazole results in decreased activity of CYP3A4 protein

NCBI chr 5:145,710,793...145,742,701
Ensembl chr 5:145,710,793...145,742,684

G

cytochrome P450, family 4, subfamily f, polypeptide 16

affects expression

Omeprazole affects the expression of CYP4F6 mRNA

NCBI chr17:32,755,517...32,770,772
Ensembl chr17:32,755,532...32,770,772

G

diazepam binding inhibitor

affects expression

Omeprazole affects the expression of DBI mRNA

NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808

G

DDB1 and CUL4 associated factor 11

affects expression

Omeprazole affects the expression of DCAF11 mRNA

NCBI chr14:55,796,557...55,807,522
Ensembl chr14:55,797,463...55,807,522

G

dicarbonyl L-xylulose reductase

affects expression

Omeprazole affects the expression of DCXR mRNA

NCBI chr11:120,615,372...120,618,110
Ensembl chr11:120,616,225...120,618,107

G

DNA-damage inducible transcript 3

increases expression

Omeprazole results in increased expression of DDIT3 protein

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

2,4-dienoyl CoA reductase 1, mitochondrial

affects expression

Omeprazole affects the expression of DECR1 mRNA

NCBI chr 4:15,917,240...15,945,377
Ensembl chr 4:15,917,240...15,945,507

G

dexamethasone-induced transcript

affects expression

Omeprazole affects the expression of DEXI mRNA

NCBI chr16:10,348,071...10,360,918
Ensembl chr16:10,320,395...10,360,918

G

diacylglycerol O-acyltransferase 1

affects expression

Omeprazole affects the expression of DGAT1 mRNA

NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153

G

24-dehydrocholesterol reductase

affects expression

Omeprazole affects the expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

dehydrogenase/reductase 4

affects expression

Omeprazole affects the expression of DHRS4 mRNA

NCBI chr14:55,715,880...55,727,797
Ensembl chr14:55,716,215...55,727,797

G

dehydrogenase/reductase 7B

affects expression

Omeprazole affects the expression of DHRS7B mRNA

NCBI chr11:60,721,457...60,749,249
Ensembl chr11:60,721,457...60,751,021

G

DEAH-box helicase 16

affects expression

Omeprazole affects the expression of DHX16 mRNA

NCBI chr17:36,190,657...36,203,562
Ensembl chr17:36,190,711...36,203,562

G

distal membrane arm assembly component 2 like

affects expression

Omeprazole affects the expression of DMAC2L mRNA

NCBI chr12:69,771,687...69,791,439
Ensembl chr12:69,771,724...69,791,434

G

DnaJ heat shock protein family (Hsp40) member C3

affects expression

Omeprazole affects the expression of DNAJC3 mRNA

NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109

G

dipeptidylpeptidase 4

affects expression

Omeprazole affects the expression of DPP4 mRNA

NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575

G

dihydropyrimidine dehydrogenase

affects expression

Omeprazole affects the expression of DPYD mRNA

NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573

G

glutamyl-tRNA synthetase 2, mitochondrial

affects expression

Omeprazole affects the expression of EARS2 mRNA

NCBI chr 7:121,633,385...121,666,436
Ensembl chr 7:121,636,436...121,666,486

G

enoyl Coenzyme A hydratase, short chain, 1, mitochondrial

affects expression

Omeprazole affects the expression of ECHS1 mRNA

NCBI chr 7:139,685,623...139,696,334
Ensembl chr 7:139,685,623...139,696,389

G

enoyl-Coenzyme A delta isomerase 1

affects expression

Omeprazole affects the expression of ECI1 mRNA

NCBI chr17:24,645,657...24,658,290
Ensembl chr17:24,645,615...24,658,322

G

enoyl-Coenzyme A delta isomerase 2

affects expression

Omeprazole affects the expression of ECI2 mRNA

NCBI chr13:35,161,731...35,211,098
Ensembl chr13:35,161,731...35,211,079

G

eukaryotic translation elongation factor 1 gamma

affects expression

Omeprazole affects the expression of EEF1G mRNA

NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843

G

epidermal growth factor

multiple interactions

Omeprazole promotes the reaction [Indomethacin results in increased expression of EGF protein]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase

affects expression

Omeprazole affects the expression of EHHADH mRNA

NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557

G

eukaryotic translation initiation factor 4A2

affects expression

Omeprazole affects the expression of EIF4A2 mRNA

NCBI chr16:22,924,846...22,932,882
Ensembl chr16:22,926,194...22,932,886

G

eukaryotic translation initiation factor 4E binding protein 1

affects expression

Omeprazole affects the expression of EIF4EBP1 mRNA

NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702

G

eukaryotic translation initiation factor 4H

affects expression

Omeprazole affects the expression of EIF4H mRNA

NCBI chr 5:134,648,726...134,668,263
Ensembl chr 5:134,648,575...134,668,344

G

ectodermal-neural cortex 1

affects expression

Omeprazole affects the expression of ENC1 mRNA

NCBI chr13:97,377,613...97,389,548
Ensembl chr13:97,377,613...97,389,542

G

enolase 1, alpha non-neuron

affects expression

Omeprazole affects the expression of ENO1 mRNA

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

glutamyl aminopeptidase

affects expression

Omeprazole affects the expression of ENPEP mRNA

NCBI chr 3:129,062,826...129,126,398
Ensembl chr 3:129,062,824...129,126,369

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

affects expression

Omeprazole affects the expression of ENPP1 mRNA

NCBI chr10:24,513,812...24,588,057
Ensembl chr10:24,513,812...24,588,057

G

E1A binding protein p300

multiple interactions

Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epithelial cell adhesion molecule

affects expression

Omeprazole affects the expression of EPCAM mRNA

NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557

G

endoplasmic reticulum protein 29

affects expression

Omeprazole affects the expression of ERP29 mRNA

NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569

G

esterase D/formylglutathione hydrolase

affects expression

Omeprazole affects the expression of ESD mRNA

NCBI chr14:74,969,591...74,988,205
Ensembl chr14:74,969,737...74,988,205

G

electron transferring flavoprotein, beta polypeptide

affects expression

Omeprazole affects the expression of ETFB mRNA

NCBI chr 7:43,093,496...43,107,224
Ensembl chr 7:43,093,507...43,107,224

G

fatty acid amide hydrolase

affects expression

Omeprazole affects the expression of FAAH mRNA

NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123

G

fatty acid desaturase 2

affects expression

Omeprazole affects the expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

fructose bisphosphatase 1

affects expression

Omeprazole affects the expression of FBP1 mRNA

NCBI chr13:63,012,567...63,036,112
Ensembl chr13:63,012,567...63,036,096

G

farnesyl diphosphate farnesyl transferase 1

affects expression

Omeprazole affects the expression of FDFT1 mRNA

NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027

G

farnesyl diphosphate synthetase

affects expression

Omeprazole affects the expression of FDPS mRNA

NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266

G

ferredoxin 2

affects expression

Omeprazole affects the expression of FDX2 mRNA

NCBI chr 9:20,978,808...20,984,827
Ensembl chr 9:20,978,816...20,984,910

G

flavin containing monooxygenase 1

affects expression

Omeprazole affects the expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

guanidinoacetate methyltransferase

affects expression

Omeprazole affects the expression of GAMT mRNA

NCBI chr10:80,093,985...80,096,846
Ensembl chr10:80,093,985...80,096,846

G

glyceraldehyde-3-phosphate dehydrogenase

affects expression

Omeprazole affects the expression of GAPDH mRNA

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

gastrin

increases expression

Omeprazole results in increased expression of GAST protein

PMID:11422300 PMID:12189558 PMID:12763636 PMID:15223672 PMID:16618411 More...

NCBI chr11:100,225,233...100,227,823
Ensembl chr11:100,225,233...100,227,822

G

1,4-alpha-glucan branching enzyme 1

affects expression

Omeprazole affects the expression of GBE1 mRNA

NCBI chr16:70,110,837...70,366,608
Ensembl chr16:70,110,837...70,366,604

G

GTP cyclohydrolase I feedback regulator

affects expression

Omeprazole affects the expression of GCHFR mRNA

NCBI chr 2:118,998,269...119,002,870
Ensembl chr 2:118,998,254...119,002,871

G

gamma-glutamyl hydrolase

affects expression

Omeprazole affects the expression of GGH mRNA

NCBI chr 4:20,041,963...20,066,111
Ensembl chr 4:20,042,052...20,066,750

G

gamma-glutamyltransferase 1

multiple interactions

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GGT1 mRNA

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

gap junction protein, beta 1

affects expression

Omeprazole affects the expression of GJB1 mRNA

NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235

G

glycosylphosphatidylinositol specific phospholipase D1

affects expression

Omeprazole affects the expression of GPLD1 mRNA

NCBI chr13:25,127,135...25,175,919
Ensembl chr13:25,127,135...25,176,484

G

glutathione peroxidase 1

affects expression

Omeprazole affects the expression of GPX1 mRNA

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione peroxidase 2

multiple interactions

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione peroxidase 4

affects expression

Omeprazole affects the expression of GPX4 mRNA

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)

affects expression

Omeprazole affects the expression of GRINA mRNA

NCBI chr15:76,130,917...76,134,109
Ensembl chr15:76,130,964...76,134,104

G

GrpE-like 1, mitochondrial

affects expression

Omeprazole affects the expression of GRPEL1 mRNA

NCBI chr 5:36,622,529...36,631,421
Ensembl chr 5:36,622,342...36,631,424

G

glutathione S-transferase, alpha 1 (Ya)

multiple interactions
increases expression

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA
Omeprazole results in increased expression of GSTA5 mRNA

PMID:17202759 PMID:22687989

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, pi 1

increases expression

Omeprazole results in increased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

affects expression

Omeprazole affects the expression of GSTT1 mRNA

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

general transcription factor IIH, polypeptide 5

affects expression

Omeprazole affects the expression of GTF2H5 mRNA

NCBI chr17:6,130,103...6,135,763
Ensembl chr17:6,130,061...6,136,792

G

granzyme A

affects expression

Omeprazole affects the expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

histocompatibility 2, class II, locus DMa

affects expression

Omeprazole affects the expression of HLA-DMA mRNA

NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075

G

histocompatibility 2, M region locus 2

affects expression

Omeprazole affects the expression of HLA-B mRNA

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

histocompatibility 2, M region locus 3

affects expression

Omeprazole affects the expression of HLA-G mRNA

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

H3.3 histone B

affects expression

Omeprazole affects the expression of H3F3B mRNA

NCBI chr11:115,912,787...115,921,313
Ensembl chr11:115,912,738...115,918,788

G

histidine ammonia lyase

affects expression

Omeprazole affects the expression of HAL mRNA

NCBI chr10:93,324,630...93,352,623
Ensembl chr10:93,324,630...93,355,166

G

hepcidin antimicrobial peptide

increases secretion
multiple interactions
increases expression

Omeprazole results in increased secretion of HAMP protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]
Omeprazole results in increased expression of HAMP mRNA; Omeprazole results in increased expression of HAMP protein

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

hydroxyacid oxidase 2

affects expression

Omeprazole affects the expression of HAO2 mRNA

NCBI chr 3:98,781,835...98,802,692
Ensembl chr 3:98,781,837...98,800,555

G

hemoglobin alpha, adult chain 2

affects expression

Omeprazole affects the expression of HBA-A2 mRNA

NCBI chr11:32,246,492...32,247,310
Ensembl chr11:32,246,489...32,247,298

G

hemoglobin, beta adult major chain

affects expression

Omeprazole affects the expression of HBB mRNA

G

histidine decarboxylase

affects expression
increases expression
increases stability
multiple interactions

Omeprazole affects the expression of HDC mRNA
Omeprazole results in increased expression of HDC mRNA
Omeprazole results in increased stability of HDC protein
Omeprazole results in increased expression of and results in increased activity of HDC protein

PMID:12763636 PMID:19483382

NCBI chr 2:126,435,579...126,465,942
Ensembl chr 2:126,435,587...126,461,219

G

homogentisate 1, 2-dioxygenase

affects expression

Omeprazole affects the expression of HGD mRNA

NCBI chr16:37,400,104...37,452,388
Ensembl chr16:37,400,515...37,452,382

G

high mobility group nucleosomal binding domain 1

affects expression

Omeprazole affects the expression of HMGN1 mRNA

NCBI chr16:95,922,788...95,928,925
Ensembl chr16:95,921,818...95,928,929

G

heme oxygenase 1

increases expression
multiple interactions

Omeprazole results in increased expression of HMOX1 mRNA; Omeprazole results in increased expression of HMOX1 protein
Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]; Omeprazole results in increased expression of and results in increased activity of HMOX1 protein

PMID:16712795 PMID:27725188

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hypoxanthine phosphoribosyltransferase 1

affects expression

Omeprazole affects the expression of HPRT1 mRNA

NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536

G

HPS5, biogenesis of lysosomal organelles complex 2 subunit 2

affects expression

Omeprazole affects the expression of HPS5 mRNA

NCBI chr 7:46,409,890...46,445,501
Ensembl chr 7:46,409,890...46,445,488

G

hydroxysteroid (17-beta) dehydrogenase 4

affects expression

Omeprazole affects the expression of HSD17B4 mRNA

NCBI chr18:50,261,268...50,329,337
Ensembl chr18:50,261,268...50,329,336

G

hydroxysteroid dehydrogenase like 2

affects expression

Omeprazole affects the expression of HSDL2 mRNA

NCBI chr 4:59,581,515...59,618,694
Ensembl chr 4:59,581,563...59,618,689

G

heat shock protein 1A

multiple interactions
decreases expression

Zinc Compounds analog inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]
Omeprazole results in decreased expression of HSPA1A mRNA; Omeprazole results in decreased expression of HSPA1A protein

PMID:15223672 PMID:16945336

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1-like

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA]

NCBI chr17:35,191,679...35,198,204
Ensembl chr17:35,191,679...35,198,261

G

HtrA serine peptidase 1

affects expression

Omeprazole affects the expression of HTRA1 mRNA

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

immediate early response 3

multiple interactions

[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

interferon gamma

multiple interactions

Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

insulin-like growth factor 1

affects expression

Omeprazole affects the expression of IGF1 mRNA

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor binding protein, acid labile subunit

affects expression

Omeprazole affects the expression of IGFALS mRNA

NCBI chr17:25,096,818...25,100,985
Ensembl chr17:25,084,971...25,100,984

G

insulin-like growth factor binding protein 2

affects expression

Omeprazole affects the expression of IGFBP2 mRNA

NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633

G

interleukin 10

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL6 protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL6 protein]

PMID:25637687 PMID:32418911

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

inositol (myo)-1(or 4)-monophosphatase 1

affects expression

Omeprazole affects the expression of IMPA1 mRNA

NCBI chr 3:10,377,016...10,396,499
Ensembl chr 3:10,377,016...10,396,499

G

inhibin beta-E

affects expression

Omeprazole affects the expression of INHBE mRNA

NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280

G

myo-inositol 1-phosphate synthase A1

affects expression

Omeprazole affects the expression of ISYNA1 mRNA

NCBI chr 8:71,047,131...71,049,940
Ensembl chr 8:71,047,023...71,049,940

G

inter alpha-trypsin inhibitor, heavy chain 4

affects expression

Omeprazole affects the expression of ITIH4 mRNA

NCBI chr14:30,608,433...30,623,943
Ensembl chr14:30,608,433...30,624,310

G

Janus kinase 1

affects expression

Omeprazole affects the expression of JAK1 mRNA

NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479

G

KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2

affects expression

Omeprazole affects the expression of KDELR2 mRNA

NCBI chr 5:143,389,575...143,407,659
Ensembl chr 5:143,389,593...143,407,656

G

kinase insert domain protein receptor

affects expression
multiple interactions

Omeprazole affects the expression of KDR mRNA
Omeprazole promotes the reaction [Oxygen results in decreased expression of KDR protein]

PMID:19483382 PMID:26272953

NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118

G

keratin 8

affects expression

Omeprazole affects the expression of KRT8 mRNA

NCBI chr15:101,905,146...101,912,777
Ensembl chr15:101,905,133...101,912,917

G

lecithin cholesterol acyltransferase

affects expression

Omeprazole affects the expression of LCAT mRNA

NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014

G

leucine carboxyl methyltransferase 1

affects expression

Omeprazole affects the expression of LCMT1 mRNA

NCBI chr 7:122,977,026...123,029,581
Ensembl chr 7:122,969,007...123,029,581

G

lipase, hepatic

affects expression

Omeprazole affects the expression of LIPC mRNA

NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508

G

lysyl oxidase

affects expression

Omeprazole affects the expression of LOX mRNA

NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939

G

low density lipoprotein receptor-related protein 3

affects expression

Omeprazole affects the expression of LRP3 mRNA

NCBI chr 7:34,900,303...34,914,770
Ensembl chr 7:34,899,452...34,914,923

G

mannosidase 2, alpha B1

affects expression

Omeprazole affects the expression of MAN2B1 mRNA

NCBI chr 8:85,809,941...85,824,215
Ensembl chr 8:85,809,899...85,824,911

G

mitogen-activated protein kinase kinase 2

affects expression

Omeprazole affects the expression of MAP2K2 mRNA

NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809

G

mitogen-activated protein kinase 14

multiple interactions

Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

MBL associated serine protease 2

affects expression

Omeprazole affects the expression of MASP2 mRNA

NCBI chr 4:148,679,079...148,699,939
Ensembl chr 4:148,687,011...148,699,956

G

malic enzyme 1, NADP(+)-dependent, cytosolic

affects expression
multiple interactions

Omeprazole affects the expression of ME1 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA

PMID:19483382 PMID:22687989

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

matrix metallopeptidase 14 (membrane-inserted)

multiple interactions

Omeprazole inhibits the reaction [Indomethacin results in decreased expression of MMP14 protein]

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 2

multiple interactions

Omeprazole inhibits the reaction [Hydrogen Peroxide results in decreased activity of MMP2 protein]

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

methylmalonyl-Coenzyme A mutase

affects expression

Omeprazole affects the expression of MMUT mRNA

NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879

G

myeloperoxidase

multiple interactions
decreases activity

Omeprazole inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Acids results in increased activity of MPO protein]
Omeprazole results in decreased activity of MPO protein
Omeprazole inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Cysteamine results in increased expression of MPO protein]; Omeprazole inhibits the reaction [Ethanol results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:16091555 PMID:17151854 PMID:20165931 PMID:25637687 PMID:27780710 More...

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

maestro

affects expression

Omeprazole affects the expression of MRO mRNA

NCBI chr18:73,992,465...74,014,405
Ensembl chr18:73,992,456...74,014,404

G

mitochondrial ribosomal protein L2

affects expression

Omeprazole affects the expression of MRPL2 mRNA

NCBI chr17:46,957,094...46,961,058
Ensembl chr17:46,957,155...46,961,065

G

mitochondrial ribosomal protein L9

affects expression

Omeprazole affects the expression of MRPL9 mRNA

NCBI chr 3:94,350,631...94,355,831
Ensembl chr 3:94,350,625...94,358,437

G

murinoglobulin 2

affects expression

Omeprazole affects the expression of PZP mRNA

NCBI chr 6:121,983,688...122,062,927
Ensembl chr 6:121,983,720...122,062,924

G

myeloid-associated differentiation marker

affects expression

Omeprazole affects the expression of MYADM mRNA

NCBI chr 7:3,337,563...3,347,871
Ensembl chr 7:3,337,605...3,348,958

G

MYC binding protein 2, E3 ubiquitin protein ligase

affects expression

Omeprazole affects the expression of MYCBP2 mRNA

NCBI chr14:103,350,847...103,584,276
Ensembl chr14:103,350,847...103,584,250

G

myosin ID

affects expression

Omeprazole affects the expression of MYO1D mRNA

NCBI chr11:80,372,945...80,670,881
Ensembl chr11:80,372,952...80,670,851

G

N(alpha)-acetyltransferase 38, NatC auxiliary subunit

affects expression

Omeprazole affects the expression of NAA38 mRNA

NCBI chr11:69,286,617...69,287,497
Ensembl chr11:69,286,313...69,287,506

G

nucleosome assembly protein 1-like 1

affects expression

Omeprazole affects the expression of NAP1L1 mRNA

NCBI chr10:111,308,754...111,334,011
Ensembl chr10:111,309,084...111,334,011

G

N-acetyltransferase 8 (GCN5-related)

affects expression

Omeprazole affects the expression of NAT8 mRNA

NCBI chr 6:85,807,369...85,813,839
Ensembl chr 6:85,807,370...85,809,064

G

nuclear receptor coactivator 1

multiple interactions

Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]

NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182

G

N-myc downstream regulated gene 2

affects expression

Omeprazole affects the expression of NDRG2 mRNA

NCBI chr14:52,142,738...52,151,463
Ensembl chr14:52,142,728...52,151,615

G

NADH:ubiquinone oxidoreductase core subunit S5

affects expression

Omeprazole affects the expression of NDUFS5 mRNA

NCBI chr 4:123,606,503...123,611,979
Ensembl chr 4:123,606,503...123,611,995

G

NADH:ubiquinone oxidoreductase core subunit V3

affects expression

Omeprazole affects the expression of NDUFV3 mRNA

NCBI chr17:31,739,089...31,750,300
Ensembl chr17:31,739,089...31,750,305

G

neuraminidase 2

affects expression

Omeprazole affects the expression of NEU2 mRNA

NCBI chr 1:87,501,749...87,525,567
Ensembl chr 1:87,437,611...87,525,567

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in decreased expression of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nuclear transcription factor, X-box binding 1

affects expression

Omeprazole affects the expression of NFX1 mRNA

NCBI chr 4:40,970,906...41,025,992
Ensembl chr 4:40,970,906...41,025,993

G

NIPA-like domain containing 2

affects expression

Omeprazole affects the expression of NIPAL2 mRNA

NCBI chr15:34,572,942...34,679,739
Ensembl chr15:34,572,945...34,679,358

G

nitrilase 1

affects expression

Omeprazole affects the expression of NIT1 mRNA

NCBI chr 1:171,168,145...171,173,209
Ensembl chr 1:171,165,576...171,173,214

G

NLR family, pyrin domain containing 3

multiple interactions

Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

NME/NM23 nucleoside diphosphate kinase 2

affects expression

Omeprazole affects the expression of NME2 mRNA

NCBI chr11:93,840,640...93,847,082
Ensembl chr11:93,840,640...93,847,085

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

Omeprazole results in increased expression of NQO1 mRNA
Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 mRNA]; Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 protein]
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA

PMID:17202759 PMID:22687989 PMID:26272953

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]

PMID:12695340 PMID:17041008 PMID:25680588 PMID:26187274 PMID:27732639

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 1, group I, member 3

affects expression
decreases metabolic processing
increases expression

Omeprazole affects the expression of NR1I3 mRNA
NR1I3 gene mutant form results in decreased metabolism of Omeprazole
Omeprazole results in increased expression of NR1I3 mRNA

PMID:19118567 PMID:19483382 PMID:27434302

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

nuclear receptor subfamily 3, group C, member 1

affects expression

Omeprazole affects the expression of NR3C1 mRNA

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

out at first homolog

affects expression

Omeprazole affects the expression of OAF mRNA

NCBI chr 9:43,132,575...43,151,113
Ensembl chr 9:43,132,532...43,151,208

G

oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

affects expression

Omeprazole affects the expression of OGDH mRNA

NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642

G

olfactory receptor family 51 subfamily E member 2

affects expression

Omeprazole affects the expression of OLR59 mRNA

NCBI chr 7:102,389,928...102,408,678
Ensembl chr 7:102,387,718...102,408,678

G

oligosaccharyltransferase complex subunit (non-catalytic)

affects expression

Omeprazole affects the expression of OSTC mRNA

NCBI chr 3:130,489,566...130,503,093
Ensembl chr 3:130,489,561...130,503,093

G

ornithine transcarbamylase

affects expression

Omeprazole affects the expression of OTC mRNA

NCBI chr X:10,118,584...10,187,275
Ensembl chr X:10,118,544...10,187,263

G

poly(A) binding protein, cytoplasmic 4

affects expression

Omeprazole affects the expression of PABPC4 mRNA

NCBI chr 4:123,172,722...123,192,718
Ensembl chr 4:123,156,144...123,192,718

G

phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoribosylaminoimidazole, succinocarboxamide synthetase

affects expression

Omeprazole affects the expression of PAICS mRNA

NCBI chr 5:77,099,149...77,115,356
Ensembl chr 5:77,099,154...77,115,356

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage

Omeprazole results in increased cleavage of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

propionyl Coenzyme A carboxylase, beta polypeptide

affects expression

Omeprazole affects the expression of PCCB mRNA

NCBI chr 9:100,864,085...100,916,993
Ensembl chr 9:100,864,085...100,916,951

G

proliferating cell nuclear antigen

multiple interactions

[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Omeprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein]
Omeprazole inhibits the reaction [Ethanol results in decreased expression of PCNA protein]

PMID:19251492 PMID:26970604

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

proprotein convertase subtilisin/kexin type 6

affects expression

Omeprazole affects the expression of PCSK6 mRNA

NCBI chr 7:65,511,884...65,700,134
Ensembl chr 7:65,511,482...65,700,134

G

phosphatidylcholine transfer protein

affects expression

Omeprazole affects the expression of PCTP mRNA

NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720

G

pyruvate carboxylase

affects expression

Omeprazole affects the expression of PCX mRNA

NCBI chr19:4,560,500...4,671,780
Ensembl chr19:4,560,500...4,671,780

G

phosducin-like 3

affects expression

Omeprazole affects the expression of PDCL3 mRNA

NCBI chr 1:39,026,895...39,036,317
Ensembl chr 1:39,024,689...39,036,319

G

protein disulfide isomerase associated 3

affects expression

Omeprazole affects the expression of PDIA3 mRNA

NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168

G

protein disulfide isomerase associated 6

affects expression

Omeprazole affects the expression of PDIA6 mRNA

NCBI chr12:17,316,590...17,334,786
Ensembl chr12:17,316,546...17,334,771

G

peroxisomal biogenesis factor 19

affects expression

Omeprazole affects the expression of PEX19 mRNA

NCBI chr 1:171,954,322...171,964,064
Ensembl chr 1:171,954,322...171,964,060

G

phosphoglycerate mutase 1

affects expression

Omeprazole affects the expression of PGAM1 mRNA

NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099

G

progesterone receptor membrane component 1

affects expression

Omeprazole affects the expression of PGRMC1 mRNA

NCBI chr X:35,861,846...35,869,732
Ensembl chr X:35,861,859...35,869,732

G

phytanoyl-CoA hydroxylase

affects expression

Omeprazole affects the expression of PHYH mRNA

NCBI chr 2:4,923,807...4,943,554
Ensembl chr 2:4,923,830...4,943,541

G

phosphatidylinositol glycan anchor biosynthesis, class P

affects expression

Omeprazole affects the expression of PIGP mRNA

NCBI chr16:94,159,622...94,171,874
Ensembl chr16:94,159,622...94,172,701

G

pyruvate kinase liver and red blood cell

affects expression

Omeprazole affects the expression of PKLR mRNA

NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091

G

phospholipase A2, group IVA (cytosolic, calcium-dependent)

increases phosphorylation
multiple interactions

Omeprazole results in increased phosphorylation of PLA2G4A protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Omeprazole results in increased phosphorylation of PLA2G4A protein]

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

G

phospholipase B domain containing 1

affects expression

Omeprazole affects the expression of PLBD1 mRNA

NCBI chr 6:136,589,069...136,639,301
Ensembl chr 6:136,589,068...136,638,926

G

plasminogen

affects expression

Omeprazole affects the expression of PLG mRNA

NCBI chr17:12,597,496...12,638,271
Ensembl chr17:12,597,495...12,638,272

G

plastin 3 (T-isoform)

affects expression

Omeprazole affects the expression of PLS3 mRNA

NCBI chr X:74,829,259...74,918,788
Ensembl chr X:74,829,260...74,918,788

G

paraoxonase 2

affects expression

Omeprazole affects the expression of PON2 mRNA

NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455

G

POU domain, class 2, transcription factor 2

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of POU2F2 protein]

NCBI chr 7:24,790,111...24,879,292
Ensembl chr 7:24,786,769...24,879,151

G

pancreatic progenitor cell differentiation and proliferation factor

affects expression

Omeprazole affects the expression of PPDPF mRNA

NCBI chr 2:180,828,615...180,830,297
Ensembl chr 2:180,829,040...180,830,564

G

peroxiredoxin 2

affects expression

Omeprazole affects the expression of PRDX2 mRNA

NCBI chr 8:85,696,251...85,701,440
Ensembl chr 8:85,696,216...85,701,463

G

peroxiredoxin 6

affects expression

Omeprazole affects the expression of PRDX6 mRNA

NCBI chr 1:161,067,682...161,078,780
Ensembl chr 1:161,067,682...161,078,789

G

prolactin

increases expression

Omeprazole results in increased expression of PRL protein

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

protein C

affects expression

Omeprazole affects the expression of PROC mRNA

NCBI chr18:32,256,179...32,272,623
Ensembl chr18:32,256,179...32,272,623

G

phosphoribosyl pyrophosphate synthetase-associated protein 1

affects expression

Omeprazole affects the expression of PRPSAP1 mRNA

NCBI chr11:116,361,641...116,385,739
Ensembl chr11:116,361,671...116,385,461

G

proteasome subunit alpha 6

affects expression

Omeprazole affects the expression of PSMA6 mRNA

NCBI chr12:55,431,007...55,465,244
Ensembl chr12:55,431,007...55,465,239

G

proteasome (prosome, macropain) subunit, beta type 1

affects expression

Omeprazole affects the expression of PSMB1 mRNA

NCBI chr17:15,695,983...15,718,538
Ensembl chr17:15,695,283...15,720,013

G

proteasome (prosome, macropain) subunit, beta type 3

affects expression

Omeprazole affects the expression of PSMB3 mRNA

NCBI chr11:97,594,260...97,604,326
Ensembl chr11:97,594,225...97,604,326

G

protease (prosome, macropain) 26S subunit, ATPase 1

affects expression

Omeprazole affects the expression of PSMC1 mRNA

NCBI chr12:100,076,461...100,089,623
Ensembl chr12:100,076,413...100,089,664

G

proteasome (prosome, macropain) 26S subunit, ATPase 3

affects expression

Omeprazole affects the expression of PSMC3 mRNA

NCBI chr 2:90,884,361...90,889,783
Ensembl chr 2:90,884,354...90,896,714

G

protease (prosome, macropain) 26S subunit, ATPase 5

affects expression

Omeprazole affects the expression of PSMC5 mRNA

NCBI chr11:106,147,011...106,153,938
Ensembl chr11:106,146,980...106,153,946

G

proteasome (prosome, macropain) 26S subunit, non-ATPase, 1

affects expression

Omeprazole affects the expression of PSMD1 mRNA

NCBI chr 1:85,992,341...86,067,017
Ensembl chr 1:85,992,109...86,066,873

G

proteasome (prosome, macropain) 26S subunit, non-ATPase, 4

affects expression

Omeprazole affects the expression of PSMD4 mRNA

NCBI chr 3:94,939,999...94,949,880
Ensembl chr 3:94,940,005...94,949,925

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA; [Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein
Omeprazole inhibits the reaction [Ethanol results in increased expression of PTGS2 protein]

PMID:23038005 PMID:26970604

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathymosin

affects expression

Omeprazole affects the expression of PTMS mRNA

NCBI chr 6:124,890,638...124,894,909
Ensembl chr 6:124,890,644...124,897,066

G

protein tyrosine phosphatase receptor type F

affects expression

Omeprazole affects the expression of PTPRF mRNA

NCBI chr 4:118,065,410...118,148,602
Ensembl chr 4:118,065,410...118,148,602

G

pituitary tumor-transforming 1 interacting protein

affects expression

Omeprazole affects the expression of PTTG1IP mRNA

NCBI chr10:77,417,489...77,434,566
Ensembl chr10:77,417,554...77,434,566

G

liver glycogen phosphorylase

affects expression

Omeprazole affects the expression of PYGL mRNA

NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262

G

RAB5 interacting factor

affects expression

Omeprazole affects the expression of RAB5IF mRNA

NCBI chr 2:156,705,042...156,715,483
Ensembl chr 2:156,705,048...156,715,483

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of RELA protein]; Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]
Omeprazole inhibits the reaction [Cisplatin affects the localization of RELA protein]

PMID:19251492 PMID:30452898 PMID:32418911

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

retinol saturase (all trans retinol 13,14 reductase)

increases expression

Omeprazole results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

reactive intermediate imine deaminase A homolog

affects expression

Omeprazole affects the expression of RIDA mRNA

NCBI chr15:34,484,168...34,495,392
Ensembl chr15:34,484,167...34,495,401

G

ribonuclease, RNase A family 4

affects expression

Omeprazole affects the expression of RNASE4 mRNA

NCBI chr14:51,328,534...51,343,608
Ensembl chr14:51,328,534...51,343,608

G

ring finger protein 103

affects expression

Omeprazole affects the expression of RNF103 mRNA

NCBI chr 6:71,470,828...71,487,864
Ensembl chr 6:71,470,878...71,487,865

G

RNA binding protein with serine rich domain 1

affects expression

Omeprazole affects the expression of RNPS1 mRNA

NCBI chr17:24,633,620...24,644,872
Ensembl chr17:24,633,539...24,644,875

G

ribosomal protein L11

affects expression

Omeprazole affects the expression of RPL11 mRNA

NCBI chr 4:135,776,665...135,780,704
Ensembl chr 4:135,755,576...135,780,739

G

ribosomal protein L13

affects expression

Omeprazole affects the expression of RPL13 mRNA

NCBI chr 8:123,829,089...123,831,983
Ensembl chr 8:123,829,089...123,831,983

G

ribosomal protein L15

affects expression

Omeprazole affects the expression of RPL15 mRNA

NCBI chr14:4,198,710...4,201,873
Ensembl chr14:4,198,305...4,201,873

G

ribosomal protein L17

affects expression

Omeprazole affects the expression of RPL17 mRNA

NCBI chr18:75,132,049...75,136,455
Ensembl chr18:75,131,629...75,136,452

G

ribosomal protein L23

affects expression

Omeprazole affects the expression of RPL23 mRNA

NCBI chr11:97,668,352...97,673,265
Ensembl chr11:97,668,353...97,673,263

G

ribosomal protein L3

affects expression

Omeprazole affects the expression of RPL3 mRNA

NCBI chr15:79,961,993...79,967,553
Ensembl chr15:79,961,992...79,976,069

G

ribosomal protein L32

affects expression

Omeprazole affects the expression of RPL32 mRNA

NCBI chr 6:115,782,475...115,785,704
Ensembl chr 6:115,782,466...115,785,708

G

ribosomal protein L4

affects expression

Omeprazole affects the expression of RPL4 mRNA

NCBI chr 9:64,080,159...64,085,805
Ensembl chr 9:64,080,657...64,085,948

G

ribophorin II

affects expression

Omeprazole affects the expression of RPN2 mRNA

NCBI chr 2:157,121,018...157,168,238
Ensembl chr 2:157,120,937...157,168,239

G

ribosomal protein S14

affects expression

Omeprazole affects the expression of RPS14 mRNA

NCBI chr18:60,907,668...60,911,618
Ensembl chr18:60,880,170...60,911,618

G

ribosomal protein S18

affects expression

Omeprazole affects the expression of RPS18 mRNA

NCBI chr17:34,170,972...34,174,639
Ensembl chr17:34,170,973...34,174,975

G

ribosomal protein S19

affects expression

Omeprazole affects the expression of RPS19 mRNA

NCBI chr 7:24,584,013...24,589,236
Ensembl chr 7:24,583,796...24,589,231

G

ribosomal protein S20

affects expression

Omeprazole affects the expression of RPS20 mRNA

NCBI chr 4:3,831,334...3,835,600
Ensembl chr 4:3,831,334...3,835,665

G

ribosomal protein S3A1

affects expression

Omeprazole affects the expression of RPS3A mRNA

NCBI chr 3:86,045,247...86,049,975
Ensembl chr 3:86,045,247...86,050,009

G

ribosomal protein S6

affects expression

Omeprazole affects the expression of RPS6 mRNA

NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649

G

ribosomal protein S8

affects expression

Omeprazole affects the expression of RPS8 mRNA

NCBI chr 4:117,011,033...117,013,329
Ensembl chr 4:117,011,024...117,013,440

G

related RAS viral (r-ras) oncogene 2

affects expression

Omeprazole affects the expression of RRAS2 mRNA

NCBI chr 7:113,646,017...113,717,016
Ensembl chr 7:113,646,017...113,717,016

G

sphingosine-1-phosphate receptor 1

affects expression

Omeprazole affects the expression of S1PR1 mRNA

NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721

G

somatomedin B and thrombospondin, type 1 domain containing

affects expression

Omeprazole affects the expression of SBSPON mRNA

NCBI chr 1:15,924,086...15,962,946
Ensembl chr 1:15,924,086...15,962,946

G

syndecan 2

affects expression

Omeprazole affects the expression of SDC2 mRNA

NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081

G

succinate dehydrogenase complex, subunit C, integral membrane protein

affects expression

Omeprazole affects the expression of SDHC mRNA

NCBI chr 1:170,956,726...170,978,209
Ensembl chr 1:170,954,734...170,978,172

G

succinate dehydrogenase complex, subunit D, integral membrane protein

affects expression

Omeprazole affects the expression of SDHD mRNA

NCBI chr 9:50,507,640...50,515,149
Ensembl chr 9:50,507,657...50,515,112

G

selectin, lymphocyte

decreases expression

Omeprazole results in decreased expression of SELL protein

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

serine incorporator 3

affects expression

Omeprazole affects the expression of SERINC3 mRNA

NCBI chr 2:163,466,577...163,487,767
Ensembl chr 2:163,465,192...163,487,051

G

serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10

affects expression

Omeprazole affects the expression of SERPINA10 mRNA

NCBI chr12:103,582,934...103,597,681
Ensembl chr12:103,581,045...103,597,703

G

serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1

affects expression

Omeprazole affects the expression of SERPINA4 mRNA

NCBI chr12:104,044,218...104,053,179
Ensembl chr12:104,046,908...104,052,983

G

serine (or cysteine) peptidase inhibitor, clade F, member 2

affects expression

Omeprazole affects the expression of SERPINF2 mRNA

NCBI chr11:75,322,562...75,330,327
Ensembl chr11:75,322,558...75,330,417

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

decreases expression

Omeprazole results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

sideroflexin 1

affects expression

Omeprazole affects the expression of SFXN1 mRNA

NCBI chr13:54,225,675...54,262,365
Ensembl chr13:54,225,888...54,262,361

G

serine hydroxymethyltransferase 2 (mitochondrial)

affects expression

Omeprazole affects the expression of SHMT2 mRNA

NCBI chr10:127,352,992...127,358,313
Ensembl chr10:127,352,992...127,358,313

G

solute carrier family 22 (organic cation transporter), member 1

affects expression

Omeprazole affects the expression of SLC22A1 mRNA

NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Omeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 22 (organic cation transporter), member 5

multiple interactions

Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions

[Omeprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

solute carrier family 23 (nucleobase transporters), member 1

affects expression

Omeprazole affects the expression of SLC23A1 mRNA

NCBI chr18:35,747,657...35,762,900
Ensembl chr18:35,747,657...35,760,297

G

solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 13

affects expression

Omeprazole affects the expression of SLC25A13 mRNA

NCBI chr 6:6,041,218...6,217,304
Ensembl chr 6:6,041,218...6,217,173

G

solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3

affects expression

Omeprazole affects the expression of SLC25A3 mRNA

NCBI chr10:90,952,436...90,959,902
Ensembl chr10:90,952,436...90,959,921

G

solute carrier family 27 (fatty acid transporter), member 2

affects expression

Omeprazole affects the expression of SLC27A2 mRNA

NCBI chr 2:126,394,944...126,430,163
Ensembl chr 2:126,394,327...126,430,163

G

solute carrier family 39 (metal ion transporter), member 8

affects expression

Omeprazole affects the expression of SLC39A8 mRNA

NCBI chr 3:135,522,644...135,594,333
Ensembl chr 3:135,531,040...135,594,333

G

solute carrier family 40 (iron-regulated transporter), member 1

decreases expression

Omeprazole results in decreased expression of SLC40A1 protein

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

solute carrier family 46, member 1

affects expression

Omeprazole affects the expression of SLC46A1 mRNA

NCBI chr11:78,356,527...78,362,771
Ensembl chr11:78,356,523...78,362,885

G

solute carrier family 66 member 2

affects expression

Omeprazole affects the expression of SLC66A2 mRNA

NCBI chr18:80,298,458...80,335,940
Ensembl chr18:80,296,507...80,335,940

G

solute carrier family 6 (neurotransmitter transporter, taurine), member 6

affects expression

Omeprazole affects the expression of SLC6A6 mRNA

NCBI chr 6:91,661,031...91,736,044
Ensembl chr 6:91,661,034...91,736,047

G

solute carrier organic anion transporter family, member 1a5

increases expression

Omeprazole results in increased expression of SLCO1A2 mRNA

NCBI chr 6:142,179,953...142,268,707
Ensembl chr 6:142,179,953...142,268,707

G

superoxide dismutase 1, soluble

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in decreased activity of SOD1 protein]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

signal peptide peptidase like 2A

affects expression

Omeprazole affects the expression of SPPL2A mRNA

NCBI chr 2:126,732,311...126,775,706
Ensembl chr 2:126,732,311...126,775,155

G

spermidine synthase

affects expression

Omeprazole affects the expression of SRM mRNA

NCBI chr 4:148,675,970...148,679,076
Ensembl chr 4:148,675,960...148,679,450

G

signal recognition particle receptor, B subunit

affects expression

Omeprazole affects the expression of SRPRB mRNA

NCBI chr 9:103,065,232...103,079,264
Ensembl chr 9:103,065,231...103,079,336

G

SSX family member 2 interacting protein

affects expression

Omeprazole affects the expression of SSX2IP mRNA

NCBI chr 3:146,110,397...146,145,899
Ensembl chr 3:146,110,397...146,145,899

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

affects expression

Omeprazole affects the expression of ST3GAL6 mRNA

NCBI chr16:58,290,105...58,344,614
Ensembl chr16:58,288,488...58,344,606

G

beta galactoside alpha 2,6 sialyltransferase 1

affects expression

Omeprazole affects the expression of ST6GAL1 mRNA

NCBI chr16:23,043,478...23,179,100
Ensembl chr16:23,043,490...23,179,100

G

succinate-CoA ligase, GDP-forming, alpha subunit

affects expression

Omeprazole affects the expression of SUCLG1 mRNA

NCBI chr 6:73,225,488...73,253,890
Ensembl chr 6:73,225,365...73,253,894

G

surfeit gene 4

affects expression

Omeprazole affects the expression of SURF4 mRNA

NCBI chr 2:26,810,052...26,823,801
Ensembl chr 2:26,810,052...26,823,940

G

synaptojanin 2 binding protein

affects expression

Omeprazole affects the expression of SYNJ2BP mRNA

NCBI chr12:81,538,968...81,579,685
Ensembl chr12:81,544,715...81,579,685

G

tachykinin receptor 1

multiple interactions

Omeprazole inhibits the reaction [Acids affects the localization of TACR1 protein]

NCBI chr 6:82,378,990...82,537,085
Ensembl chr 6:82,379,315...82,537,085

G

transforming growth factor, beta 1

increases expression

Omeprazole results in increased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta induced

affects expression

Omeprazole affects the expression of TGFBI mRNA

NCBI chr13:56,757,399...56,787,172
Ensembl chr13:56,757,336...56,787,375

G

threonine synthase-like 2 (bacterial)

affects expression

Omeprazole affects the expression of THNSL2 mRNA

NCBI chr 6:71,105,150...71,121,364
Ensembl chr 6:71,105,150...71,121,423

G

translocase of inner mitochondrial membrane 21

affects expression

Omeprazole affects the expression of TIMM21 mRNA

NCBI chr18:84,964,316...84,970,168
Ensembl chr18:84,964,316...84,969,649

G

tissue inhibitor of metalloproteinase 2

multiple interactions

Omeprazole inhibits the reaction [Indomethacin results in increased expression of TIMP2 protein]

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

triokinase, FMN cyclase

affects expression

Omeprazole affects the expression of TKFC mRNA

NCBI chr19:10,565,153...10,583,257
Ensembl chr19:10,565,155...10,583,018

G

toll-like receptor 4

multiple interactions

Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

transmembrane BAX inhibitor motif containing 1

affects expression

Omeprazole affects the expression of TMBIM1 mRNA

NCBI chr 1:74,327,406...74,343,495
Ensembl chr 1:74,327,406...74,344,781

G

transmembrane and coiled-coil domains 1

affects expression

Omeprazole affects the expression of TMCO1 mRNA

NCBI chr 1:167,136,239...167,161,547
Ensembl chr 1:167,135,947...167,161,547

G

transmembrane p24 trafficking protein 2

affects expression

Omeprazole affects the expression of TMED2 mRNA

NCBI chr 5:124,678,835...124,688,566
Ensembl chr 5:124,678,758...124,688,569

G

transmembrane p24 trafficking protein 7

affects expression

Omeprazole affects the expression of TMED7 mRNA

NCBI chr18:46,718,995...46,730,602
Ensembl chr18:46,693,302...46,730,602

G

transmembrane protein 123

affects expression

Omeprazole affects the expression of TMEM123 mRNA

NCBI chr 9:7,764,078...7,794,334
Ensembl chr 9:7,764,042...7,794,334

G

transmembrane protein 97

affects expression

Omeprazole affects the expression of TMEM97 mRNA

NCBI chr11:78,432,643...78,441,561
Ensembl chr11:78,432,643...78,441,603

G

tumor necrosis factor

multiple interactions

Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein]
Omeprazole inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of TNF protein]

PMID:19232345 PMID:25637687 PMID:26970604 PMID:30452898 PMID:32418911

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

thioredoxin 1

affects expression

Omeprazole affects the expression of TXN1 mRNA

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

G

thioredoxin-like 1

affects expression

Omeprazole affects the expression of TXNL1 mRNA

NCBI chr18:63,795,872...63,825,535
Ensembl chr18:63,794,165...63,841,872

G

tyrosinase

multiple interactions
decreases expression

Omeprazole affects the N-linked glycosylation of and results in increased degradation of TYR protein; Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein]
Omeprazole results in decreased expression of TYR protein

NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720

G

ubiquitin A-52 residue ribosomal protein fusion product 1

affects expression

Omeprazole affects the expression of UBA52 mRNA

NCBI chr 8:70,960,913...70,963,067
Ensembl chr 8:70,960,913...70,963,451

G

ubiquitin-conjugating enzyme E2N

affects expression

Omeprazole affects the expression of UBE2N mRNA

NCBI chr10:95,351,024...95,381,520
Ensembl chr10:95,351,007...95,381,519

G

ubiquitin recognition factor in ER-associated degradation 1

affects expression

Omeprazole affects the expression of UFD1 mRNA

NCBI chr16:18,630,486...18,654,011
Ensembl chr16:18,630,529...18,654,011

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression
affects expression

Omeprazole results in increased expression of UGT1A1 mRNA
Omeprazole affects the expression of UGT1A1 mRNA

PMID:19118567 PMID:19483382 PMID:25626140

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glycosyltransferase 1 family, polypeptide A10

increases expression

Omeprazole results in increased expression of UGT1A10 mRNA

NCBI chr 1:87,983,133...88,147,724
Ensembl chr 1:87,983,110...88,146,726

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Omeprazole results in increased expression of UGT1A2 mRNA; Omeprazole results in increased expression of UGT1A3 mRNA

NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A5

increases expression

Omeprazole results in increased expression of UGT1A4 mRNA

NCBI chr 1:88,093,734...88,147,724
Ensembl chr 1:88,093,734...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

increases expression
multiple interactions

Omeprazole results in increased expression of UGT1A6 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of UGT1A6 mRNA

PMID:19118567 PMID:22687989

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UDP glucuronosyltransferase 1 family, polypeptide A9

increases expression

Omeprazole results in increased expression of UGT1A9 mRNA

NCBI chr 1:87,998,501...88,147,724
Ensembl chr 1:87,998,522...88,146,719

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

Omeprazole results in increased expression of UGT2B1 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

ubiquinol-cytochrome c reductase, complex III subunit XI

affects expression

Omeprazole affects the expression of UQCR11 mRNA

NCBI chr10:80,238,831...80,242,655
Ensembl chr10:80,238,831...80,242,664

G

vanin 1

affects expression

Omeprazole affects the expression of VNN1 mRNA

NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241

G

WD repeat domain 26

affects expression

Omeprazole affects the expression of WDR26 mRNA

NCBI chr 1:181,000,791...181,046,211
Ensembl chr 1:181,000,793...181,039,566

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide

affects expression

Omeprazole affects the expression of YWHAG mRNA

NCBI chr 5:135,937,233...135,963,495
Ensembl chr 5:135,937,263...135,963,470

G

zinc finger, DHHC domain containing 23

affects expression

Omeprazole affects the expression of ZDHHC23 mRNA

NCBI chr16:43,785,396...43,800,295
Ensembl chr16:43,785,396...43,800,154

G

zona pellucida 3 receptor

decreases expression
affects expression

Omeprazole results in decreased expression of C4BPA mRNA
Omeprazole affects the expression of C4BPA mRNA

PMID:19483382 PMID:25626140

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

G

ZW10 interactor

affects expression

Omeprazole affects the expression of ZWINT mRNA

NCBI chr10:72,490,678...72,510,796
Ensembl chr10:72,490,677...72,510,796

albendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase 7

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of ADCY7 mRNA

NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590

G

ADP-ribosylation factor-like 4C

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of ARL4C mRNA

NCBI chr 1:88,625,947...88,629,913
Ensembl chr 1:88,600,847...88,629,943

G

BCL2-associated athanogene 3

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of BAG3 mRNA

NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705

G

C-C motif chemokine ligand 2

increases expression

Albendazole results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 3

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of CCL3 protein

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine receptor 7

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of CCR7 mRNA

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

chaperonin containing TCP1 subunit 3

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of CCT3 mRNA

NCBI chr 3:88,204,442...88,229,073
Ensembl chr 3:88,204,423...88,229,074

G

CD86 antigen

multiple interactions

[Albendazole co-treated with CYP3A4 protein] results in increased expression of CD86 protein

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cathepsin L

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of CTSL mRNA

NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704

G

C-X-C motif chemokine ligand 15

increases expression
multiple interactions
increases secretion

Albendazole results in increased expression of CXCL8 protein
[Ivermectin co-treated with Albendazole] results in increased expression of CXCL8 protein; U 0126 inhibits the reaction [Albendazole results in increased secretion of CXCL8 protein]

PMID:16861626 PMID:20116850 PMID:20848085

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
decreases activity
increases expression

Albendazole results in increased activity of CYP1A1 promoter; Albendazole results in increased activity of CYP1A1 protein
Albendazole results in decreased activity of CYP1A1 protein
Albendazole results in increased expression of CYP1A1 mRNA

PMID:12451431 PMID:16714371 PMID:18502397 PMID:33814510

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
affects metabolic processing

Albendazole results in increased expression of CYP1A2 mRNA
CYP1A2 protein affects the metabolism of Albendazole

PMID:12451431 PMID:12920490

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Albendazole results in decreased activity of CYP1B1 protein

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of DNAJB1 mRNA

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

dihydropyrimidinase-like 2

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of DPYSL2 mRNA

NCBI chr14:67,040,313...67,148,490
Ensembl chr14:67,040,313...67,148,410

G

GTP binding protein overexpressed in skeletal muscle

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of GEM mRNA

NCBI chr 4:11,702,379...11,714,993
Ensembl chr 4:11,704,457...11,714,752

G

G protein-coupled receptor 183

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of GPR183 mRNA

NCBI chr14:122,189,743...122,202,605
Ensembl chr14:122,189,963...122,202,607

G

histocompatibility 2, class II, locus Mb1

affects expression

Albendazole affects the expression of HLA-DMB mRNA

NCBI chr17:34,372,165...34,379,203
Ensembl chr17:34,372,046...34,379,204

G

heat shock factor 1

increases activity

Albendazole results in increased activity of HSF1 protein

NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113

G

heat shock protein 90, alpha (cytosolic), class A member 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AA1 mRNA

NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162

G

heat shock protein 90 alpha (cytosolic), class B member 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSP90AB1 mRNA

NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197

G

heat shock protein 4

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSPA4 mRNA

NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284

G

heat shock protein 8

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 1 (chaperonin)

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSPD1 mRNA

NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402

G

heat shock protein 1 (chaperonin 10)

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSPE1 mRNA

NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466

G

heat shock 105kDa/110kDa protein 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of HSPH1 mRNA

NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841

G

intercellular adhesion molecule 1

multiple interactions

[Albendazole co-treated with CYP3A4 protein] results in increased expression of ICAM1 protein

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

interleukin 10

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 alpha

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of IL1A protein

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 receptor, type I

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of IL1R1 mRNA

NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417

G

interleukin 6 receptor, alpha

increases expression

Albendazole results in increased expression of IL6R protein modified form

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

mitogen-activated protein kinase kinase kinase 8

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of MAP3K8 mRNA

NCBI chr18:4,331,325...4,352,978
Ensembl chr18:4,331,327...4,353,015

G

microtubule-associated protein tau

decreases expression

Albendazole results in decreased expression of MAPT mRNA; Albendazole results in decreased expression of MAPT protein

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Albendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

peptidylprolyl isomerase D (cyclophilin D)

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of PPID mRNA

NCBI chr 3:79,498,644...79,511,117
Ensembl chr 3:79,498,649...79,510,957

G

peptidylprolyl isomerase F (cyclophilin F)

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of PPIF mRNA

NCBI chr14:25,693,998...25,700,892
Ensembl chr14:25,694,578...25,700,892

G

prostaglandin E synthase 3

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of PTGES3 mRNA

NCBI chr10:127,894,851...127,913,123
Ensembl chr10:127,894,823...127,913,141

G

src family associated phosphoprotein 2

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of SKAP2 mRNA

NCBI chr 6:51,836,145...51,989,529
Ensembl chr 6:51,834,402...51,989,529

G

superoxide dismutase 2, mitochondrial

multiple interactions

[SOD2 co-treated with CYP3A4] affects the susceptibility to Albendazole

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

sphingosine kinase 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of SPHK1 mRNA

NCBI chr11:116,421,662...116,427,502
Ensembl chr11:116,421,751...116,427,501

G

suppression of tumorigenicity 13

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of ST13 mRNA

NCBI chr15:81,247,869...81,284,278
Ensembl chr15:81,247,870...81,284,278

G

t-complex protein 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in increased expression of TCP1 mRNA

NCBI chr17:13,135,216...13,143,954
Ensembl chr17:13,134,588...13,143,954

G

TGFB-induced factor homeobox 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of TGIF1 mRNA

NCBI chr17:71,151,200...71,160,527
Ensembl chr17:71,151,200...71,160,541

G

tumor necrosis factor

multiple interactions
increases secretion

U 0126 inhibits the reaction [Albendazole results in increased secretion of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

affects activity

Albendazole affects the activity of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

TSC22 domain family, member 1

multiple interactions

[Ivermectin co-treated with Albendazole] results in decreased expression of TSC22D1 mRNA

NCBI chr14:76,652,401...76,745,205
Ensembl chr14:76,652,401...76,745,205

G

vascular endothelial growth factor A

increases expression

Albendazole results in increased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

albendazole S-oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2 (Junior blood group)

affects transport

ABCG2 protein affects the transport of albendazole sulfoxide

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

albendazole sulfoxide inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

transformation related protein 53

affects activity

albendazole sulfoxide affects the activity of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

astemizole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

multiple interactions
decreases activity

Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Astemizole results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

adenylate kinase 3

increases expression

Astemizole results in increased expression of AK3 mRNA

NCBI chr19:28,968,715...29,026,122
Ensembl chr19:28,998,233...29,025,361

G

aminolevulinic acid synthase 2, erythroid

increases expression

Astemizole results in increased expression of ALAS2 mRNA

NCBI chr X:149,330,443...149,353,614
Ensembl chr X:149,330,371...149,353,634

G

angiopoietin 2

increases expression

Astemizole results in increased expression of ANGPT2 mRNA

NCBI chr 8:18,740,279...18,791,578
Ensembl chr 8:18,740,279...18,791,578

G

activating transcription factor 3

increases expression

Astemizole results in increased expression of ATF3 mRNA

NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

increases expression

Astemizole results in increased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Na+/K+ transporting, beta 2 polypeptide

decreases expression

Astemizole results in decreased expression of ATP1B2 mRNA

NCBI chr11:69,490,554...69,496,786
Ensembl chr11:69,490,562...69,496,768

G

ATP synthase F1 subunit epsilon

increases expression

Astemizole results in increased expression of ATP5F1E mRNA

NCBI chr 2:174,302,868...174,305,894
Ensembl chr 2:174,302,865...174,305,898

G

B cell leukemia/lymphoma 2

decreases expression

Astemizole results in decreased expression of BCL2 mRNA

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

bone morphogenetic protein 1

decreases expression

Astemizole results in decreased expression of BMP1 mRNA

NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674

G

calcium/calmodulin-dependent protein kinase II, delta

decreases expression

Astemizole results in decreased expression of CAMK2D mRNA

NCBI chr 3:126,389,136...126,639,975
Ensembl chr 3:126,389,951...126,639,975

G

catalase

increases expression

Astemizole results in increased expression of CAT mRNA

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine ligand 7

decreases expression

Astemizole results in decreased expression of CCL7 mRNA

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

CCAAT/enhancer binding protein beta

increases expression

Astemizole results in increased expression of CEBPB mRNA

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

CCAAT/enhancer binding protein gamma

decreases expression

Astemizole results in decreased expression of CEBPG mRNA

NCBI chr 7:34,745,847...34,755,991
Ensembl chr 7:34,745,847...34,755,998

G

complement component factor h

decreases expression

Astemizole results in decreased expression of CFH mRNA

NCBI chr 1:140,013,593...140,111,149
Ensembl chr 1:140,012,446...140,111,502

G

collectin sub-family member 12

decreases expression

Astemizole results in decreased expression of COLEC12 mRNA

NCBI chr18:9,707,648...9,877,995
Ensembl chr18:9,707,595...9,882,644

G

corticotropin releasing hormone

multiple interactions

Astemizole inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]

NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560

G

C-X-C motif chemokine ligand 3

decreases expression

Astemizole results in decreased expression of CXCL3 mRNA

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

C-X-C motif chemokine ligand 9

decreases expression

Astemizole results in decreased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

cytochrome P450, family 2, subfamily j, polypeptide 9

decreases methylation
multiple interactions
increases metabolic processing

CYP2J2 protein results in decreased methylation of Astemizole
Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole]; ebastine inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole]
CYP2J2 protein results in increased metabolism of Astemizole

PMID:12386130 PMID:15861034 PMID:17162467

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

ELL associated factor 1

increases expression

Astemizole results in increased expression of EAF1 mRNA

NCBI chr14:31,217,036...31,231,815
Ensembl chr14:31,216,356...31,231,815

G

egl-9 family hypoxia-inducible factor 1

increases expression

Astemizole results in increased expression of EGLN1 mRNA

NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063

G

eukaryotic translation initiation factor 4A1

increases expression

Astemizole results in increased expression of EIF4A1 mRNA

NCBI chr11:69,557,762...69,563,249
Ensembl chr11:69,557,762...69,563,249

G

ERBB receptor feedback inhibitor 1

decreases expression

Astemizole results in decreased expression of ERRFI1 mRNA

NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349

G

ets variant 5

decreases expression

Astemizole results in decreased expression of ETV5 mRNA

NCBI chr16:22,200,063...22,258,320
Ensembl chr16:22,200,059...22,258,469

G

family with sequence similarity 124, member A

increases expression

Astemizole results in increased expression of FAM124A mRNA

NCBI chr14:62,793,186...62,845,935
Ensembl chr14:62,793,186...62,845,935

G

Fc receptor, IgE, high affinity I, alpha polypeptide

multiple interactions

Astemizole inhibits the reaction [FCER1A protein results in increased secretion of HEXB protein]

NCBI chr 1:173,048,836...173,054,799
Ensembl chr 1:173,048,851...173,054,781

G

growth differentiation factor 10

increases expression

Astemizole results in increased expression of GDF10 mRNA

NCBI chr14:33,645,544...33,658,471
Ensembl chr14:33,645,544...33,659,940

G

GTPase, IMAP family member 1

increases expression

Astemizole results in increased expression of GIMAP1 mRNA

NCBI chr 6:48,715,981...48,720,729
Ensembl chr 6:48,715,988...48,720,729

G

glycoprotein m6b

increases expression

Astemizole results in increased expression of GPM6B mRNA

NCBI chr X:165,021,911...165,172,028
Ensembl chr X:165,021,907...165,171,984

G

glutathione peroxidase 4

increases expression

Astemizole results in increased expression of GPX4 mRNA

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

hexosaminidase B

increases secretion
multiple interactions

Astemizole results in increased secretion of HEXB protein
Astemizole inhibits the reaction [FCER1A protein results in increased secretion of HEXB protein]

NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865

G

heme oxygenase 1

increases expression

Astemizole results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

histamine receptor H1

multiple interactions

[Astemizole binds to and results in decreased activity of HRH1 protein] which affects the susceptibility to Aminophylline
Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]

PMID:12147327 PMID:16129921

NCBI chr 6:114,374,897...114,459,432
Ensembl chr 6:114,374,897...114,460,257

G

heat shock protein 90 alpha (cytosolic), class B member 1

decreases expression

Astemizole results in decreased expression of HSP90AB1 mRNA

NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197

G

heat shock protein 8

increases expression

Astemizole results in increased expression of HSPA8 mRNA

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 8

increases expression

Astemizole results in increased expression of HSPB8 mRNA

NCBI chr 5:116,546,550...116,560,923
Ensembl chr 5:116,546,550...116,560,923

G

heat shock 105kDa/110kDa protein 1

decreases expression

Astemizole results in decreased expression of HSPH1 mRNA

NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841

G

intercellular adhesion molecule 1

multiple interactions

Astemizole inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

Astemizole results in decreased expression of IFIT3 mRNA

NCBI chr19:34,560,519...34,566,382
Ensembl chr19:34,560,931...34,566,131

G

insulin-like growth factor 1

multiple interactions

Astemizole inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein]

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

immunoglobulin superfamily, member 6

decreases expression

Astemizole results in decreased expression of IGSF6 mRNA

NCBI chr 7:120,663,290...120,673,753
Ensembl chr 7:120,663,290...120,673,795

G

interleukin 1 beta

multiple interactions

Astemizole inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Astemizole inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 36 receptor antagonist

increases expression

Astemizole results in increased expression of IL36RN mRNA

NCBI chr 2:24,166,966...24,172,444
Ensembl chr 2:24,166,966...24,173,438

G

interleukin 7 receptor

decreases expression

Astemizole results in decreased expression of IL7R mRNA

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

integrin alpha 8

increases expression

Astemizole results in increased expression of ITGA8 mRNA

NCBI chr 2:12,111,443...12,306,755
Ensembl chr 2:12,111,443...12,306,733

G

potassium voltage-gated channel, subfamily H (eag-related), member 1

multiple interactions
decreases activity
affects binding

Astemizole binds to and results in decreased activity of KCNH1 protein; Astemizole inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein]
Astemizole results in decreased activity of KCNH1 protein
Astemizole binds to KCNH1 protein

PMID:14985237 PMID:16816845 PMID:17520698 PMID:18471075 PMID:18497958 More...

NCBI chr 1:191,871,759...192,192,467
Ensembl chr 1:191,873,082...192,192,467

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions
affects binding
decreases activity
affects localization

Astemizole binds to and results in decreased activity of KCNH2 protein; Astemizole inhibits the reaction [arsenic trioxide results in increased degradation of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased activity of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased metabolism of KCNH2 protein modified form]; Astemizole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; dofetilide analog inhibits the reaction [Astemizole binds to KCNH2 protein]; Hydrogen Peroxide inhibits the reaction [Astemizole results in decreased activity of KCNH2 protein mutant form]; Potassium promotes the reaction [Astemizole binds to KCNH2 protein]
Astemizole binds to KCNH2 gene polymorphism; Astemizole binds to KCNH2 protein
Astemizole affects the localization of KCNH2 protein mutant form

PMID:8641472 PMID:9658196 PMID:10376921 PMID:10422790 PMID:10531299 More...

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

potassium voltage-gated channel, subfamily Q, member 2

multiple interactions

Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]

NCBI chr 2:180,717,372...180,777,368
Ensembl chr 2:180,717,372...180,777,093

G

potassium voltage-gated channel, subfamily Q, member 3

multiple interactions

Astemizole inhibits the reaction [Histamine results in decreased activity of [KCNQ2 protein co-treated with KCNQ3 protein co-treated with HRH1 protein]]

NCBI chr15:65,858,223...66,158,485
Ensembl chr15:65,858,236...66,158,491

G

monoamine oxidase A

decreases expression

Astemizole results in decreased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

microtubule-associated protein tau

affects binding

Astemizole binds to MAPT protein alternative form

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

matrix metallopeptidase 2

decreases expression

Astemizole results in decreased expression of MMP2 mRNA

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

membrane-spanning 4-domains, subfamily A, member 6C

decreases expression

Astemizole results in decreased expression of MS4A6A mRNA

NCBI chr19:11,446,718...11,464,433
Ensembl chr19:11,446,730...11,459,556

G

metallothionein 2

increases expression

Astemizole results in increased expression of MT2A mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

metal response element binding transcription factor 1

multiple interactions

MTF1 protein affects the reaction [Astemizole results in increased expression of MT1M mRNA]

NCBI chr 4:124,696,342...124,743,593
Ensembl chr 4:124,695,897...124,743,593

G

mitochondrial tumor suppressor 1

decreases expression

Astemizole results in decreased expression of MTUS1 mRNA

NCBI chr 8:41,443,949...41,587,318
Ensembl chr 8:41,443,951...41,586,763

G

myosin, heavy polypeptide 6, cardiac muscle, alpha

increases expression

Astemizole results in increased expression of MYH6 mRNA

NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384

G

NADH:ubiquinone oxidoreductase core subunit S7

increases expression

Astemizole results in increased expression of NDUFS7 mRNA

NCBI chr10:80,084,939...80,092,628
Ensembl chr10:80,084,955...80,092,628

G

NADH:ubiquinone oxidoreductase core subunit V2

increases expression

Astemizole results in increased expression of NDUFV2 mRNA

NCBI chr17:66,385,790...66,408,554
Ensembl chr17:66,385,633...66,408,554

G

N-terminal EF-hand calcium binding protein 1

decreases expression

Astemizole results in decreased expression of NECAB1 mRNA

NCBI chr 4:14,952,245...15,149,804
Ensembl chr 4:14,952,245...15,149,794

G

nuclear receptor subfamily 4, group A, member 3

increases expression

Astemizole results in increased expression of NR4A3 mRNA

NCBI chr 4:48,045,098...48,086,446
Ensembl chr 4:48,045,153...48,086,447

G

2'-5' oligoadenylate synthetase-like 1

decreases expression

Astemizole results in decreased expression of OASL1 mRNA

NCBI chr 5:115,061,236...115,075,970
Ensembl chr 5:115,061,299...115,075,974

G

oxysterol binding protein-like 3

increases expression

Astemizole results in increased expression of OSBPL3 mRNA

NCBI chr 6:50,270,307...50,433,334
Ensembl chr 6:50,270,310...50,433,181

G

O-sialoglycoprotein endopeptidase-like 1

increases expression

Astemizole results in increased expression of OSGEPL1 mRNA

NCBI chr 1:53,352,070...53,365,502
Ensembl chr 1:53,352,783...53,365,502

G

Parkinson disease (autosomal recessive, early onset) 7

increases expression

Astemizole results in increased expression of PARK7 mRNA

NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894

G

protocadherin 17

decreases expression

Astemizole results in decreased expression of PCDH17 mRNA

NCBI chr14:84,680,626...84,775,005
Ensembl chr14:84,681,003...84,776,442

G

pellino 2

increases expression

Astemizole results in increased expression of PELI2 mRNA

NCBI chr14:48,358,096...48,519,035
Ensembl chr14:48,358,280...48,519,032

G

proteasome (prosome, macropain) subunit, beta type 5

increases expression

Astemizole results in increased expression of PSMB5 mRNA

NCBI chr14:54,851,577...54,855,452
Ensembl chr14:54,851,576...54,855,479

G

prostaglandin-endoperoxide synthase 1

decreases expression

Astemizole results in decreased expression of PTGS1 mRNA

NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284

G

pyrroline-5-carboxylate reductase 3

increases expression

Astemizole results in increased expression of PYCR3 mRNA

NCBI chr15:75,788,319...75,793,369
Ensembl chr15:75,788,326...75,793,409

G

muscle glycogen phosphorylase

increases expression

Astemizole results in increased expression of PYGM mRNA

NCBI chr19:6,434,438...6,448,494
Ensembl chr19:6,434,429...6,448,489

G

S100 calcium binding protein A8 (calgranulin A)

increases expression

Astemizole results in increased expression of S100A8 mRNA

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

G

S100 protein, beta polypeptide, neural

decreases expression

Astemizole results in decreased expression of S100B mRNA

NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993

G

salt inducible kinase 1

decreases expression

Astemizole results in decreased expression of SIK1 mRNA

NCBI chr17:32,063,222...32,074,808
Ensembl chr17:32,063,224...32,074,778

G

solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1

increases expression

Astemizole results in increased expression of SLC1A1 mRNA

NCBI chr19:28,812,535...28,891,360
Ensembl chr19:28,812,449...28,891,360

G

superoxide dismutase 2, mitochondrial

increases expression

Astemizole results in increased expression of SOD2 mRNA

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

sequestosome 1

increases expression

Astemizole results in increased expression of SQSTM1 mRNA

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

transforming growth factor, beta 2

increases expression

Astemizole results in increased expression of TGFB2 mRNA

NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186

G

toll-like receptor 2

decreases expression

Astemizole results in decreased expression of TLR2 mRNA

NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074

G

toll-like receptor 7

decreases expression

Astemizole results in decreased expression of TLR7 mRNA

NCBI chr X:166,086,376...166,113,570
Ensembl chr X:166,087,925...166,113,554

G

tropomodulin 1

increases expression

Astemizole results in increased expression of TMOD1 mRNA

NCBI chr 4:46,038,940...46,116,032
Ensembl chr 4:46,038,935...46,116,032

G

transferrin

decreases expression

Astemizole results in decreased expression of TF mRNA

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

vascular cell adhesion molecule 1

multiple interactions

Astemizole inhibits the reaction [IL1B protein results in increased expression of VCAM1 protein]

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

versican

decreases expression

Astemizole results in decreased expression of VCAN mRNA

NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628

azilsartan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated X protein

multiple interactions

[Zinc Sulfate binds to azilsartan] which results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

BCL2-like 1

multiple interactions

[Zinc Sulfate binds to azilsartan] which results in decreased expression of BCL2L1 protein

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

caspase 9

multiple interactions

[Zinc Sulfate binds to azilsartan] which results in increased expression of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

benomyl

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

a disintegrin and metallopeptidase domain 33

increases expression
multiple interactions

Benomyl results in increased expression of ADAM33 protein
ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]

NCBI chr 2:130,892,739...130,905,734
Ensembl chr 2:130,892,511...130,905,734

G

thymoma viral proto-oncogene 1

decreases expression

Benomyl results in decreased expression of AKT1 mRNA

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

aldehyde dehydrogenase 2, mitochondrial

decreases activity

Benomyl metabolite results in decreased activity of ALDH2 protein; Benomyl results in decreased activity of ALDH2 protein

PMID:9585485 PMID:10513990 PMID:11142365 PMID:15331769 PMID:17010440

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldhehyde dehydrogenase family 5, subfamily A1

decreases activity

Benomyl results in decreased activity of ALDH5A1 protein

NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
Ensembl chr13:25,091,562...25,121,644

G

adenosine monophosphate deaminase 3

decreases expression

Benomyl results in decreased expression of AMPD3 mRNA

NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612

G

androgen receptor

multiple interactions

Benomyl inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

BCL2-associated X protein

multiple interactions

Benomyl inhibits the reaction [BCL2 protein binds to BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions
increases phosphorylation

Benomyl inhibits the reaction [BCL2 protein binds to BAX protein]
Benomyl results in increased phosphorylation of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BUB1B, mitotic checkpoint serine/threonine kinase

increases expression

Benomyl results in increased expression of BUB1B protein

NCBI chr 2:118,428,684...118,472,073
Ensembl chr 2:118,428,692...118,472,072

G

carbonic anhydrase 2

increases expression

Benomyl results in increased expression of CA2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

C-C motif chemokine ligand 17

increases expression
multiple interactions

Benomyl results in increased expression of CCL17 mRNA
ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]

NCBI chr 8:95,535,996...95,538,666
Ensembl chr 8:95,537,081...95,538,664

G

cyclin B1

increases response to substance

CCNB1 protein results in increased susceptibility to Benomyl

NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078

G

cyclin B2

increases response to substance

CCNB2 protein results in increased susceptibility to Benomyl

NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829

G

CD38 antigen

decreases expression

Benomyl results in decreased expression of CD38 mRNA

NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717

G

C-X-C motif chemokine ligand 15

multiple interactions
increases expression

ORMDL3 protein affects the reaction [Benomyl results in increased expression of CXCL8 mRNA]

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
multiple interactions

Benomyl results in decreased expression of CYP17A1 mRNA
Benomyl results in decreased expression of and results in decreased activity of CYP17A1 protein

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity
increases expression

Benomyl results in increased activity of CYP19A1 protein
Benomyl results in increased expression of CYP19A1 mRNA

PMID:14691014 PMID:25543211

NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

Benomyl results in increased expression of DDIT3 protein
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of DDIT3 protein]

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases expression
multiple interactions

Benomyl results in increased expression of EIF2AK3 protein
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of EIF2AK3 protein]

NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229

G

endoplasmic reticulum to nucleus signalling 1

increases expression
multiple interactions

Benomyl results in increased expression of ERN1 protein
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ERN1 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ERN1 protein]

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

estrogen receptor 1 (alpha)

multiple interactions
affects binding

Benomyl binds to and results in increased activity of ESR1 protein; Benomyl inhibits the reaction [Estradiol binds to ESR1 protein]
Benomyl binds to ESR1 protein

PMID:14579009 PMID:16626760

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

fibroblast growth factor receptor 4

increases expression

Benomyl results in increased expression of FGFR4 mRNA

NCBI chr13:55,300,631...55,316,572
Ensembl chr13:55,300,453...55,316,572

G

GIPC PDZ domain containing family, member 1

increases expression

Benomyl results in increased expression of GIPC1 mRNA

NCBI chr 8:84,376,037...84,391,418
Ensembl chr 8:84,379,306...84,391,323

G

glycine-N-acyltransferase

increases expression

Benomyl results in increased expression of GLYAT mRNA

NCBI chr19:12,610,672...12,629,101
Ensembl chr19:12,610,672...12,631,275

G

histone deacetylase 1

decreases activity

Benomyl results in decreased activity of HDAC1 protein

NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506

G

heat shock protein 5

increases expression
multiple interactions

Benomyl results in increased expression of HSPA5 protein
Acetylcysteine inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of HSPA5 protein]

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

heat shock protein 1

increases expression

Benomyl results in increased expression of HSPB1 mRNA

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

interferon beta 1, fibroblast

multiple interactions

Benomyl inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]

NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011

G

integrin alpha 5 (fibronectin receptor alpha)

decreases expression

Benomyl results in decreased expression of ITGA5 mRNA

NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190

G

integrin beta 1 (fibronectin receptor beta)

decreases expression

Benomyl results in decreased expression of ITGB1 mRNA

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

G

mitogen-activated protein kinase 8

increases expression

Benomyl results in increased expression of MAPK8 mRNA

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

microRNA 21a

decreases expression

Benomyl results in decreased expression of MIR21 mRNA

NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984

G

matrix metallopeptidase 2

decreases expression
multiple interactions
increases expression

Benomyl results in decreased expression of MMP2 mRNA
ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]

PMID:25530041 PMID:27784618

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

decreases expression

Benomyl results in decreased expression of MMP9 protein
Benomyl results in decreased expression of MMP9 mRNA

PMID:10026946 PMID:25530041

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

multimerin 1

increases expression

Benomyl results in increased expression of MMRN1 mRNA

NCBI chr 6:60,921,301...60,966,362
Ensembl chr 6:60,901,960...60,966,362

G

beta-microseminoprotein

increases expression

Benomyl results in increased expression of MSMB mRNA

NCBI chr14:31,863,980...31,880,284
Ensembl chr14:31,863,980...31,880,327

G

metallothionein 2

increases expression

Benomyl results in increased expression of MT2A mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

Benomyl inhibits the reaction [Lipopolysaccharides results in increased activity of NFKB1 protein]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Benomyl inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

olfactory receptor family 13 subfamily P member 4

increases expression

Benomyl results in increased expression of OR13P4 mRNA

NCBI chr 4:118,546,349...118,550,231
Ensembl chr 4:118,544,683...118,549,953

G

ORM1-like 3 (S. cerevisiae)

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; MitoTEMPO inhibits the reaction [Benomyl results in increased expression of ORMDL3 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of ADAM33 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CCL17 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of CXCL8 mRNA]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of MMP2 protein]; ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]

NCBI chr11:98,472,120...98,478,071
Ensembl chr11:98,472,082...98,478,194

G

Parkinson disease (autosomal recessive, early onset) 7

decreases activity

Benomyl results in decreased activity of PARK7 protein

NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage

Benomyl results in increased cleavage of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

plasminogen activator, urokinase

decreases expression

Benomyl results in decreased expression of PLAU mRNA

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

phosphatase and tensin homolog

increases expression

Benomyl results in increased expression of PTEN mRNA

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

increases expression

Benomyl results in increased expression of RELA mRNA

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

stearoyl-Coenzyme A desaturase 1

decreases expression

Benomyl results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

serine (or cysteine) peptidase inhibitor, clade E, member 2

increases expression

Benomyl results in increased expression of SERPINE2 mRNA

NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897

G

SH2 domain containing 4A

increases expression

Benomyl results in increased expression of SH2D4A mRNA

NCBI chr 8:68,729,180...68,800,356
Ensembl chr 8:68,729,219...68,800,351

G

tissue inhibitor of metalloproteinase 1

increases expression

Benomyl results in increased expression of TIMP1 mRNA

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tissue inhibitor of metalloproteinase 2

increases expression

Benomyl results in increased expression of TIMP2 mRNA

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

tumor necrosis factor

decreases expression

Benomyl results in decreased expression of TNF mRNA

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

affects activity

Benomyl affects the activity of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thymic stromal lymphopoietin

increases expression
multiple interactions

Benomyl results in increased expression of TSLP mRNA
ORMDL3 protein affects the reaction [Benomyl results in increased expression of TSLP mRNA]

NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850

G

ubiquitin-like modifier activating enzyme 1

multiple interactions

Benomyl results in increased activity of and results in increased ubiquitination of UBA1 protein

NCBI chr X:20,524,660...20,549,420
Ensembl chr X:20,524,565...20,549,418

G

vasodilator-stimulated phosphoprotein

multiple interactions

Benomyl inhibits the reaction [Nitroglycerin results in increased phosphorylation of VASP protein]; Benomyl inhibits the reaction [Pentaerythritol Tetranitrate results in increased phosphorylation of VASP protein]

NCBI chr 7:18,990,854...19,005,779
Ensembl chr 7:18,990,854...19,005,742

binimetinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

candesartan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects expression

candesartan affects the expression of ACE mRNA

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

decreases expression

candesartan results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression
decreases expression

[candesartan co-treated with Fenofibrate] results in increased expression of ADIPOQ protein; candesartan promotes the reaction [Ramipril results in increased expression of ADIPOQ]; Ramipril promotes the reaction [candesartan results in increased expression of ADIPOQ]
candesartan results in increased expression of ADIPOQ; candesartan results in increased expression of ADIPOQ protein
candesartan results in decreased expression of ADIPOQ

PMID:16443859 PMID:17483542 PMID:19059660

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

angiotensinogen

multiple interactions

candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]; candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Nitric Oxide]; candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Reactive Oxygen Species]
candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG protein]; candesartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]; candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; candesartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]]
candesartan inhibits the reaction [AGT protein modified form results in increased expression of COL1A2 protein]; candesartan inhibits the reaction [AGT results in increased expression of NOS3 protein]; candesartan inhibits the reaction [AGT results in increased expression of PTGS2 protein]; candesartan inhibits the reaction [AGT results in increased expression of VEGFA protein]

PMID:10525314 PMID:11729239 PMID:12065685 PMID:15539634 PMID:15728788 More...

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

multiple interactions
decreases expression

candesartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]]
candesartan results in decreased expression of AGTR1A mRNA
candesartan binds to and results in decreased activity of AGTR1 protein

PMID:15728788 PMID:18796534 PMID:21474964

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

angiotensin II receptor, type 2

multiple interactions
decreases expression

[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein]
candesartan results in decreased expression of AGTR2 mRNA

PMID:18551021 PMID:18796534

NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403

G

A kinase anchor protein 11

increases expression

candesartan results in increased expression of AKAP11 mRNA

NCBI chr14:78,729,686...78,774,306
Ensembl chr14:78,729,686...78,774,248

G

aldo-keto reductase family 1 member B

decreases expression

candesartan results in decreased expression of AKR1B1 mRNA

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

thymoma viral proto-oncogene 1

decreases phosphorylation

candesartan results in decreased phosphorylation of AKT1 protein

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

autophagy related 5

multiple interactions

candesartan inhibits the reaction [Galactose results in decreased expression of ATG5 mRNA]

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

multiple interactions

candesartan inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 protein]

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

BCL2-associated X protein

increases expression

candesartan results in increased expression of BAX mRNA; candesartan results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

bradykinin receptor, beta 2

decreases expression

candesartan results in decreased expression of BDKRB2 mRNA

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

beclin 1, autophagy related

multiple interactions

candesartan inhibits the reaction [Galactose results in decreased expression of BECN1 mRNA]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

carbonic anhydrase 1

decreases activity

candesartan results in decreased activity of CA1 protein

NCBI chr 3:14,831,274...14,873,425
Ensembl chr 3:14,831,276...14,873,428

G

caspase 3

multiple interactions

[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]

PMID:23300732 PMID:30368989

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

candesartan inhibits the reaction [Galactose results in decreased activity of CAT protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cellular communication network factor 2

decreases expression

candesartan results in decreased expression of CCN2 mRNA

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

CD36 molecule

multiple interactions
decreases expression
increases expression

T 0070907 inhibits the reaction [candesartan results in increased expression of CD36 mRNA]
candesartan results in decreased expression of CD36 mRNA

PMID:14871019 PMID:22124178

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

CD40 ligand

multiple interactions
decreases expression

candesartan promotes the reaction [Fenofibrate results in decreased expression of CD40LG protein]; Fenofibrate promotes the reaction [candesartan results in decreased expression of CD40LG protein]

NCBI chr X:56,257,448...56,269,402
Ensembl chr X:56,257,503...56,269,402

G

collagen, type I, alpha 2

multiple interactions

candesartan inhibits the reaction [AGT protein modified form results in increased expression of COL1A2 protein]

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

cysteine-rich secretory protein LCCL domain containing 2

decreases expression

candesartan results in decreased expression of CRISPLD2 mRNA

NCBI chr 8:120,719,177...120,779,533
Ensembl chr 8:120,719,177...120,779,532

G

C-reactive protein, pentraxin-related

multiple interactions
decreases expression

candesartan promotes the reaction [Fenofibrate results in decreased expression of CRP protein]; Fenofibrate promotes the reaction [candesartan results in decreased expression of CRP protein]

PMID:14620923 PMID:16443859

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

C-X-C motif chemokine ligand 1

multiple interactions

candesartan inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein]

NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974

G

C-X-C motif chemokine ligand 15

decreases expression

candesartan results in decreased expression of CXCL8

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome b-245, alpha polypeptide

decreases expression
multiple interactions

candesartan results in decreased expression of CYBA protein
candesartan results in decreased expression of CYBA; candesartan results in decreased expression of CYBA mRNA
Amlodipine promotes the reaction [candesartan results in decreased expression of CYBA]; candesartan inhibits the reaction [Streptozocin results in increased expression of CYBA mRNA]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBA]

PMID:16139267 PMID:16685210 PMID:18551021 PMID:21107329

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

multiple interactions
decreases expression

Amlodipine promotes the reaction [candesartan results in decreased expression of CYBB]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of CYBB]
candesartan results in decreased expression of CYBB; candesartan results in decreased expression of CYBB mRNA

PMID:16685210 PMID:21107329

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome P450, family 11, subfamily b, polypeptide 2

affects response to substance
decreases expression

CYP11B2 protein polymorphism affects the susceptibility to candesartan
candesartan results in decreased expression of CYP11B2 mRNA

PMID:12065207 PMID:18796534

NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,467...74,728,167

G

endoglin

multiple interactions

candesartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of ENG protein]

NCBI chr 2:32,536,607...32,572,681
Ensembl chr 2:32,536,607...32,572,681

G

Fas ligand

multiple interactions

candesartan inhibits the reaction [Daunorubicin results in increased expression of FASLG protein]

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

FBJ osteosarcoma oncogene

multiple interactions

candesartan inhibits the reaction [[Acetaldehyde co-treated with Cyanamide] results in increased expression of FOS protein]; candesartan inhibits the reaction [Acetaldehyde promotes the reaction [Cyanamide results in increased expression of FOS protein]]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

forkhead box O1

multiple interactions

[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]; candesartan inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]

NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642

G

glucagon

multiple interactions

[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of FOXO1 protein]; [GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]

NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994

G

glial cell line derived neurotrophic factor

multiple interactions

candesartan inhibits the reaction [Galactose results in decreased expression of GDNF mRNA]

NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056

G

heat shock protein 1 (chaperonin 10)

decreases expression

candesartan results in decreased expression of HSPE1 mRNA

NCBI chr 1:55,127,307...55,130,476
Ensembl chr 1:55,127,291...55,130,466

G

intercellular adhesion molecule 1

multiple interactions

candesartan inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein]

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

inhibitor of DNA binding 1, HLH protein

decreases expression

candesartan results in decreased expression of ID1 mRNA

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

interleukin 1 beta

multiple interactions

[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of IL1B protein]; candesartan inhibits the reaction [Gentamicins results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

candesartan inhibits the reaction [AGT protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; candesartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin receptor substrate 2

multiple interactions

[GCG protein co-treated with candesartan] inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]; candesartan inhibits the reaction [Palmitic Acid results in decreased phosphorylation of IRS2 protein]

NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458

G

potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4

decreases expression

candesartan decreases expression of KCNN4 mRNA and protein in CD4-positive, alpha-beta T cell

RGD

NCBI chr 7:24,069,750...24,084,635
Ensembl chr 7:24,069,688...24,086,115

G

kallikrein 1

decreases expression

candesartan results in decreased expression of KLK1 mRNA

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

G

leptin

multiple interactions
increases response to substance
decreases expression

candesartan promotes the reaction [Ramipril results in increased expression of LEP]; Ramipril promotes the reaction [candesartan results in increased expression of LEP]
LEP protein results in increased susceptibility to candesartan
candesartan results in decreased expression of LEP

PMID:17483542 PMID:19059660 PMID:21287150

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

mitogen-activated protein kinase 1

multiple interactions

candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

candesartan inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

multiple interactions

candesartan inhibits the reaction [Isoproterenol results in increased phosphorylation of MAPK8 protein]

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

matrix metallopeptidase 13

increases expression

candesartan results in increased expression of MMP13 protein

NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331

G

matrix metallopeptidase 15

increases expression

candesartan results in increased expression of MMP15 mRNA

NCBI chr 8:96,078,924...96,100,921
Ensembl chr 8:96,078,896...96,101,708

G

matrix metallopeptidase 9

decreases expression

candesartan results in decreased expression of MMP9 mRNA; candesartan results in decreased expression of MMP9 protein

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

multiple interactions

candesartan inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nitric oxide synthase 2, inducible

multiple interactions

candesartan inhibits the reaction [Streptozocin results in increased expression of NOS2 protein]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

multiple interactions

[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein]
candesartan inhibits the reaction [Streptozocin results in increased expression of NOS3 mRNA]; candesartan inhibits the reaction [Streptozocin results in increased expression of NOS3 protein]
candesartan inhibits the reaction [AGT results in increased expression of NOS3 protein]

PMID:12065685 PMID:16139267 PMID:18551021

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

NADPH oxidase 1

multiple interactions
decreases expression

Amlodipine promotes the reaction [candesartan results in decreased expression of NOX1]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX1]

NCBI chr X:132,987,170...133,038,455
Ensembl chr X:132,987,170...133,122,705

G

NADPH oxidase 4

decreases expression
multiple interactions

candesartan results in decreased expression of NOX4 protein
Amlodipine promotes the reaction [candesartan results in decreased expression of NOX4]; Hydrochlorothiazide promotes the reaction [candesartan results in decreased expression of NOX4]

PMID:18551021 PMID:21107329

NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918

G

natriuretic peptide type A

increases expression
increases secretion

candesartan results in increased expression of NPPA mRNA; candesartan results in increased expression of NPPA protein
candesartan results in increased secretion of NPPA protein

NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536

G

nuclear receptor subfamily 3, group C, member 2

affects expression

candesartan affects the expression of NR3C2 mRNA

NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641

G

phospholamban

multiple interactions

candesartan inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein]

NCBI chr10:53,213,782...53,222,095
Ensembl chr10:53,213,763...53,222,083

G

pro-melanin-concentrating hormone

decreases expression

candesartan results in decreased expression of PMCH mRNA

NCBI chr10:87,926,934...87,928,236
Ensembl chr10:87,926,934...87,928,237

G

prostaglandin I2 (prostacyclin) synthase

decreases expression

candesartan results in decreased expression of PTGIS mRNA

NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524

G

prostaglandin-endoperoxide synthase 2

multiple interactions

candesartan inhibits the reaction [AGT results in increased expression of PTGS2 protein]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathyroid hormone-like peptide

multiple interactions

candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; candesartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]

NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]; candesartan inhibits the reaction [Gentamicins results in increased phosphorylation of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

renin 1 structural

multiple interactions
increases expression
decreases activity

candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]
candesartan results in increased expression of REN mRNA
candesartan results in decreased activity of REN protein

PMID:18679781 PMID:18796534 PMID:19047581

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

ryanodine receptor 2, cardiac

multiple interactions

candesartan inhibits the reaction [Isoproterenol results in increased phosphorylation of RYR2 protein]

NCBI chr13:11,567,985...12,121,831
Ensembl chr13:11,567,988...12,121,831

G

solute carrier family 22 (organic anion transporter), member 19

multiple interactions

candesartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate]

NCBI chr19:7,650,440...7,688,675
Ensembl chr19:7,650,426...7,688,675

G

SMAD family member 3

multiple interactions

[benazepril co-treated with candesartan] results in decreased expression of SMAD3 protein

NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276

G

transforming growth factor, beta 1

multiple interactions

[benazepril co-treated with candesartan] results in decreased expression of TGFB1 protein; candesartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of TGFB1 mRNA]

PMID:16778335 PMID:19487956

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

thrombomodulin

multiple interactions

candesartan inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]

NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108

G

tissue inhibitor of metalloproteinase 2

decreases expression

candesartan results in decreased expression of TIMP2 mRNA

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

tissue inhibitor of metalloproteinase 3

decreases expression

candesartan results in decreased expression of TIMP3 mRNA

NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370

G

tumor necrosis factor

multiple interactions
decreases expression

candesartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; candesartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; T 0070907 inhibits the reaction [candesartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
candesartan results in decreased expression of TNF mRNA
[candesartan co-treated with epigallocatechin gallate] inhibits the reaction [Gentamicins results in increased expression of TNF protein]; candesartan inhibits the reaction [Galactose results in increased expression of TNF mRNA]; candesartan inhibits the reaction [Gentamicins results in increased expression of TNF protein]

PMID:22124178 PMID:30368989 PMID:34906534

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

increases expression

candesartan results in increased expression of TP53 mRNA; candesartan results in increased expression of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

uncoupling protein 2 (mitochondrial, proton carrier)

decreases expression
multiple interactions

candesartan results in decreased expression of UCP2 mRNA
candesartan inhibits the reaction [Palmitic Acid results in increased expression of UCP2 mRNA]

PMID:16685210 PMID:20667613

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

vascular cell adhesion molecule 1

multiple interactions

candesartan inhibits the reaction [Streptozocin results in increased expression of VCAM1 protein]

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vascular endothelial growth factor A

decreases expression
multiple interactions

candesartan results in decreased expression of VEGFA
candesartan inhibits the reaction [VEGFA protein results in increased expression of VEGFA mRNA]
candesartan inhibits the reaction [AGT results in increased expression of VEGFA protein]

PMID:12065685 PMID:16202860 PMID:16675585

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

Y box protein 3

decreases expression

candesartan results in decreased expression of YBX3 mRNA

NCBI chr 6:131,341,821...131,365,413
Ensembl chr 6:131,341,818...131,365,439

carbendazim

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

abl interactor 2

increases expression

carbendazim results in increased expression of ABI2 mRNA

NCBI chr 1:60,444,927...60,521,104
Ensembl chr 1:60,448,778...60,520,317

G

acetyl-Coenzyme A carboxylase alpha

increases expression

carbendazim results in increased expression of ACACA mRNA

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acetylcholinesterase

multiple interactions

[carbendazim co-treated with mancozeb] results in increased activity of ACHE protein

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

1-acylglycerol-3-phosphate O-acyltransferase 2

increases expression

carbendazim results in increased expression of AGPAT2 mRNA

NCBI chr 2:26,483,069...26,494,429
Ensembl chr 2:26,483,069...26,494,429

G

aryl-hydrocarbon receptor

multiple interactions
affects localization

AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein]
carbendazim affects the localization of AHR protein

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

albumin

decreases expression

carbendazim results in decreased expression of ALB protein

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

annexin A10

increases expression

carbendazim results in increased expression of ANXA10 mRNA

NCBI chr 8:62,510,076...62,576,227
Ensembl chr 8:62,510,076...62,576,184

G

arginase, liver

decreases expression

carbendazim results in decreased expression of ARG1 mRNA

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

BCL2-associated athanogene 1

increases expression

carbendazim results in increased expression of BAG1 mRNA

NCBI chr 4:40,936,398...40,948,294
Ensembl chr 4:40,936,398...40,948,294

G

BCL2-associated X protein

increases expression

carbendazim results in increased expression of BAX mRNA; carbendazim results in increased expression of BAX protein

PMID:35437878 PMID:35513110

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

decreases expression

carbendazim results in decreased expression of BCL2 mRNA

PMID:35437878 PMID:35513110

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2 like 14

increases expression

carbendazim results in increased expression of BCL2L14 mRNA

NCBI chr 6:134,373,292...134,415,687
Ensembl chr 6:134,373,281...134,415,699

G

BUB1B, mitotic checkpoint serine/threonine kinase

increases activity

carbendazim results in increased activity of BUB1B protein

NCBI chr 2:118,428,684...118,472,073
Ensembl chr 2:118,428,692...118,472,072

G

caspase 3

increases activity
multiple interactions
increases expression

carbendazim results in increased activity of CASP3 protein
Chitosan inhibits the reaction [carbendazim results in increased expression of CASP3 protein]

PMID:30851412 PMID:35705592

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

decreases activity
decreases expression
multiple interactions

carbendazim results in decreased activity of CAT protein
carbendazim results in decreased expression of CAT protein
[Chlorpyrifos co-treated with carbendazim] results in decreased activity of CAT protein; Chitosan inhibits the reaction [carbendazim results in decreased expression of CAT protein]

PMID:27268782 PMID:35513110 PMID:35705592

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cyclin B1

increases expression

carbendazim results in increased expression of CCNB1 protein

NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078

G

chloride channel accessory 2

multiple interactions

[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of CLCA2 mRNA

NCBI chr 3:144,776,021...144,805,204
Ensembl chr 3:144,776,024...144,805,204

G

claudin 11

multiple interactions

[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein

NCBI chr 3:31,204,069...31,218,475
Ensembl chr 3:31,204,069...31,218,473

G

clusterin

decreases expression
increases expression

carbendazim results in decreased expression of CLU mRNA
carbendazim results in increased expression of CLU mRNA

PMID:22952946 PMID:27466211

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity
increases expression

carbendazim results in increased activity of CYP19A1 protein
carbendazim results in increased expression of CYP19A1 mRNA

NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

carbendazim results in increased expression of CYP1A1 mRNA; carbendazim results in increased expression of CYP1A1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]; AHR protein affects the reaction [carbendazim results in increased expression of CYP1A1 protein]; salicylamide inhibits the reaction [carbendazim results in increased expression of CYP1A1 protein]

PMID:10103034 PMID:21784029 PMID:27286660 PMID:32194361

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

carbendazim results in increased expression of CYP1A2 mRNA; carbendazim results in increased expression of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily a, polypeptide 5

increases expression

carbendazim results in increased expression of CYP2A6 mRNA

NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973

G

cytochrome P450, family 2, subfamily b, polypeptide 10

increases expression

carbendazim results in increased expression of CYP2B6 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily c, polypeptide 38

decreases expression

carbendazim results in decreased expression of CYP2C19 protein

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily d, polypeptide 22

decreases activity

carbendazim results in decreased activity of CYP2D6 protein

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 7, subfamily a, polypeptide 1

decreases expression

carbendazim results in decreased expression of CYP7A1 mRNA; carbendazim results in decreased expression of CYP7A1 protein

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

diacylglycerol O-acyltransferase 1

increases expression

carbendazim results in increased expression of DGAT1 mRNA

NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153

G

diacylglycerol O-acyltransferase 2

increases expression

carbendazim results in increased expression of DGAT2 mRNA

NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926

G

dynein axonemal assembly factor 11

decreases expression

carbendazim results in decreased expression of DNAAF11 mRNA

NCBI chr15:66,251,707...66,372,769
Ensembl chr15:66,251,707...66,372,759

G

dipeptidylpeptidase 7

multiple interactions

[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of DPP7 mRNA

NCBI chr 2:25,242,302...25,246,365
Ensembl chr 2:25,242,288...25,246,371

G

estrogen receptor 1 (alpha)

decreases expression
affects localization

carbendazim results in decreased expression of ESR1 mRNA
carbendazim affects the localization of ESR1 protein

PMID:28576679 PMID:37506866

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

decreases expression

carbendazim results in decreased expression of ESR2 mRNA

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

fatty acid binding protein 9, testis

decreases expression
multiple interactions

carbendazim results in decreased expression of FABP9 mRNA; carbendazim results in decreased expression of FABP9 protein
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]

NCBI chr 3:10,258,683...10,262,343
Ensembl chr 3:10,258,681...10,262,343

G

fibronectin type 3 and ankyrin repeat domains 1

increases expression

carbendazim results in increased expression of FANK1 mRNA

NCBI chr 7:133,378,594...133,483,261
Ensembl chr 7:133,378,590...133,483,261

G

forkhead box A2

increases expression

carbendazim results in increased expression of FOXA2 mRNA

NCBI chr 2:147,884,797...147,888,889
Ensembl chr 2:147,884,797...147,888,889

G

follicle stimulating hormone beta

multiple interactions
decreases expression

Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]

NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

carbendazim results in decreased expression of G6PC1 mRNA

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

glial fibrillary acidic protein

increases expression

carbendazim results in increased expression of GFAP protein

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

gap junction protein, alpha 1

multiple interactions

[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases secretion

Chitosan inhibits the reaction [carbendazim results in increased secretion of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

increases expression
multiple interactions
increases secretion

carbendazim results in increased expression of GPT protein
Chitosan inhibits the reaction [carbendazim results in increased secretion of GPT protein]

PMID:35437878 PMID:35705592

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

heme oxygenase 1

decreases expression
multiple interactions

carbendazim results in decreased expression of HMOX1 mRNA
Chitosan inhibits the reaction [carbendazim results in decreased expression of HMOX1 mRNA]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

intraflagellar transport 81

decreases expression

carbendazim results in decreased expression of IFT81 mRNA

PMID:22952946 PMID:27466211

NCBI chr 5:122,678,328...122,752,614
Ensembl chr 5:122,688,267...122,752,581

G

interleukin 10

decreases expression
multiple interactions

carbendazim results in decreased expression of IL10 protein
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

increases expression

carbendazim results in increased expression of IL1B mRNA; carbendazim results in increased expression of IL1B protein

PMID:26071454 PMID:35513110

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

increases expression
multiple interactions

carbendazim results in increased expression of IL6 mRNA; carbendazim results in increased expression of IL6 protein
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]

PMID:26071454 PMID:33965443

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

integrin alpha 5 (fibronectin receptor alpha)

decreases expression

carbendazim results in decreased expression of ITGA5 mRNA

NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190

G

integrin beta 1 (fibronectin receptor beta)

decreases expression

carbendazim results in decreased expression of ITGB1 mRNA

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

G

kelch-like ECH-associated protein 1

increases expression
multiple interactions

carbendazim results in increased expression of KEAP1 mRNA
Chitosan inhibits the reaction [carbendazim results in increased expression of KEAP1 mRNA]

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

luteinizing hormone beta

multiple interactions
decreases expression

Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

lysyl oxidase-like 1

multiple interactions
increases expression

2,5-hexanedione promotes the reaction [carbendazim results in increased expression of LOXL1 protein]; [carbendazim co-treated with 2,5-hexanedione] results in decreased expression of LOXL1 mRNA

NCBI chr 9:58,195,006...58,220,495
Ensembl chr 9:58,195,021...58,220,469

G

lipoprotein lipase

decreases expression

carbendazim results in decreased expression of LPL protein

NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100

G

mono-ADP ribosylhydrolase 1

multiple interactions

[carbendazim co-treated with 2,5-hexanedione] results in decreased expression of MACROD1 mRNA

NCBI chr19:7,034,065...7,175,427
Ensembl chr19:7,034,178...7,175,422

G

mitogen-activated protein kinase 1

affects localization

carbendazim affects the localization of MAPK1 protein modified form

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

affects localization

carbendazim affects the localization of MAPK3 protein modified form

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

increases expression

carbendazim results in increased expression of MAPK8 mRNA

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

microfibrillar-associated protein 3-like

increases expression

carbendazim results in increased expression of MFAP3L mRNA

NCBI chr 8:61,085,859...61,129,765
Ensembl chr 8:61,085,861...61,129,763

G

microRNA 128-1

increases expression

carbendazim results in increased expression of MIR128-1 mRNA

NCBI chr 1:128,130,098...128,130,167
Ensembl chr 1:128,130,098...128,130,167

G

microRNA 423

increases expression

carbendazim results in increased expression of MIR423 mRNA

NCBI chr11:76,968,890...76,968,998
Ensembl chr11:76,968,890...76,968,998

G

matrix metallopeptidase 2

decreases expression

carbendazim results in decreased expression of MMP2 mRNA

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

decreases expression

carbendazim results in decreased expression of MMP9 mRNA

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

multiple interactions
increases activity

[Chlorpyrifos co-treated with carbendazim] results in increased activity of MPO protein
carbendazim results in increased activity of MPO protein

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nuclear factor, erythroid derived 2, like 2

increases expression
multiple interactions
decreases expression

carbendazim results in increased expression of NFE2L2 protein
Chitosan inhibits the reaction [carbendazim results in decreased expression of NFE2L2 mRNA]

PMID:30851412 PMID:35705592

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nitric oxide synthase 2, inducible

increases expression
multiple interactions

carbendazim results in increased expression of NOS2 protein
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Chitosan inhibits the reaction [carbendazim results in increased expression of NOS2 protein]

PMID:33965443 PMID:35705592

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

carbendazim inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

occludin

decreases expression
multiple interactions

carbendazim results in decreased expression of OCLN protein
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

proviral integration site 1

increases expression

carbendazim results in increased expression of PIM1 mRNA

NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086

G

plasminogen activator, urokinase

decreases expression

carbendazim results in decreased expression of PLAU mRNA

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

prostaglandin D2 synthase (brain)

decreases expression

carbendazim results in decreased expression of PTGDS mRNA

NCBI chr 2:25,356,723...25,360,080
Ensembl chr 2:25,356,721...25,360,058

G

pituitary tumor-transforming gene 1

increases expression

carbendazim results in increased expression of PTTG1 protein

NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

increases expression
multiple interactions

carbendazim results in increased expression of RELA protein
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

serine (or cysteine) peptidase inhibitor, clade E, member 2

increases expression

carbendazim results in increased expression of SERPINE2 mRNA

NCBI chr 1:79,772,038...79,836,382
Ensembl chr 1:79,771,914...79,838,897

G

SH3 and multiple ankyrin repeat domains 3

multiple interactions

[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA

NCBI chr15:89,376,929...89,444,464
Ensembl chr15:89,383,826...89,444,464

G

SIL1 nucleotide exchange factor

decreases expression

carbendazim results in decreased expression of SIL1 mRNA

PMID:22952946 PMID:27466211

NCBI chr18:35,399,449...35,632,443
Ensembl chr18:35,399,449...35,632,833

G

superoxide dismutase 3, extracellular

increases expression

carbendazim results in increased expression of SOD3 mRNA

NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760

G

sterol regulatory element binding transcription factor 1

increases expression

carbendazim results in increased expression of SREBF1 mRNA

NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407

G

steroidogenic acute regulatory protein

multiple interactions
decreases expression

Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]
carbendazim results in decreased expression of STAR mRNA; carbendazim results in decreased expression of STAR protein

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

G

TBC1 domain family, member 5

decreases expression

carbendazim results in decreased expression of TBC1D5 mRNA

NCBI chr17:51,040,155...51,488,228
Ensembl chr17:51,040,152...51,486,380

G

tissue inhibitor of metalloproteinase 1

increases expression

carbendazim results in increased expression of TIMP1 mRNA

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tissue inhibitor of metalloproteinase 2

increases expression

carbendazim results in increased expression of TIMP2 mRNA

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

tumor necrosis factor

increases expression
multiple interactions

carbendazim results in increased expression of TNF protein
Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]

PMID:33965443 PMID:35437878 PMID:35513110

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transition protein 1

increases expression

carbendazim results in increased expression of TNP1 mRNA

NCBI chr 1:73,054,233...73,055,058
Ensembl chr 1:73,054,233...73,055,068

G

transition protein 2

increases expression

carbendazim results in increased expression of TNP2 mRNA

NCBI chr16:10,605,799...10,606,519
Ensembl chr16:10,605,800...10,606,524

G

transformation related protein 53

increases expression
affects activity

carbendazim results in increased expression of TP53 mRNA
carbendazim affects the activity of TP53 protein

PMID:35435491 PMID:35513110

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thyroid stimulating hormone, beta subunit

increases expression

carbendazim results in increased expression of TSHB protein

NCBI chr 3:102,684,621...102,718,175
Ensembl chr 3:102,682,781...102,690,034

CGP 12177

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenergic receptor, beta 1

multiple interactions
affects binding
increases activity

[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 12177 binds to and results in decreased activity of ADRB1 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB1 protein]; CGP 12177 inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 20712A inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]

PMID:2462161 PMID:9593075 PMID:10217540 PMID:12535855 PMID:12761341 More...

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

adrenergic receptor, beta 2

multiple interactions
affects binding

[CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; CGP 12177 binds to and results in decreased activity of ADRB2 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB2 protein]
Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]

PMID:2462161 PMID:9593075 PMID:12535855 PMID:14730417 PMID:17628611 More...

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

adrenergic receptor, beta 3

multiple interactions
affects binding
increases activity
affects response to substance

[CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; CGP 12177 binds to and results in increased activity of ADRB3 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB3 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB3 protein]
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [CGP 12177 results in increased activity of ADRB3 protein]; CGP 12177 binds to and results in increased activity of ADRB3 protein
ADRB3 affects the susceptibility to CGP 12177

PMID:7815362 PMID:8569714 PMID:10217540 PMID:10952688 PMID:11159692 More...

NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644

G

cystic fibrosis transmembrane conductance regulator

multiple interactions
increases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; Pertussis Toxin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; U 0126 inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; wortmannin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

growth hormone

multiple interactions

GH1 protein promotes the reaction [CGP 12177 results in increased metabolism of Lipids]

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

lipoprotein lipase

increases expression

CGP 12177 results in increased expression of LPL mRNA

NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100

G

mitogen-activated protein kinase 1

increases activity

CGP 12177 results in increased activity of MAPK1 protein

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

increases activity

CGP 12177 results in increased activity of MAPK3 protein

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

upstream transcription factor 1

multiple interactions

USF1 gene polymorphism promotes the reaction [CGP 12177 results in increased metabolism of Lipids]; USF1 protein affects the reaction [CGP 12177 results in increased metabolism of Lipids]

NCBI chr 1:171,238,881...171,246,327
Ensembl chr 1:171,238,881...171,246,710

G

vascular endothelial growth factor A

increases expression

CGP 12177 results in increased expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

chlormidazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

estrogen receptor 1 (alpha)

multiple interactions

chlormidazole inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen related receptor, alpha

multiple interactions

chlormidazole inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; chlormidazole inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]

NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208

G

isocitrate dehydrogenase 3 (NAD+) alpha

decreases expression

chlormidazole results in decreased expression of IDH3A mRNA

NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945

G

nuclear factor, erythroid derived 2, like 2

increases activity

chlormidazole results in increased activity of NFE2L2 protein

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear receptor subfamily 1, group I, member 3

increases activity

chlormidazole results in increased activity of NR1I3 protein

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

multiple interactions

chlormidazole inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

ciclobendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ciclobendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

clemizole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions

[clemizole co-treated with Cisplatin] results in decreased expression of CAT protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cytochrome P450, family 2, subfamily b, polypeptide 10

increases expression
multiple interactions

clemizole results in increased expression of CYP2B6 mRNA
[clemizole co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [clemizole co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

glucose-6-phosphatase catalytic subunit 1

increases expression

clemizole results in increased expression of G6PC1 mRNA

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

lipocalin 2

multiple interactions

[clemizole co-treated with Cisplatin] results in increased expression of LCN2 protein; clemizole inhibits the reaction [Cisplatin results in increased expression of LCN2 protein]

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

mediator complex subunit 1

multiple interactions

clemizole promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]

NCBI chr11:98,042,980...98,084,121
Ensembl chr11:98,042,980...98,084,119

G

nuclear receptor coactivator 1

multiple interactions

clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein]

NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182

G

nuclear receptor coactivator 3

multiple interactions

clemizole promotes the reaction [NCOA3 protein binds to NR1I3 protein]

NCBI chr 2:165,834,557...165,915,162
Ensembl chr 2:165,834,545...165,915,162

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[clemizole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 1, group I, member 3

affects localization
affects binding
multiple interactions

clemizole affects the localization of NR1I3 protein mutant form
clemizole binds to NR1I3 protein
[clemizole co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; [clemizole co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; clemizole binds to and results in increased activity of NR1I3 protein alternative form; clemizole inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; clemizole promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein alternative form]; clemizole promotes the reaction [NCOA1 protein binds to NR1I3 protein]; clemizole promotes the reaction [NCOA3 protein binds to NR1I3 protein]

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

phosphoenolpyruvate carboxykinase 1, cytosolic

increases expression

clemizole results in increased expression of PCK1 mRNA

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

G

Rac family small GTPase 1

multiple interactions

clemizole inhibits the reaction [Cisplatin results in increased expression of RAC1 protein]

NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791

G

stearoyl-Coenzyme A desaturase 2

decreases expression

clemizole results in decreased expression of SCD mRNA

NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303

G

sperm microtubule inner protein 11

multiple interactions

[Cisplatin co-treated with clemizole] results in decreased expression of NPHS1 protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of NPHS1 protein]

NCBI chr15:98,468,885...98,487,469
Ensembl chr15:98,468,885...98,487,461

G

synaptopodin

multiple interactions

[Cisplatin co-treated with clemizole] results in decreased expression of SYNPO protein; clemizole inhibits the reaction [Cisplatin results in decreased expression of SYNPO protein]

NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214

G

thyroid hormone responsive

affects expression

clemizole affects the expression of THRSP mRNA

NCBI chr 7:97,062,140...97,066,757
Ensembl chr 7:97,062,145...97,066,937

dabigatran

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

allograft inflammatory factor 1

decreases expression

Dabigatran results in decreased expression of AIF1 protein

NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044

G

aldehyde dehydrogenase family 1, subfamily A2

decreases expression

Dabigatran results in decreased expression of ALDH1A2 mRNA

NCBI chr 9:71,123,071...71,203,525
Ensembl chr 9:71,123,071...71,203,525

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

Dabigatran results in decreased expression of EYA1 mRNA

NCBI chr 1:14,239,177...14,381,259
Ensembl chr 1:14,239,178...14,380,459

G

coagulation factor II

decreases activity

Dabigatran results in decreased activity of F2 protein

PMID:17911567 PMID:25138021

NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759

G

fibrinogen alpha chain

multiple interactions

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 3:82,933,460...82,940,934
Ensembl chr 3:82,933,383...82,940,934

G

fibrinogen beta chain

multiple interactions

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170

G

fibroblast growth factor 8

increases expression

Dabigatran results in increased expression of FGF8 mRNA

NCBI chr19:45,724,930...45,731,380
Ensembl chr19:45,725,237...45,731,354

G

fibrinogen gamma chain

multiple interactions

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 3:82,915,031...82,922,363
Ensembl chr 3:82,915,031...82,922,356

G

forkhead box C2

decreases expression

Dabigatran results in decreased expression of FOXC2 mRNA

NCBI chr 8:121,842,910...121,845,634
Ensembl chr 8:121,842,910...121,845,634

G

glial cell line derived neurotrophic factor

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of GDNF mRNA]

NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056

G

glial fibrillary acidic protein

decreases expression

Dabigatran results in decreased expression of GFAP protein

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

homeobox B9

increases expression

Dabigatran results in increased expression of HOXB9 mRNA

NCBI chr11:96,162,156...96,167,421
Ensembl chr11:96,162,283...96,167,421

G

mesenchyme homeobox 1

decreases expression

Dabigatran results in decreased expression of MEOX1 mRNA

NCBI chr11:101,768,336...101,785,309
Ensembl chr11:101,768,336...101,785,200

G

MER proto-oncogene tyrosine kinase

increases expression

Dabigatran results in increased expression of MERTK mRNA

NCBI chr 2:128,540,836...128,645,082
Ensembl chr 2:128,540,876...128,644,814

G

neurogenin 2

increases expression

Dabigatran results in increased expression of NEUROG2 mRNA

NCBI chr 3:127,426,382...127,429,285
Ensembl chr 3:127,426,784...127,429,280

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of NR4A2 mRNA]

NCBI chr 2:56,996,845...57,014,152
Ensembl chr 2:56,996,842...57,014,015

G

oligodendrocyte transcription factor 3

increases expression

Dabigatran results in increased expression of OLIG3 mRNA

NCBI chr10:19,232,287...19,234,352
Ensembl chr10:19,232,281...19,234,352

G

paired box 3

decreases expression

Dabigatran results in decreased expression of PAX3 mRNA

NCBI chr 1:78,077,904...78,173,773
Ensembl chr 1:78,077,904...78,173,771

G

paired box 6

increases expression

Dabigatran results in increased expression of PAX6 mRNA

NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709

G

proteolipid protein (myelin) 1

increases expression

Dabigatran results in increased expression of PLP1 mRNA

NCBI chr X:135,720,897...135,739,331
Ensembl chr X:135,723,420...135,740,482

G

REST corepressor 2

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of RCOR2 mRNA]

NCBI chr19:7,244,759...7,252,590
Ensembl chr19:7,244,690...7,252,590

G

ret proto-oncogene

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of RET protein]

NCBI chr 6:118,128,709...118,174,705
Ensembl chr 6:118,128,706...118,174,679

G

solute carrier family 18 (vesicular monoamine), member 2

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA]

NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444

G

synuclein, alpha

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in increased expression of SNCA mRNA]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

transcription factor 15

decreases expression

Dabigatran results in decreased expression of TCF15 mRNA

NCBI chr 2:151,984,973...151,991,017
Ensembl chr 2:151,985,481...151,991,017

G

tyrosine hydroxylase

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in decreased expression of TH mRNA]

NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865

G

tumor necrosis factor

multiple interactions

Dabigatran inhibits the reaction [Rotenone results in increased expression of TNF mRNA]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

UNC homeobox

decreases expression

Dabigatran results in decreased expression of UNCX mRNA

NCBI chr 5:139,529,620...139,533,934
Ensembl chr 5:139,529,249...139,533,934

desmethylastemizole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel, subfamily H (eag-related), member 1

decreases activity

desmethylastemizole results in decreased activity of KCNH1 protein

NCBI chr 1:191,871,759...192,192,467
Ensembl chr 1:191,873,082...192,192,467

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions

desmethylastemizole binds to and results in decreased activity of KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

domperidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

affects response to substance

ABCB1 gene SNP affects the susceptibility to Domperidone

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

adrenergic receptor, alpha 1d

affects response to substance

ADRA1D gene SNP affects the susceptibility to Domperidone

NCBI chr 2:131,387,277...131,404,417
Ensembl chr 2:131,387,770...131,404,203

G

C-X-C motif chemokine ligand 2

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL2 mRNA]

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Domperidone results in increased expression of CYP1A1 mRNA

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases hydroxylation

CYP1A2 protein results in increased hydroxylation of Domperidone

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 10

increases hydroxylation

CYP2B6 protein results in increased hydroxylation of Domperidone

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily c, polypeptide 29

increases hydroxylation

CYP2C8 protein results in increased hydroxylation of Domperidone

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily d, polypeptide 22

increases hydroxylation

CYP2D6 protein results in increased hydroxylation of Domperidone

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

dopamine receptor D1

multiple interactions
affects binding

Cyclosporine promotes the reaction [Domperidone binds to DRD1 protein]

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

G

dopamine receptor D2

multiple interactions
affects binding

Cyclosporine promotes the reaction [Domperidone binds to DRD2 protein]
Domperidone binds to and results in decreased activity of DRD2 protein

PMID:2571179 PMID:8103596 PMID:10626749 PMID:12071432 PMID:12130853 More...

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

G

interleukin 6

decreases expression

Domperidone results in decreased expression of IL6 protein

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity
multiple interactions
affects response to substance

Domperidone results in decreased activity of KCNH2 protein
Domperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
KCNH2 gene SNP affects the susceptibility to Domperidone

PMID:15640612 PMID:19583963 PMID:21063774 PMID:28551711

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

myeloperoxidase

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nitric oxide synthase 2, inducible

multiple interactions

Domperidone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

prolactin

multiple interactions
increases expression

Domperidone inhibits the reaction [Deoxyepinephrine results in decreased expression of PRL protein]; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Domperidone results in increased expression of PRL protein

PMID:1304515 PMID:1874184 PMID:6736848 PMID:8532072

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Domperidone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

transforming growth factor, beta 1

decreases expression

Domperidone results in decreased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

thyroid hormone receptor alpha

multiple interactions

Domperidone binds to and results in decreased activity of THRA protein

NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832

droperidol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity
multiple interactions

Droperidol results in decreased activity of KCNH2 protein
Droperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

PMID:16757186 PMID:21158687 PMID:28551711

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Droperidol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

emedastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity

emedastine results in decreased activity of KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

esomeprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

Mycophenolic Acid promotes the reaction [Esomeprazole results in increased expression of CYP1A1 mRNA]

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

fenbendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Araf proto-oncogene, serine/threonine kinase

decreases expression

Fenbendazole analog results in decreased expression of ARAF protein

NCBI chr X:20,663,946...20,726,760
Ensembl chr X:20,664,053...20,726,758

G

aurora kinase B

increases expression

Fenbendazole results in increased expression of AURKB protein

NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490

G

BCL2-associated X protein

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; Acetylcysteine inhibits the reaction [Fenbendazole results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole results in increased expression of BAX protein]
Fenbendazole analog results in increased expression of BAX protein; Fenbendazole results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

decreases expression

Fenbendazole analog results in decreased expression of BCL2 protein; Fenbendazole results in decreased expression of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

caspase 3

increases expression
increases cleavage

Fenbendazole analog results in increased expression of CASP3 mRNA
Fenbendazole analog results in increased cleavage of CASP3 protein; Fenbendazole results in increased cleavage of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases expression

Fenbendazole analog results in increased expression of CASP8 mRNA; Fenbendazole results in increased expression of CASP8 mRNA

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

increases expression
increases cleavage

Fenbendazole analog results in increased expression of CASP9 mRNA; Fenbendazole results in increased expression of CASP9 mRNA
Fenbendazole analog results in increased cleavage of CASP9 protein; Fenbendazole results in increased cleavage of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

chromobox 5

increases expression

Fenbendazole results in increased expression of CBX5 protein

NCBI chr15:103,099,973...103,148,337
Ensembl chr15:103,099,971...103,148,243

G

C-C motif chemokine ligand 2

increases expression

Fenbendazole results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cyclin D1

increases expression

Fenbendazole results in increased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin E2

increases expression

Fenbendazole results in increased expression of CCNE2 mRNA

NCBI chr 4:11,190,489...11,204,781
Ensembl chr 4:11,191,351...11,204,779

G

cadherin 1

increases expression

Fenbendazole analog results in increased expression of CDH1 protein; Fenbendazole results in increased expression of CDH1 protein

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

affects expression

Fenbendazole affects the expression of CDH2 protein; Fenbendazole analog affects the expression of CDH2 protein

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

cyclin dependent kinase 1

increases expression

Fenbendazole results in increased expression of CDK1 mRNA; Fenbendazole results in increased expression of CDK1 protein

NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768

G

cyclin dependent kinase inhibitor 1A

increases expression

Fenbendazole results in increased expression of CDKN1A mRNA; Fenbendazole results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 2A

increases methylation
increases expression
decreases expression

Fenbendazole results in increased methylation of CDKN2A gene
Fenbendazole results in increased expression of CDKN2A protein
Fenbendazole results in decreased expression of CDKN2A protein

PMID:22659510 PMID:23411599

NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890

G

cyclin dependent kinase inhibitor 2B

increases expression

Fenbendazole results in increased expression of CDKN2B mRNA

NCBI chr 4:89,224,526...89,229,269
Ensembl chr 4:89,224,536...89,229,276

G

cerebellar degeneration-related 2

increases expression

Fenbendazole results in increased expression of CDR2 mRNA

NCBI chr 7:120,556,259...120,581,535
Ensembl chr 7:120,556,259...120,581,535

G

C-X-C motif chemokine ligand 15

increases secretion
multiple interactions
increases expression

Fenbendazole results in increased secretion of CXCL8 protein
U 0126 inhibits the reaction [Fenbendazole results in increased secretion of CXCL8 protein]
Fenbendazole analog results in increased expression of CXCL8 mRNA; Fenbendazole results in increased expression of CXCL8 mRNA; Fenbendazole results in increased expression of CXCL8 protein

PMID:20116850 PMID:20848085 PMID:35569513

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Fenbendazole results in decreased activity of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

dynamin 1-like

increases expression

Fenbendazole analog results in increased expression of DNM1L mRNA; Fenbendazole results in increased expression of DNM1L mRNA

NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823

G

glutathione S-transferase, pi 1

multiple interactions

Fenbendazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

H2A.X variant histone

increases expression

Fenbendazole analog results in increased expression of H2AX protein; Fenbendazole results in increased expression of H2AX protein

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

heat shock factor 1

increases activity

Fenbendazole results in increased activity of HSF1 protein

NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113

G

interferon gamma

increases expression

Fenbendazole analog results in increased expression of IFNG mRNA; Fenbendazole results in increased expression of IFNG mRNA

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interleukin 6

increases expression

Fenbendazole analog results in increased expression of IL6 mRNA; Fenbendazole results in increased expression of IL6 mRNA

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 receptor, alpha

increases expression

Fenbendazole results in increased expression of IL6R protein modified form

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

inner centromere protein

increases expression

Fenbendazole results in increased expression of INCENP protein

NCBI chr19:9,849,659...9,876,853
Ensembl chr19:9,849,660...9,876,915

G

microtubule-associated protein tau

decreases expression

Fenbendazole results in decreased expression of MAPT protein

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

malate dehydrogenase 2, NAD (mitochondrial)

increases expression

Fenbendazole analog results in increased expression of MDH2 mRNA; Fenbendazole results in increased expression of MDH2 mRNA

NCBI chr 5:135,807,503...135,819,240
Ensembl chr 5:135,807,334...135,819,252

G

transformed mouse 3T3 cell double minute 2

increases expression

Fenbendazole results in increased expression of MDM2 mRNA

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

mitofusin 2

increases expression

Fenbendazole results in increased expression of MFN2 mRNA

NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161

G

antigen identified by monoclonal antibody Ki 67

increases expression

Fenbendazole results in increased expression of MKI67 protein

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

matrix metallopeptidase 2

decreases expression

Fenbendazole analog results in decreased expression of MMP2 mRNA; Fenbendazole analog results in decreased expression of MMP2 protein

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

affects expression
decreases expression

Fenbendazole affects the expression of MMP9 protein; Fenbendazole analog affects the expression of MMP9 protein
Fenbendazole analog results in decreased expression of MMP9 mRNA; Fenbendazole results in decreased expression of MMP9 mRNA

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Fenbendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

OPA1, mitochondrial dynamin like GTPase

increases expression

Fenbendazole results in increased expression of OPA1 mRNA

NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702

G

prostaglandin-endoperoxide synthase 2

decreases expression

Fenbendazole results in decreased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Fenbendazole analog results in increased phosphorylation of RELA protein]; Acetylcysteine inhibits the reaction [Fenbendazole results in increased phosphorylation of RELA protein]
Fenbendazole analog results in increased phosphorylation of RELA protein; Fenbendazole results in increased phosphorylation of RELA protein

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

sirtuin 1

increases expression

Fenbendazole analog results in increased expression of SIRT1 mRNA; Fenbendazole results in increased expression of SIRT1 mRNA

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 2 (facilitated glucose transporter), member 1

decreases expression

Fenbendazole analog results in decreased expression of SLC2A1 mRNA; Fenbendazole results in decreased expression of SLC2A1 mRNA

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

solute carrier family 2 (facilitated glucose transporter), member 4

decreases expression

Fenbendazole analog results in decreased expression of SLC2A4 mRNA; Fenbendazole results in decreased expression of SLC2A4 mRNA

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

succinate-CoA ligase, GDP-forming, alpha subunit

increases expression

Fenbendazole analog results in increased expression of SUCLG1 mRNA; Fenbendazole results in increased expression of SUCLG1 mRNA

NCBI chr 6:73,225,488...73,253,890
Ensembl chr 6:73,225,365...73,253,894

G

transmembrane protein 70

multiple interactions

[Diethylnitrosamine co-treated with Fenbendazole] results in decreased expression of TMEM70 protein

NCBI chr 1:16,735,415...16,748,501
Ensembl chr 1:16,735,431...16,748,499

G

tumor necrosis factor

increases secretion
increases expression
multiple interactions

Fenbendazole results in increased secretion of TNF protein
Fenbendazole analog results in increased expression of TNF mRNA
U 0126 inhibits the reaction [Fenbendazole results in increased secretion of TNF protein]

PMID:20848085 PMID:35569513

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

increases expression

Fenbendazole results in increased expression of TP53 protein
Fenbendazole analog results in increased expression of TP53 protein; Fenbendazole results in increased expression of TP53 protein

PMID:23411599 PMID:35569513

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

ubiquitin-conjugating enzyme E2E 2

multiple interactions

[Diethylnitrosamine co-treated with Fenbendazole] results in decreased expression of UBE2E2 protein

NCBI chr14:3,575,429...3,896,133
Ensembl chr14:3,575,429...3,896,121

G

vascular endothelial growth factor A

increases expression

Fenbendazole results in increased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

WEE 1 homolog 1 (S. pombe)

decreases expression

Fenbendazole results in decreased expression of WEE1 protein modified form

NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493

flubendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Rho/Rac guanine nucleotide exchange factor 2

decreases expression

flubendazole results in decreased expression of ARHGEF2 protein

NCBI chr 3:88,500,427...88,556,839
Ensembl chr 3:88,513,273...88,555,359

G

B cell leukemia/lymphoma 2

increases phosphorylation

flubendazole results in increased phosphorylation of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2-like 1

increases phosphorylation

flubendazole results in increased phosphorylation of BCL2L1 protein

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

caspase 3

multiple interactions
increases cleavage

BAY 11-7085 affects the reaction [flubendazole results in increased cleavage of CASP3 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; Cyclosporine inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

cadherin 1

multiple interactions

flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

multiple interactions

flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

mitogen-activated protein kinase 8

increases activity

flubendazole results in increased activity of MAPK8 protein

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

myeloid cell leukemia sequence 1

increases phosphorylation

flubendazole results in increased phosphorylation of MCL1 protein

NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

flubendazole results in increased expression of PMAIP1 protein

NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636

G

PTK2 protein tyrosine kinase 2

decreases expression

flubendazole results in decreased expression of PTK2 protein

NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129

G

Rac family small GTPase 1

decreases expression

flubendazole results in decreased expression of RAC1 protein

NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
increases activity

4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine affects the reaction [flubendazole results in increased activity of RELA protein]; BAY 11-7085 affects the reaction [flubendazole results in increased activity of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

ras homolog family member A

decreases expression

flubendazole results in decreased expression of RHOA protein

NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133

G

transforming growth factor, beta 1

multiple interactions

flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; flubendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transformation related protein 53

increases activity

flubendazole results in increased activity of TP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

lansoprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

increases expression

Lansoprazole results in increased expression of ABCA1 protein
Lansoprazole results in increased expression of ABCA1 mRNA; Lansoprazole results in increased expression of ABCA1 protein

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family B member 1A

affects response to substance

ABCB1 affects the susceptibility to Lansoprazole

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

apolipoprotein E

increases expression

Lansoprazole results in increased expression of APOE mRNA; Lansoprazole results in increased expression of APOE protein

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

aquaporin 4

increases expression

Lansoprazole results in increased expression of AQP4 mRNA; Lansoprazole results in increased expression of AQP4 protein

NCBI chr18:15,522,451...15,544,039
Ensembl chr18:15,522,553...15,544,039

G

B cell leukemia/lymphoma 2

multiple interactions

Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in decreased expression of BCL2 mRNA]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

Lansoprazole results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, C chain

decreases expression

Lansoprazole results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

caspase 3

multiple interactions

Lansoprazole inhibits the reaction [Demecolcine results in increased activity of CASP3 protein]
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of CASP3 mRNA]; Lansoprazole inhibits the reaction [Ethanol results in increased expression of CASP3 protein]

PMID:12530016 PMID:28412091 PMID:29339218

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of CAT protein]

PMID:18726076 PMID:29339218

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

complement component factor i

decreases expression

Lansoprazole results in decreased expression of CFI mRNA

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

C-X-C motif chemokine ligand 1

decreases expression
multiple interactions

Lansoprazole results in decreased expression of CXCL1 mRNA; Lansoprazole results in decreased expression of CXCL1 protein
Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]; Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein]

PMID:15334676 PMID:16328016

NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974

G

C-X-C motif chemokine ligand 15

decreases expression

Lansoprazole results in decreased expression of CXCL8 mRNA; Lansoprazole results in decreased expression of CXCL8 protein

PMID:15089887 PMID:15513378

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
decreases activity
increases expression

Lansoprazole results in increased activity of CYP1A1 promoter
Lansoprazole results in decreased activity of CYP1A1 protein
Lansoprazole results in increased expression of CYP1A1 mRNA; Lansoprazole results in increased expression of CYP1A1 protein

PMID:8169844 PMID:8647108 PMID:8900397 PMID:9041675 PMID:9152597 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Lansoprazole results in increased expression of CYP1A2 mRNA; Lansoprazole results in increased expression of CYP1A2 protein

PMID:8169844 PMID:9152597 PMID:9744552 PMID:12623754 PMID:14550749 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
decreases activity

Lansoprazole results in increased expression of CYP1B1 mRNA
Lansoprazole results in decreased activity of CYP1B1 protein

PMID:12623754 PMID:33814510

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily b, polypeptide 13

increases expression

Lansoprazole results in increased expression of CYP2B2 protein

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 29

affects metabolic processing
increases expression
increases hydroxylation

CYP2C8 protein affects the metabolism of Lansoprazole
Lansoprazole results in increased expression of CYP2C6 mRNA; Lansoprazole results in increased expression of CYP2C6 protein
CYP2C8 protein results in increased hydroxylation of Lansoprazole

PMID:7870052 PMID:8627562 PMID:9152597 PMID:14550749

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily c, polypeptide 38

affects response to substance
decreases activity
increases hydroxylation
affects metabolic processing
increases metabolic processing
decreases metabolic processing
multiple interactions

CYP2C19 gene affects the susceptibility to Lansoprazole; CYP2C19 gene polymorphism affects the susceptibility to Lansoprazole
Lansoprazole results in decreased activity of CYP2C19 protein
CYP2C19 protein results in increased hydroxylation of Lansoprazole
CYP2C19 protein affects the metabolism of Lansoprazole
CYP2C19 protein results in increased metabolism of Lansoprazole; Lansoprazole results in increased metabolism of CYP2C19 protein
CYP2C19 gene polymorphism results in decreased metabolism of Lansoprazole
CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]; Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]

PMID:8627562 PMID:8930576 PMID:9272410 PMID:11829200 PMID:11929404 More...

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene

increases hydroxylation

CYP2C18 protein results in increased hydroxylation of Lansoprazole

NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733

G

cytochrome P450, family 2, subfamily c, polypeptide 65

increases hydroxylation
multiple interactions

CYP2C9 protein results in increased hydroxylation of Lansoprazole
Lansoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]

PMID:8627562 PMID:12975331 PMID:15258107

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
decreases degradation

Lansoprazole results in increased expression of and results in increased activity of CYP2E1 protein
Lansoprazole results in decreased degradation of CYP2E1 protein

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 3, subfamily a, polypeptide 13

multiple interactions

CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 4, subfamily a, polypeptide 12B

increases expression

Lansoprazole results in increased expression of CYP4A1 protein

NCBI chr 4:115,268,821...115,296,231
Ensembl chr 4:115,268,821...115,296,231

G

epidermal growth factor receptor

increases expression

Lansoprazole results in increased expression of EGFR protein

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

Fas cell surface death receptor

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in increased expression of FAS protein]

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

Fas ligand

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in increased expression of FASLG protein]

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

fibroblast growth factor 2

decreases expression

Lansoprazole results in decreased expression of FGF2 protein

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor 21

increases expression

Lansoprazole results in increased expression of FGF21 protein

NCBI chr 7:45,263,314...45,264,914
Ensembl chr 7:45,263,310...45,264,914

G

gastrin

increases expression

Lansoprazole results in increased expression of GAST protein

PMID:7750667 PMID:8792694 PMID:11680587 PMID:11975934 PMID:12189558 More...

NCBI chr11:100,225,233...100,227,823
Ensembl chr11:100,225,233...100,227,822

G

glutathione S-transferase, pi 1

multiple interactions

Lansoprazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

hepcidin antimicrobial peptide

increases expression

Lansoprazole results in increased expression of HAMP mRNA

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

heme oxygenase 1

multiple interactions
increases expression
increases activity

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; Lansoprazole results in increased activity of and results in increased expression of HMOX1 protein
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Lansoprazole results in increased expression of HMOX1 protein]
Lansoprazole results in increased expression of HMOX1 mRNA; Lansoprazole results in increased expression of HMOX1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased activity of HMOX1 promoter]

PMID:16712795 PMID:19628634 PMID:19764090 PMID:28412091

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

interferon gamma

multiple interactions
decreases expression

Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
Lansoprazole results in decreased expression of IFNG mRNA

PMID:16932910 PMID:19232345

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interleukin 10

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

decreases expression
multiple interactions

Lansoprazole results in decreased expression of IL1B mRNA
Lansoprazole inhibits the reaction [Ethanol results in increased expression of IL1B protein]

PMID:16932910 PMID:29339218

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression
multiple interactions

Lansoprazole results in decreased expression of IL6 mRNA
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 mRNA]

PMID:16932910 PMID:28412091

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

kelch-like ECH-associated protein 1

increases oxidation

Lansoprazole results in increased oxidation of KEAP1 protein

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

luteinizing hormone beta

multiple interactions
increases expression

Lansoprazole inhibits the reaction [LHB protein results in increased abundance of Testosterone]
Lansoprazole results in increased expression of LHB protein

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

mitogen-activated protein kinase 1

increases phosphorylation

Lansoprazole results in increased phosphorylation of MAPK1 protein

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

increases phosphorylation

Lansoprazole results in increased phosphorylation of MAPK3 protein

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

microtubule-associated protein tau

affects binding

Lansoprazole binds to MAPT protein alternative form

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

myeloperoxidase

multiple interactions

Lansoprazole inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:17151854 PMID:17895592 PMID:18726076 PMID:24337826

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
increases expression
increases phosphorylation

Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of NFE2L2 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein]
Lansoprazole results in increased expression of NFE2L2 mRNA
Lansoprazole results in increased phosphorylation of NFE2L2 protein

PMID:19628634 PMID:28412091

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nuclear receptor subfamily 1, group H, member 2

increases activity

Lansoprazole results in increased activity of NR1H2 protein

NCBI chr 7:44,199,040...44,204,928
Ensembl chr 7:44,199,040...44,203,375

G

nuclear receptor subfamily 1, group H, member 3

increases activity

Lansoprazole results in increased activity of NR1H3 protein

NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Lansoprazole results in increased activity of NR1I2 protein

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

phosphatase, orphan 1

decreases activity

Lansoprazole results in decreased activity of PHOSPHO1 protein

NCBI chr11:95,715,326...95,722,966
Ensembl chr11:95,715,325...95,722,966

G

pro-opiomelanocortin-alpha

increases expression

Lansoprazole results in increased expression of POMC protein

NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

AG-041R inhibits the reaction [Lansoprazole results in increased expression of PTGS2 protein]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

retinol saturase (all trans retinol 13,14 reductase)

decreases expression

Lansoprazole results in decreased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

decreases expression

Lansoprazole results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

sonic hedgehog

decreases expression

Lansoprazole results in decreased expression of SHH mRNA

NCBI chr 5:28,661,838...28,672,099
Ensembl chr 5:28,661,813...28,672,254

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Lansoprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions

[Lansoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

transforming growth factor alpha

increases expression

Lansoprazole results in increased expression of TGFA protein

NCBI chr 6:86,172,020...86,252,726
Ensembl chr 6:86,172,205...86,252,701

G

transforming growth factor, beta 1

increases expression

Lansoprazole results in increased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tumor necrosis factor

multiple interactions
decreases expression

Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
Lansoprazole inhibits the reaction [Ethanol results in increased expression of TNF protein]
Lansoprazole results in decreased expression of TNF mRNA

PMID:16932910 PMID:19232345 PMID:29339218

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

multiple interactions

Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression

Lansoprazole results in increased expression of UGT1A1 mRNA

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

Lansoprazole results in increased expression of UGT2B1 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

zona pellucida 3 receptor

decreases expression

Lansoprazole results in decreased expression of C4BPA mRNA

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

ledipasvir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2 (Junior blood group)

affects binding

ledipasvir binds to ABCG2 protein

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

killer cell lectin-like receptor subfamily C, member 1

decreases expression

ledipasvir co-treated with sofosbuvir decreases expression of NCR1 protein in natural killer cells

RGD

NCBI chr 6:129,642,978...129,659,815
Ensembl chr 6:129,642,978...129,655,936

G

natural cytotoxicity triggering receptor 1

affects expression

ledipasvir co-treated sofosbuvir with affects expression of NCR1 protein in natural killer cells

RGD

NCBI chr 7:4,340,714...4,348,183
Ensembl chr 7:4,340,723...4,348,163

liarozole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 26, subfamily a, polypeptide 1

decreases activity
multiple interactions

liarozole results in decreased activity of CYP26A1 protein
[liarozole co-treated with Tretinoin] results in increased expression of CYP26A1 mRNA; liarozole promotes the reaction [Tretinoin results in increased expression of CYP26A1 mRNA]

PMID:15597402 PMID:16279770 PMID:21428449 PMID:21838328

NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984

mebendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

decreases expression

Mebendazole results in decreased expression of ABCB1 mRNA; Mebendazole results in decreased expression of ABCB1 protein

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family C member 1

decreases expression

Mebendazole results in decreased expression of ABCC1 mRNA

NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601

G

advanced glycosylation end product-specific receptor

increases expression

Mebendazole results in increased expression of AGER mRNA

NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910

G

Rho/Rac guanine nucleotide exchange factor 2

decreases expression

Mebendazole results in decreased expression of ARHGEF2 protein

NCBI chr 3:88,500,427...88,556,839
Ensembl chr 3:88,513,273...88,555,359

G

BCL2-associated X protein

multiple interactions

[Mebendazole results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

affects response to substance
multiple interactions
increases phosphorylation

BCL2 protein affects the susceptibility to Mebendazole
[Mebendazole results in increased phosphorylation of BCL2 protein] inhibits the reaction [BCL2 protein binds to BAX protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

bone morphogenetic protein 6

increases expression

Mebendazole results in increased expression of BMP6 mRNA

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

caspase 3

increases activity

Mebendazole results in increased activity of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 7

increases activity

Mebendazole results in increased activity of CASP7 protein

NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776

G

C-C motif chemokine ligand 2

increases expression

Mebendazole results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cadherin 1

multiple interactions

Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

multiple interactions

Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

C-X-C motif chemokine ligand 15

increases expression
multiple interactions
increases secretion

Mebendazole results in increased expression of CXCL8 mRNA; Mebendazole results in increased expression of CXCL8 protein
U 0126 inhibits the reaction [Mebendazole results in increased secretion of CXCL8 protein]

PMID:20116850 PMID:20848085 PMID:24747151 PMID:32816093

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Mebendazole results in increased expression of CYP1A1 mRNA; Mebendazole results in increased expression of CYP1A1 protein

PMID:9860486 PMID:12841937

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Mebendazole results in increased expression of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

epiregulin

increases expression

Mebendazole results in increased expression of EREG mRNA

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

FBJ osteosarcoma oncogene

increases expression

Mebendazole results in increased expression of FOS mRNA

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

glyceraldehyde-3-phosphate dehydrogenase

decreases expression
affects binding

Mebendazole results in decreased expression of GAPDH mRNA
Mebendazole binds to GAPDH protein

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

glutathione S-transferase, pi 1

multiple interactions

Mebendazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

hes family bHLH transcription factor 1

decreases expression

Mebendazole results in decreased expression of HES1 protein

NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614

G

hexokinase 1

affects binding
decreases expression

Mebendazole binds to HK1 protein
Mebendazole results in decreased expression of HK1 mRNA

NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687

G

interleukin 1 alpha

increases expression

Mebendazole results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases expression

Mebendazole results in increased expression of IL1B mRNA

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 24

increases expression

Mebendazole results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 6 receptor, alpha

increases expression

Mebendazole results in increased expression of IL6R protein modified form

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

lactate dehydrogenase A

decreases expression
decreases activity
affects binding

Mebendazole results in decreased expression of LDHA mRNA
Mebendazole results in decreased activity of LDHA protein
Mebendazole binds to LDHA protein

NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051

G

mitogen-activated protein kinase 1

increases phosphorylation

Mebendazole results in increased phosphorylation of MAPK1 protein

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

increases phosphorylation

Mebendazole results in increased phosphorylation of MAPK3 protein

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

increases phosphorylation

Mebendazole results in increased phosphorylation of MAPK8 protein

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

mitogen-activated protein kinase 9

increases phosphorylation

Mebendazole results in increased phosphorylation of MAPK9 protein

NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248

G

microtubule-associated protein tau

decreases expression

Mebendazole results in decreased expression of MAPT protein

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

met proto-oncogene

increases expression

Mebendazole results in increased expression of MET mRNA

NCBI chr 6:17,463,351...17,573,979
Ensembl chr 6:17,463,799...17,573,979

G

myelocytomatosis oncogene

decreases expression

Mebendazole results in decreased expression of MYC mRNA; Mebendazole results in decreased expression of MYC protein

PMID:31207347 PMID:32277947

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

NLR family, pyrin domain containing 3

increases expression

Mebendazole results in increased expression of NLRP3 mRNA

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

notch 1

decreases expression

Mebendazole results in decreased expression of NOTCH1 protein

NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Mebendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

phosphotyrosine interaction domain containing 1

increases expression

Mebendazole results in increased expression of PID1 mRNA

NCBI chr 1:84,014,014...84,317,550
Ensembl chr 1:84,014,017...84,341,901

G

prostaglandin-endoperoxide synthase 2

increases expression

Mebendazole results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

PTK2 protein tyrosine kinase 2

decreases expression

Mebendazole results in decreased expression of PTK2 protein

NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129

G

Rac family small GTPase 1

decreases expression

Mebendazole results in decreased expression of RAC1 protein

NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791

G

ras homolog family member A

decreases expression

Mebendazole results in decreased expression of RHOA protein

NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133

G

S100 calcium binding protein A8 (calgranulin A)

increases expression

Mebendazole results in increased expression of S100A8 mRNA

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

G

S100 calcium binding protein A9 (calgranulin B)

increases expression

Mebendazole results in increased expression of S100A9 mRNA

NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028

G

solute carrier family 2 (facilitated glucose transporter), member 1

affects binding
decreases expression

Mebendazole binds to SLC2A1 protein
Mebendazole results in decreased expression of SLC2A1 mRNA

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

solute carrier family 47, member 1

decreases expression

Mebendazole results in decreased expression of SLC47A1 mRNA

NCBI chr11:61,234,226...61,269,668
Ensembl chr11:61,234,227...61,269,171

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Mebendazole results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

secretory leukocyte peptidase inhibitor

increases expression

Mebendazole results in increased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

G

transforming growth factor, beta 1

multiple interactions

Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; Mebendazole inhibits the reaction [TGFB1 protein results in increased expression of CDH2 protein]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

thyroid hormone receptor alpha

multiple interactions

Mebendazole binds to and results in decreased activity of THRA protein

NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832

G

tumor necrosis factor

multiple interactions
increases expression
increases secretion

U 0126 inhibits the reaction [Mebendazole results in increased secretion of TNF protein]
Mebendazole results in increased expression of TNF mRNA

PMID:20848085 PMID:24747151

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

vascular endothelial growth factor A

increases expression

Mebendazole results in increased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

Mizolastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

intercellular adhesion molecule 1

decreases expression

mizolastine results in decreased expression of ICAM1

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity

mizolastine results in decreased activity of KCNH2 protein

PMID:11082114 PMID:28551711

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

nocodazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family member 2

decreases expression

Nocodazole results in decreased expression of ABCC2 mRNA; Nocodazole results in decreased expression of ABCC2 protein

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

increases expression

Nocodazole results in increased expression of ABCC3 mRNA

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

actin alpha 2, smooth muscle, aorta

multiple interactions
increases expression

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Nocodazole results in increased expression of ACTA2 mRNA]

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

aryl-hydrocarbon receptor

decreases activity

Nocodazole results in decreased activity of AHR protein

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

anaphase promoting complex subunit 2

multiple interactions

Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein]

NCBI chr 2:25,162,469...25,175,928
Ensembl chr 2:25,162,490...25,175,927

G

androgen receptor

multiple interactions
decreases localization

Nocodazole inhibits the reaction [Dihydrotestosterone results in increased localization of AR protein]
Nocodazole results in decreased localization of AR protein

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ataxia telangiectasia mutated

multiple interactions

Doxorubicin inhibits the reaction [Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]]; Nocodazole inhibits the reaction [Hydroxyurea results in increased phosphorylation of ATM protein]

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

G

ATPase, copper transporting, beta polypeptide

multiple interactions

Nocodazole inhibits the reaction [Copper affects the localization of ATP7B protein]

NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321

G

aurora kinase A

multiple interactions

[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased expression of and results in increased phosphorylation of AURKA protein; MLN8054 inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKA protein]

NCBI chr 2:172,198,116...172,212,825
Ensembl chr 2:172,198,110...172,212,455

G

aurora kinase B

multiple interactions

4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein]; [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Nocodazole] results in increased phosphorylation of AURKB protein

NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490

G

BCL2-associated X protein

increases expression

Nocodazole analog results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

increases phosphorylation
decreases expression
multiple interactions

Nocodazole results in increased phosphorylation of BCL2 protein
Nocodazole analog results in decreased expression of BCL2 protein
TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]

PMID:15907805 PMID:28412508

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

baculoviral IAP repeat-containing 5

multiple interactions

Nocodazole affects the reaction [BIRC5 protein affects the susceptibility to Melphalan]

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

BUB1, mitotic checkpoint serine/threonine kinase

multiple interactions
increases phosphorylation

[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form; chromium hexavalent ion inhibits the reaction [Nocodazole results in increased phosphorylation of BUB1 protein]

NCBI chr 2:127,642,117...127,673,790
Ensembl chr 2:127,643,036...127,673,785

G

capping actin protein of muscle Z-line subunit alpha 1

multiple interactions

[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole

NCBI chr 3:104,730,097...104,771,821
Ensembl chr 3:104,730,095...104,771,821

G

capping actin protein of muscle Z-line subunit alpha 2

multiple interactions

[CAPZA1 protein co-treated with CAPZA2 protein] results in decreased susceptibility to Nocodazole

NCBI chr 6:17,637,009...17,666,971
Ensembl chr 6:17,636,233...17,666,971

G

caspase 3

increases cleavage
multiple interactions
decreases expression

Nocodazole results in increased cleavage of CASP3 protein
[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; [Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]
Nocodazole analog results in decreased expression of CASP3 protein

PMID:21903591 PMID:28412508 PMID:31597699

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases cleavage
multiple interactions

Nocodazole analog results in increased cleavage of CASP8 protein
Caspase Inhibitors inhibits the reaction [Nocodazole analog results in increased expression of CASP8 protein modified form]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

increases cleavage

Nocodazole analog results in increased cleavage of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

cell division cycle and apoptosis regulator 1

multiple interactions
increases expression

Nocodazole inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein]; Nocodazole promotes the reaction [CCAR1 protein binds to ANAPC2 protein]
Nocodazole results in increased expression of CCAR1 protein

PMID:19073175 PMID:21903591

NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065

G

C-C motif chemokine ligand 2

increases expression

Nocodazole results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cyclin B1

increases expression

Nocodazole analog results in increased expression of CCNB1 protein; Nocodazole results in increased expression of CCNB1 protein

PMID:21670593 PMID:28412508

NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078

G

cyclin dependent kinase 1

increases expression

Nocodazole analog results in increased expression of CDK1 protein

NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768

G

chromatin licensing and DNA replication factor 1

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of and results in decreased phosphorylation of CDT1 protein

NCBI chr 8:123,294,754...123,299,869
Ensembl chr 8:123,294,754...123,300,293

G

cystic fibrosis transmembrane conductance regulator

affects localization
multiple interactions

Nocodazole affects the localization of CFTR protein
Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]

PMID:12529251 PMID:15994425

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

checkpoint kinase 1

decreases expression

Nocodazole results in decreased expression of CHEK1 protein

NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361

G

colony stimulating factor 2 (granulocyte-macrophage)

multiple interactions

Nocodazole inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Nocodazole inhibits the reaction [Quercetin results in increased secretion of CSF2 protein]

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

C-X-C motif chemokine ligand 15

increases expression

Nocodazole results in increased expression of CXCL8 protein

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Nocodazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of and results in increased activity of CYP1A1 protein]; Nocodazole inhibits the reaction [benzotriphenylene results in increased expression of CYP1A1 mRNA]

PMID:8190110 PMID:16611024

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

epidermal growth factor

multiple interactions

Nocodazole inhibits the reaction [EGF protein results in increased expression of PSA mRNA]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

Fas ligand

multiple interactions

[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

F-box protein 5

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in decreased expression of FBXO5 protein

NCBI chr10:5,749,155...5,755,465
Ensembl chr10:5,749,160...5,755,600

G

fission, mitochondrial 1

increases expression

Nocodazole results in increased expression of FIS1 protein

NCBI chr 5:136,982,129...136,995,088
Ensembl chr 5:136,982,129...136,995,088

G

geminin

multiple interactions

[Nocodazole co-treated with chromium hexavalent ion] results in increased ubiquitination of GMNN protein

NCBI chr13:24,935,828...24,954,222
Ensembl chr13:24,935,828...24,945,906

G

H2A.X variant histone

increases expression

Nocodazole results in increased expression of H2AX protein modified form

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

hepcidin antimicrobial peptide

decreases expression

Nocodazole results in decreased expression of HAMP mRNA

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

heat shock protein 5

increases expression

Nocodazole results in increased expression of HSPA5 protein

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

interleukin 1 beta

multiple interactions

Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 receptor, alpha

increases expression

Nocodazole results in increased expression of IL6R protein modified form

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

jun proto-oncogene

increases phosphorylation
multiple interactions

Nocodazole results in increased phosphorylation of JUN protein
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

leucine carboxyl methyltransferase 1

decreases response to substance

LCMT1 results in decreased susceptibility to Nocodazole

NCBI chr 7:122,977,026...123,029,581
Ensembl chr 7:122,969,007...123,029,581

G

leucine zipper, putative tumor suppressor 1

affects response to substance

LZTS1 protein affects the susceptibility to Nocodazole

NCBI chr 8:69,585,311...69,636,901
Ensembl chr 8:69,585,321...69,636,877

G

mitogen-activated protein kinase 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]
Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]

PMID:15907805 PMID:17822405

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]

PMID:15907805 PMID:17822405

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

mitogen-activated protein kinase 9

increases phosphorylation
multiple interactions

Nocodazole results in increased phosphorylation of MAPK9 protein
TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]

NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248

G

microtubule-associated protein tau

decreases expression

Nocodazole results in decreased expression of MAPT protein

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

myelin transcription factor 1

increases phosphorylation

Nocodazole results in increased phosphorylation of MYT1 protein

NCBI chr 2:181,405,099...181,469,579
Ensembl chr 2:181,405,125...181,469,590

G

Nanog homeobox

decreases expression

Nocodazole results in decreased expression of NANOG protein

NCBI chr 6:122,684,448...122,691,592
Ensembl chr 6:122,684,448...122,691,592

G

nerve growth factor

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]; Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK1 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of MAPK3 protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]

NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329

G

notch 1

multiple interactions
decreases expression

BI 2536 inhibits the reaction [Nocodazole results in decreased expression of NOTCH1 protein]; Doxorubicin inhibits the reaction [Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]]; Nocodazole promotes the reaction [Hydroxyurea results in decreased expression of NOTCH1 protein]; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]]

NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675

G

NPC intracellular cholesterol transporter 1

multiple interactions

Nocodazole inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]

NCBI chr18:12,322,751...12,369,851
Ensembl chr18:12,322,749...12,369,457

G

nucleophosmin 1

affects phosphorylation

Nocodazole affects the phosphorylation of NPM1 protein

NCBI chr11:33,102,498...33,114,143
Ensembl chr11:33,102,287...33,113,206

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

Nocodazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

neurotrophic tyrosine kinase, receptor, type 1

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of NTRK1 protein]

NCBI chr 3:87,685,551...87,702,549
Ensembl chr 3:87,685,551...87,702,469

G

optineurin

affects localization

Nocodazole affects the localization of OPTN protein

NCBI chr 2:5,023,902...5,069,210
Ensembl chr 2:5,025,453...5,068,862

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions
increases cleavage

TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]
Nocodazole analog results in increased cleavage of PARP1 protein; Nocodazole results in increased cleavage of PARP1 protein

PMID:15907805 PMID:21903591 PMID:28412508

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

polo like kinase 1

multiple interactions
decreases phosphorylation

[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein; Doxorubicin affects the reaction [[Hydroxyurea co-treated with Nocodazole] affects the expression of and affects the phosphorylation of PLK1 protein]
Nocodazole results in decreased phosphorylation of PLK1 protein

NCBI chr 7:121,758,658...121,769,107
Ensembl chr 7:121,758,662...121,769,096

G

POU domain, class 5, transcription factor 1

decreases expression

Nocodazole results in decreased expression of POU5F1 protein

NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669

G

protein phosphatase 2, regulatory subunit B, alpha

decreases response to substance

PPP2R2A results in decreased susceptibility to Nocodazole

NCBI chr14:67,251,505...67,309,920
Ensembl chr14:67,251,505...67,309,893

G

glutamine-rich 1

multiple interactions
increases phosphorylation

Genistein inhibits the reaction [Nocodazole results in increased phosphorylation of QRICH1 protein]

NCBI chr 9:108,394,010...108,437,366
Ensembl chr 9:108,394,005...108,437,362

G

RAN GTPase activating protein 1

multiple interactions

Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]

NCBI chr15:81,588,449...81,614,120
Ensembl chr15:81,588,449...81,629,731

G

RAS-related protein 1a

multiple interactions

Nocodazole inhibits the reaction [NGF protein affects the localization of RAP1A protein]; Nocodazole inhibits the reaction [NGF protein results in increased activity of RAP1A protein]

NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Nocodazole inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Nocodazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

small ubiquitin-like modifier 1

multiple interactions

Nocodazole results in increased phosphorylation of [SUMO1 protein binds to RANGAP1 protein]

NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993

G

tumor necrosis factor

multiple interactions

Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nocodazole inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transferrin

decreases expression

Nocodazole results in decreased expression of TRF protein

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

transformation related protein 53

multiple interactions
increases expression

TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of JUN protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK8 protein]; TP53 protein affects the reaction [Nocodazole results in increased phosphorylation of MAPK9 protein]
Nocodazole analog results in increased expression of TP53 protein; Nocodazole results in increased expression of TP53 protein

PMID:12221076 PMID:21559451 PMID:28412508

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

tubulin, alpha 1A

multiple interactions

Nocodazole inhibits the reaction [TUBA1A protein binds to TUBA1A protein]

NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584

G

thymidine phosphorylase

multiple interactions

[TYMP co-treated with Nocodazole] results in decreased expression of FASLG mRNA; [TYMP co-treated with Nocodazole] results in decreased expression of FASLG protein; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK1 protein]; TYMP affects the reaction [Nocodazole results in increased phosphorylation of and results in increased activity of MAPK3 protein]; TYMP inhibits the reaction [Nocodazole results in increased cleavage of PARP1 protein]; TYMP inhibits the reaction [Nocodazole results in increased phosphorylation of BCL2 protein]

NCBI chr15:89,255,834...89,261,282
Ensembl chr15:89,256,134...89,261,242

G

vascular endothelial growth factor A

increases expression

Nocodazole results in increased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

NS 1619

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

B cell leukemia/lymphoma 2

multiple interactions

NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

FMS-like tyrosine kinase 1

multiple interactions

NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]; paxilline inhibits the reaction [NS 1619 inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

G

potassium large conductance calcium-activated channel, subfamily M, alpha member 1

multiple interactions

NS 1619 binds to and results in increased activity of KCNMA1 protein; NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]

NCBI chr14:23,342,356...24,055,173
Ensembl chr14:23,339,499...24,064,559

G

potassium large conductance calcium-activated channel, subfamily M, beta member 1

multiple interactions

NS 1619 inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]]; NS 1619 inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]

NCBI chr11:33,912,955...33,923,641
Ensembl chr11:33,913,013...33,923,641

omeprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

increases expression

Omeprazole results in increased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family B member 11

decreases activity

Omeprazole results in decreased activity of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

affects expression
multiple interactions

Omeprazole affects the expression of ABCB1A mRNA
Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein]
Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein]

PMID:19483382 PMID:30452898

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 4

decreases expression

Omeprazole results in decreased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family member 2

multiple interactions

[Omeprazole results in increased susceptibility to Cisplatin] which results in decreased expression of ABCC2 protein

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

increases expression

Omeprazole results in increased expression of ABCC3 mRNA

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 6

affects expression

Omeprazole affects the expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP binding cassette subfamily G member 2 (Junior blood group)

increases expression
multiple interactions

Omeprazole results in increased expression of ABCG2 mRNA alternative form; Omeprazole results in increased expression of ABCG2 protein
Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow]

PMID:20804740 PMID:31348918

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

ATP binding cassette subfamily G member 5

affects expression

Omeprazole affects the expression of ABCG5 mRNA

NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439

G

abhydrolase domain containing 1

affects expression

Omeprazole affects the expression of ABHD1 mRNA

NCBI chr 5:31,107,410...31,112,439
Ensembl chr 5:31,107,410...31,112,435

G

abhydrolase domain containing 14b

affects expression

Omeprazole affects the expression of ABHD14B mRNA

NCBI chr 9:106,324,936...106,330,122
Ensembl chr 9:106,324,658...106,330,122

G

abhydrolase domain containing 17A

affects expression

Omeprazole affects the expression of ABHD17A mRNA

NCBI chr10:80,419,483...80,426,199
Ensembl chr10:80,419,488...80,426,175

G

acetyl-Coenzyme A carboxylase alpha

affects expression

Omeprazole affects the expression of ACACA mRNA

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A dehydrogenase, long-chain

affects expression

Omeprazole affects the expression of ACADL mRNA

NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436

G

angiotensin converting enzyme 2

decreases expression

Omeprazole results in decreased expression of ACE2 mRNA

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

aconitase 1

affects expression

Omeprazole affects the expression of ACO1 mRNA

NCBI chr 4:40,143,429...40,199,011
Ensembl chr 4:40,143,081...40,198,338

G

aconitase 2, mitochondrial

affects expression

Omeprazole affects the expression of ACO2 mRNA

NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334

G

acyl-CoA thioesterase 12

affects expression

Omeprazole affects the expression of ACOT12 mRNA

NCBI chr13:91,889,635...91,934,271
Ensembl chr13:91,889,631...91,934,267

G

acyl-CoA thioesterase 4

affects expression

Omeprazole affects the expression of ACOT4 mRNA

NCBI chr12:84,084,028...84,091,497
Ensembl chr12:84,085,153...84,095,375

G

ADAM metallopeptidase domain 15

affects expression

Omeprazole affects the expression of ADAM15 mRNA

NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303

G

adducin 1

affects expression

Omeprazole affects the expression of ADD1 mRNA

NCBI chr 5:34,731,008...34,789,652
Ensembl chr 5:34,731,008...34,789,652

G

alcohol dehydrogenase 1 (class I)

decreases expression

Omeprazole results in decreased expression of ADH1C mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

alcohol dehydrogenase 4 (class II), pi polypeptide

affects expression

Omeprazole affects the expression of ADH4 mRNA

NCBI chr 3:138,121,217...138,138,444
Ensembl chr 3:138,121,227...138,136,653

G

androgen dependent TFPI regulating protein

affects expression

Omeprazole affects the expression of ADTRP mRNA

NCBI chr13:41,916,621...42,001,092
Ensembl chr13:41,916,624...42,001,160

G

afamin

affects expression

Omeprazole affects the expression of AFM mRNA

NCBI chr 5:90,666,808...90,701,403
Ensembl chr 5:90,666,791...90,701,402

G

angiotensinogen

affects expression

Omeprazole affects the expression of AGT mRNA

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

affects expression

Omeprazole affects the expression of AGTR1A mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

aryl-hydrocarbon receptor

multiple interactions
decreases activity
increases activity
increases expression
decreases expression
affects localization
increases response to substance

AG-879 inhibits the reaction [Omeprazole results in increased activity of AHR protein]; AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of AHR mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]; Omeprazole binds to and results in increased activity of AHR protein; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; Puromycin inhibits the reaction [Omeprazole results in increased expression of AHR protein]
Omeprazole results in decreased activity of AHR protein
Omeprazole affects the localization of AHR protein
AHR protein results in increased susceptibility to Omeprazole
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]

PMID:9139728 PMID:9395520 PMID:14742684 PMID:16109480 PMID:20171196 More...

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

aldo-keto reductase family 1, member A1

affects expression

Omeprazole affects the expression of AKR1A1 mRNA

NCBI chr 4:116,493,707...116,508,871
Ensembl chr 4:116,493,707...116,508,877

G

aldo-keto reductase family 7, member A5

affects expression

Omeprazole affects the expression of AKR7A2 mRNA

NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737

G

aldehyde dehydrogenase family 1, subfamily A1

affects expression
multiple interactions

Omeprazole affects the expression of ALDH1A1 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ALDH1A1 mRNA

PMID:19483382 PMID:22687989

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A3

increases expression

Omeprazole results in increased expression of ALDH1A3 mRNA

NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265

G

aldehyde dehydrogenase 2, mitochondrial

affects expression

Omeprazole affects the expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase family 3, subfamily A1

increases expression

Omeprazole results in increased expression of ALDH3A1 mRNA

NCBI chr11:61,099,336...61,109,244
Ensembl chr11:61,098,363...61,109,247

G

alkB homolog 7

affects expression

Omeprazole affects the expression of ALKBH7 mRNA

NCBI chr17:57,304,339...57,306,340
Ensembl chr17:57,304,339...57,306,322

G

ankyrin repeat domain 40

increases expression

Omeprazole results in increased expression of TMPRSS2 mRNA

NCBI chr11:94,218,827...94,232,673
Ensembl chr11:94,218,827...94,232,667

G

adaptor-related protein complex 2, mu 1 subunit

affects expression

Omeprazole affects the expression of AP2M1 mRNA

NCBI chr16:20,354,230...20,363,659
Ensembl chr16:20,354,228...20,363,659

G

amyloid P component, serum

affects expression

Omeprazole affects the expression of APCS mRNA

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

apolipoprotein A-IV

affects expression

Omeprazole affects the expression of APOA4 mRNA

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein H

affects expression

Omeprazole affects the expression of APOH mRNA

NCBI chr11:108,286,123...108,305,222
Ensembl chr11:108,234,180...108,305,222

G

apolipoprotein O-like

affects expression

Omeprazole affects the expression of APOOL mRNA

NCBI chr X:111,221,049...111,282,452
Ensembl chr X:111,221,031...111,282,452

G

arginase, liver

affects expression

Omeprazole affects the expression of ARG1 mRNA

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

ADP-ribosylation factor-like 6 interacting protein 1

affects expression

Omeprazole affects the expression of ARL6IP1 mRNA

NCBI chr 7:117,718,113...117,728,848
Ensembl chr 7:117,718,114...117,728,885

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions
affects localization

Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]
Omeprazole affects the localization of ARNT protein
Omeprazole affects the localization of [ARNT protein co-treated with AHR protein]

PMID:9395520 PMID:21703235 PMID:25826687

NCBI chr 3:95,341,674...95,404,551
Ensembl chr 3:95,341,699...95,404,551

G

asialoglycoprotein receptor 2

affects expression

Omeprazole affects the expression of ASGR2 mRNA

NCBI chr11:69,983,470...69,997,013
Ensembl chr11:69,983,470...69,997,013

G

activating transcription factor 5

affects expression

Omeprazole affects the expression of ATF5 mRNA

NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082

G

ATP synthase F1 subunit epsilon

affects expression

Omeprazole affects the expression of ATP5F1E mRNA

NCBI chr 2:174,302,868...174,305,894
Ensembl chr 2:174,302,865...174,305,898

G

ATPase, H+ transporting, lysosomal accessory protein 2

affects expression

Omeprazole affects the expression of ATP6AP2 mRNA

NCBI chr X:12,453,998...12,483,290
Ensembl chr X:12,454,040...12,483,288

G

ATPase, H+ transporting, lysosomal V1 subunit A

affects expression

Omeprazole affects the expression of ATP6V1A mRNA

NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068

G

ATPase, H+ transporting, lysosomal V1 subunit F

affects expression

Omeprazole affects the expression of ATP6V1F mRNA

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

ATPase, copper transporting, alpha polypeptide

multiple interactions

Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein]
Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein]

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

bile acid-Coenzyme A: amino acid N-acyltransferase

affects expression

Omeprazole affects the expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BCL2-associated X protein

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell CLL/lymphoma 6, member B

affects expression

Omeprazole affects the expression of BCL6B mRNA

NCBI chr11:70,114,953...70,120,624
Ensembl chr11:70,114,954...70,120,624

G

bridge-like lipid transfer protein family member 3B

affects expression

Omeprazole affects the expression of BLTP3B mRNA

NCBI chr10:89,580,830...89,655,753
Ensembl chr10:89,580,853...89,655,733

G

BCL2 modifying factor

affects expression

Omeprazole affects the expression of BMF mRNA

NCBI chr 2:118,359,238...118,385,240
Ensembl chr 2:118,359,238...118,380,168

G

BMX non-receptor tyrosine kinase

multiple interactions

BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]

NCBI chr X:162,975,838...163,041,189
Ensembl chr X:162,975,838...163,041,189

G

BCL2/adenovirus E1B interacting protein 3

affects expression

Omeprazole affects the expression of BNIP3 mRNA

NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248

G

basic transcription factor 3

affects expression

Omeprazole affects the expression of BTF3 mRNA

NCBI chr13:98,446,405...98,453,514
Ensembl chr13:98,446,404...98,453,514

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

Omeprazole results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent binding protein

affects expression

Omeprazole affects the expression of C1QBP mRNA

NCBI chr11:70,868,672...70,873,852
Ensembl chr11:70,868,662...70,873,852

G

complement component 1, q subcomponent, C chain

decreases expression

Omeprazole results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

complement component 1, s subcomponent 1

affects expression

Omeprazole affects the expression of C1S mRNA

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

C2 calcium-dependent domain containing 2

affects expression

Omeprazole affects the expression of C2CD2 mRNA

NCBI chr16:97,656,409...97,727,248
Ensembl chr16:97,656,409...97,763,798

G

complement component 7

affects expression

Omeprazole affects the expression of C7 mRNA

NCBI chr15:5,017,232...5,093,230
Ensembl chr15:5,018,244...5,093,222

G

complement component 8, beta polypeptide

affects expression

Omeprazole affects the expression of C8B mRNA

NCBI chr 4:104,623,514...104,661,745
Ensembl chr 4:104,623,514...104,661,745

G

Ca2+-dependent activator protein for secretion 2

affects expression

Omeprazole affects the expression of CADPS2 mRNA

NCBI chr 6:23,262,765...23,840,662
Ensembl chr 6:23,262,772...23,839,420

G

cell cycle associated protein 1

affects expression

Omeprazole affects the expression of CAPRIN1 mRNA

NCBI chr 2:103,593,292...103,627,946
Ensembl chr 2:103,593,286...103,627,994

G

carbonic anhydrase 2

affects expression

Omeprazole affects the expression of CA2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

carbonic anhydrase 3

affects expression

Omeprazole affects the expression of CAR3 mRNA

NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583

G

caspase 3

increases activity
multiple interactions
affects expression
increases cleavage

Omeprazole analog results in increased activity of CASP3 protein; Omeprazole results in increased activity of CASP3 protein
Omeprazole inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
Omeprazole inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]
Omeprazole affects the expression of CASP3 mRNA
Omeprazole results in increased cleavage of CASP3 protein

PMID:15461867 PMID:18336733 PMID:19251492 PMID:19483382 PMID:25637687 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases cleavage

Omeprazole analog results in increased cleavage of CASP8 protein

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

increases activity
multiple interactions

Omeprazole results in increased activity of CAT protein
Omeprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]
Omeprazole inhibits the reaction [Acetic Acid results in increased activity of CAT protein]

PMID:18547560 PMID:28849987 PMID:33245926

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

carbonyl reductase 1

affects expression

Omeprazole affects the expression of CBR1 mRNA

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

cholecystokinin B receptor

multiple interactions

[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

cyclin D1

decreases expression

Omeprazole results in decreased expression of CCND1 mRNA

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin dependent kinase inhibitor 1A

increases expression

Omeprazole results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cysteine dioxygenase 1, cytosolic

affects expression

Omeprazole affects the expression of CDO1 mRNA

NCBI chr18:46,846,260...46,861,569
Ensembl chr18:46,846,260...46,861,462

G

choline/ethanolaminephosphotransferase 1

affects expression

Omeprazole affects the expression of CEPT1 mRNA

NCBI chr 3:106,409,576...106,455,118
Ensembl chr 3:106,409,576...106,455,118

G

carboxylesterase 2H

affects expression

Omeprazole affects the expression of CES2 mRNA

NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810

G

complement component factor i

affects expression
decreases expression

Omeprazole affects the expression of CFI mRNA
Omeprazole results in decreased expression of CFI mRNA

PMID:19483382 PMID:25626140

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

cystic fibrosis transmembrane conductance regulator

affects metabolic processing

CFTR protein affects the metabolism of Omeprazole

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

calcineurin-like EF hand protein 1

affects expression

Omeprazole affects the expression of CHP1 mRNA

NCBI chr 2:119,378,172...119,417,505
Ensembl chr 2:119,378,178...119,417,508

G

CDGSH iron sulfur domain 1

affects expression

Omeprazole affects the expression of CISD1 mRNA

NCBI chr10:71,166,324...71,180,679
Ensembl chr10:71,166,310...71,180,784

G

chloride channel, voltage-sensitive 4

affects expression

Omeprazole affects the expression of CLCN4 mRNA

NCBI chr 7:7,285,308...7,303,837
Ensembl chr 7:7,285,308...7,303,850

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

affects expression

Omeprazole affects the expression of CLPP mRNA

NCBI chr17:57,297,264...57,303,371
Ensembl chr17:57,297,305...57,303,188

G

CLPTM1-like

affects expression

Omeprazole affects the expression of CLPTM1L mRNA

NCBI chr13:73,752,121...73,768,758
Ensembl chr13:73,752,125...73,768,724

G

carboxymethylenebutenolidase homolog

affects expression

Omeprazole affects the expression of CMBL mRNA

NCBI chr15:31,565,314...31,590,266
Ensembl chr15:31,565,535...31,590,265

G

cytidine/uridine monophosphate kinase 1

affects expression

Omeprazole affects the expression of CMPK1 mRNA

NCBI chr 4:114,817,810...114,844,425
Ensembl chr 4:114,816,533...114,844,438

G

coatomer protein complex, subunit gamma 1

affects expression

Omeprazole affects the expression of COPG1 mRNA

NCBI chr 6:87,864,801...87,890,577
Ensembl chr 6:87,864,796...87,890,577

G

COP9 signalosome subunit 4

affects expression

Omeprazole affects the expression of COPS4 mRNA

NCBI chr 5:100,666,223...100,695,668
Ensembl chr 5:100,666,175...100,695,669

G

coenzyme Q3 methyltransferase

affects expression

Omeprazole affects the expression of COQ3 mRNA

NCBI chr 4:21,879,646...21,912,163
Ensembl chr 4:21,879,673...21,912,162

G

cytochrome c oxidase subunit 4I1

affects expression

Omeprazole affects the expression of COX4I1 mRNA

NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946

G

carboxypeptidase N, polypeptide 1

affects expression

Omeprazole affects the expression of CPN1 mRNA

NCBI chr19:43,944,746...43,974,990
Ensembl chr19:43,944,746...43,974,995

G

carboxypeptidase Q

affects expression

Omeprazole affects the expression of CPQ mRNA

NCBI chr15:33,083,275...33,594,698
Ensembl chr15:33,083,275...33,594,698

G

cAMP responsive element modulator

affects expression

Omeprazole affects the expression of CREM mRNA

NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748

G

casein kinase 2, beta polypeptide

affects expression

Omeprazole affects the expression of CSNK2B mRNA

NCBI chr17:35,335,171...35,341,029
Ensembl chr17:35,335,172...35,341,029

G

cysteine and glycine-rich protein 1

affects expression

Omeprazole affects the expression of CSRP1 mRNA

NCBI chr 1:135,614,650...135,679,970
Ensembl chr 1:135,647,799...135,679,970

G

catenin alpha 1

affects expression

Omeprazole affects the expression of CTNNA1 mRNA

NCBI chr18:35,251,955...35,387,829
Ensembl chr18:35,251,912...35,387,832

G

cathepsin B

decreases activity

Omeprazole results in decreased activity of CTSB protein

NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372

G

cathepsin D

multiple interactions

Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

cathepsin E

decreases expression

Omeprazole results in decreased expression of CTSE

NCBI chr 1:131,566,052...131,603,245
Ensembl chr 1:131,566,044...131,603,243

G

C-X-C motif chemokine receptor 4

decreases expression
multiple interactions

Omeprazole results in decreased expression of CXCR4 mRNA
AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]

NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
multiple interactions
decreases activity
increases expression

Omeprazole results in increased activity of CYP1A1 promoter
Omeprazole inhibits the reaction [Oxygen results in increased expression of CYP1A1 protein]; Omeprazole promotes the reaction [Oxygen results in decreased expression of CYP1A1 mRNA]
Omeprazole results in decreased activity of CYP1A1 protein
Omeprazole results in increased expression of CYP1A1 mRNA; Omeprazole results in increased expression of CYP1A1 protein
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; lavendustin A inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]
AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]

PMID:8647108 PMID:8900397 PMID:9041675 PMID:9139728 PMID:9152597 More...

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases activity
increases expression
decreases activity
multiple interactions

Omeprazole results in increased activity of CYP1A2 promoter; Omeprazole results in increased activity of CYP1A2 protein
Omeprazole results in increased expression of CYP1A2 mRNA; Omeprazole results in increased expression of CYP1A2 protein
Omeprazole results in decreased activity of CYP1A2 protein
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA
[Omeprazole results in increased expression of CYP1A2 protein] which results in decreased alkylation of Phenacetin; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; Omeprazole results in increased expression of and results in increased activity of CYP1A2 protein

PMID:9152597 PMID:9744552 PMID:12040753 PMID:12623754 PMID:12841937 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
affects expression
decreases activity
increases expression

Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]
Omeprazole affects the expression of CYP1B1 mRNA
Omeprazole results in decreased activity of CYP1B1 protein
Omeprazole results in increased expression of CYP1B1 mRNA

PMID:12040753 PMID:12623754 PMID:18420780 PMID:21703235 PMID:25826687

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily a, polypeptide 22

affects expression

Omeprazole affects the expression of CYP2A1 mRNA

NCBI chr 7:26,631,564...26,638,838
Ensembl chr 7:26,631,056...26,638,809

G

cytochrome P450, family 2, subfamily b, polypeptide 10

decreases activity
affects expression
increases expression
increases activity

Omeprazole results in decreased activity of CYP2B10 protein
Omeprazole affects the expression of CYP2B3 mRNA
Omeprazole results in increased expression of CYP2B6 mRNA
Omeprazole results in increased activity of CYP2B6 protein

PMID:17954527 PMID:18420780 PMID:19118567 PMID:19483382 PMID:22524704

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

increases expression
affects expression

Omeprazole results in increased expression of CYP2B2 protein
Omeprazole affects the expression of CYP2B2 mRNA

PMID:9152597 PMID:19483382

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2. subfamily c, polypeptide 37

multiple interactions
increases metabolic processing

[CYP2C37 protein results in increased metabolism of Omeprazole] which results in increased chemical synthesis of 5-hydroxymethylomeprazole

NCBI chr19:39,980,868...40,000,687
Ensembl chr19:39,980,868...40,000,687

G

cytochrome P450, family 2, subfamily c, polypeptide 38

affects metabolic processing
multiple interactions
decreases activity
increases metabolic processing
increases hydroxylation
decreases metabolic processing

CYP2C19 protein affects the metabolism of Omeprazole
[5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]; Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of Clopidogrel]
CYP2C19 protein results in increased metabolism of Omeprazole
CYP2C19 protein results in increased hydroxylation of Omeprazole
CYP2C19 gene alternative form results in decreased metabolism of Omeprazole

PMID:8930576 PMID:9600717 PMID:11752104 PMID:12464242 PMID:12467917 More...

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions
decreases activity

Omeprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]
Omeprazole results in decreased activity of CYP2C9 protein

PMID:15258107 PMID:18420780

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily d, polypeptide 22

affects expression
decreases activity

Omeprazole affects the expression of CYP2D4 mRNA
Omeprazole results in decreased activity of CYP2D6 protein

PMID:18420780 PMID:19483382

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Omeprazole results in increased expression of and results in increased activity of CYP2E1 protein

PMID:15802389 PMID:36243147

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily f, polypeptide 2

affects expression

Omeprazole affects the expression of CYP2F4 mRNA

NCBI chr 7:26,819,380...26,833,085
Ensembl chr 7:26,819,334...26,833,085

G

cytochrome P450, family 2, subfamily j, polypeptide 9

affects expression

Omeprazole affects the expression of CYP2J4 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 3, subfamily a, polypeptide 11

decreases activity

Omeprazole results in decreased activity of CYP3A11 protein

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

affects expression
increases expression

Omeprazole affects the expression of CYP3A9 mRNA
Omeprazole results in increased expression of CYP3A5 mRNA

PMID:19118567 PMID:19483382

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 44

decreases activity

Omeprazole results in decreased activity of CYP3A4 protein

NCBI chr 5:145,710,793...145,742,701
Ensembl chr 5:145,710,793...145,742,684

G

cytochrome P450, family 4, subfamily f, polypeptide 16

affects expression

Omeprazole affects the expression of CYP4F6 mRNA

NCBI chr17:32,755,517...32,770,772
Ensembl chr17:32,755,532...32,770,772

G

diazepam binding inhibitor

affects expression

Omeprazole affects the expression of DBI mRNA

NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808

G

DDB1 and CUL4 associated factor 11

affects expression

Omeprazole affects the expression of DCAF11 mRNA

NCBI chr14:55,796,557...55,807,522
Ensembl chr14:55,797,463...55,807,522

G

dicarbonyl L-xylulose reductase

affects expression

Omeprazole affects the expression of DCXR mRNA

NCBI chr11:120,615,372...120,618,110
Ensembl chr11:120,616,225...120,618,107

G

DNA-damage inducible transcript 3

increases expression

Omeprazole results in increased expression of DDIT3 protein

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

2,4-dienoyl CoA reductase 1, mitochondrial

affects expression

Omeprazole affects the expression of DECR1 mRNA

NCBI chr 4:15,917,240...15,945,377
Ensembl chr 4:15,917,240...15,945,507

G

dexamethasone-induced transcript

affects expression

Omeprazole affects the expression of DEXI mRNA

NCBI chr16:10,348,071...10,360,918
Ensembl chr16:10,320,395...10,360,918

G

diacylglycerol O-acyltransferase 1

affects expression

Omeprazole affects the expression of DGAT1 mRNA

NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153

G

24-dehydrocholesterol reductase

affects expression

Omeprazole affects the expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

dehydrogenase/reductase 4

affects expression

Omeprazole affects the expression of DHRS4 mRNA

NCBI chr14:55,715,880...55,727,797
Ensembl chr14:55,716,215...55,727,797

G

dehydrogenase/reductase 7B

affects expression

Omeprazole affects the expression of DHRS7B mRNA

NCBI chr11:60,721,457...60,749,249
Ensembl chr11:60,721,457...60,751,021

G

DEAH-box helicase 16

affects expression

Omeprazole affects the expression of DHX16 mRNA

NCBI chr17:36,190,657...36,203,562
Ensembl chr17:36,190,711...36,203,562

G

distal membrane arm assembly component 2 like

affects expression

Omeprazole affects the expression of DMAC2L mRNA

NCBI chr12:69,771,687...69,791,439
Ensembl chr12:69,771,724...69,791,434

G

DnaJ heat shock protein family (Hsp40) member C3

affects expression

Omeprazole affects the expression of DNAJC3 mRNA

NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109

G

dipeptidylpeptidase 4

affects expression

Omeprazole affects the expression of DPP4 mRNA

NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575

G

dihydropyrimidine dehydrogenase

affects expression

Omeprazole affects the expression of DPYD mRNA

NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573

G

glutamyl-tRNA synthetase 2, mitochondrial

affects expression

Omeprazole affects the expression of EARS2 mRNA

NCBI chr 7:121,633,385...121,666,436
Ensembl chr 7:121,636,436...121,666,486

G

enoyl Coenzyme A hydratase, short chain, 1, mitochondrial

affects expression

Omeprazole affects the expression of ECHS1 mRNA

NCBI chr 7:139,685,623...139,696,334
Ensembl chr 7:139,685,623...139,696,389

G

enoyl-Coenzyme A delta isomerase 1

affects expression

Omeprazole affects the expression of ECI1 mRNA

NCBI chr17:24,645,657...24,658,290
Ensembl chr17:24,645,615...24,658,322

G

enoyl-Coenzyme A delta isomerase 2

affects expression

Omeprazole affects the expression of ECI2 mRNA

NCBI chr13:35,161,731...35,211,098
Ensembl chr13:35,161,731...35,211,079

G

eukaryotic translation elongation factor 1 gamma

affects expression

Omeprazole affects the expression of EEF1G mRNA

NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843

G

epidermal growth factor

multiple interactions

Omeprazole promotes the reaction [Indomethacin results in increased expression of EGF protein]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase

affects expression

Omeprazole affects the expression of EHHADH mRNA

NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557

G

eukaryotic translation initiation factor 4A2

affects expression

Omeprazole affects the expression of EIF4A2 mRNA

NCBI chr16:22,924,846...22,932,882
Ensembl chr16:22,926,194...22,932,886

G

eukaryotic translation initiation factor 4E binding protein 1

affects expression

Omeprazole affects the expression of EIF4EBP1 mRNA

NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702

G

eukaryotic translation initiation factor 4H

affects expression

Omeprazole affects the expression of EIF4H mRNA

NCBI chr 5:134,648,726...134,668,263
Ensembl chr 5:134,648,575...134,668,344

G

ectodermal-neural cortex 1

affects expression

Omeprazole affects the expression of ENC1 mRNA

NCBI chr13:97,377,613...97,389,548
Ensembl chr13:97,377,613...97,389,542

G

enolase 1, alpha non-neuron

affects expression

Omeprazole affects the expression of ENO1 mRNA

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

glutamyl aminopeptidase

affects expression

Omeprazole affects the expression of ENPEP mRNA

NCBI chr 3:129,062,826...129,126,398
Ensembl chr 3:129,062,824...129,126,369

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

affects expression

Omeprazole affects the expression of ENPP1 mRNA

NCBI chr10:24,513,812...24,588,057
Ensembl chr10:24,513,812...24,588,057

G

E1A binding protein p300

multiple interactions

Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epithelial cell adhesion molecule

affects expression

Omeprazole affects the expression of EPCAM mRNA

NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557

G

endoplasmic reticulum protein 29

affects expression

Omeprazole affects the expression of ERP29 mRNA

NCBI chr 5:121,582,816...121,590,537
Ensembl chr 5:121,566,653...121,590,569

G

esterase D/formylglutathione hydrolase

affects expression

Omeprazole affects the expression of ESD mRNA

NCBI chr14:74,969,591...74,988,205
Ensembl chr14:74,969,737...74,988,205

G

electron transferring flavoprotein, beta polypeptide

affects expression

Omeprazole affects the expression of ETFB mRNA

NCBI chr 7:43,093,496...43,107,224
Ensembl chr 7:43,093,507...43,107,224

G

fatty acid amide hydrolase

affects expression

Omeprazole affects the expression of FAAH mRNA

NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123

G

fatty acid desaturase 2

affects expression

Omeprazole affects the expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

fructose bisphosphatase 1

affects expression

Omeprazole affects the expression of FBP1 mRNA

NCBI chr13:63,012,567...63,036,112
Ensembl chr13:63,012,567...63,036,096

G

farnesyl diphosphate farnesyl transferase 1

affects expression

Omeprazole affects the expression of FDFT1 mRNA

NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027

G

farnesyl diphosphate synthetase

affects expression

Omeprazole affects the expression of FDPS mRNA

NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266

G

ferredoxin 2

affects expression

Omeprazole affects the expression of FDX2 mRNA

NCBI chr 9:20,978,808...20,984,827
Ensembl chr 9:20,978,816...20,984,910

G

flavin containing monooxygenase 1

affects expression

Omeprazole affects the expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

guanidinoacetate methyltransferase

affects expression

Omeprazole affects the expression of GAMT mRNA

NCBI chr10:80,093,985...80,096,846
Ensembl chr10:80,093,985...80,096,846

G

glyceraldehyde-3-phosphate dehydrogenase

affects expression

Omeprazole affects the expression of GAPDH mRNA

NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430

G

gastrin

increases expression

Omeprazole results in increased expression of GAST protein

PMID:11422300 PMID:12189558 PMID:12763636 PMID:15223672 PMID:16618411 More...

NCBI chr11:100,225,233...100,227,823
Ensembl chr11:100,225,233...100,227,822

G

1,4-alpha-glucan branching enzyme 1

affects expression

Omeprazole affects the expression of GBE1 mRNA

NCBI chr16:70,110,837...70,366,608
Ensembl chr16:70,110,837...70,366,604

G

GTP cyclohydrolase I feedback regulator

affects expression

Omeprazole affects the expression of GCHFR mRNA

NCBI chr 2:118,998,269...119,002,870
Ensembl chr 2:118,998,254...119,002,871

G

gamma-glutamyl hydrolase

affects expression

Omeprazole affects the expression of GGH mRNA

NCBI chr 4:20,041,963...20,066,111
Ensembl chr 4:20,042,052...20,066,750

G

gamma-glutamyltransferase 1

multiple interactions

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GGT1 mRNA

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

gap junction protein, beta 1

affects expression

Omeprazole affects the expression of GJB1 mRNA

NCBI chr X:100,419,982...100,429,235
Ensembl chr X:100,419,984...100,429,235

G

glycosylphosphatidylinositol specific phospholipase D1

affects expression

Omeprazole affects the expression of GPLD1 mRNA

NCBI chr13:25,127,135...25,175,919
Ensembl chr13:25,127,135...25,176,484

G

glutathione peroxidase 1

affects expression

Omeprazole affects the expression of GPX1 mRNA

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione peroxidase 2

multiple interactions

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione peroxidase 4

affects expression

Omeprazole affects the expression of GPX4 mRNA

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)

affects expression

Omeprazole affects the expression of GRINA mRNA

NCBI chr15:76,130,917...76,134,109
Ensembl chr15:76,130,964...76,134,104

G

GrpE-like 1, mitochondrial

affects expression

Omeprazole affects the expression of GRPEL1 mRNA

NCBI chr 5:36,622,529...36,631,421
Ensembl chr 5:36,622,342...36,631,424

G

glutathione S-transferase, alpha 1 (Ya)

multiple interactions
increases expression

[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA
Omeprazole results in increased expression of GSTA5 mRNA

PMID:17202759 PMID:22687989

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, pi 1

increases expression

Omeprazole results in increased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

affects expression

Omeprazole affects the expression of GSTT1 mRNA

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

general transcription factor IIH, polypeptide 5

affects expression

Omeprazole affects the expression of GTF2H5 mRNA

NCBI chr17:6,130,103...6,135,763
Ensembl chr17:6,130,061...6,136,792

G

granzyme A

affects expression

Omeprazole affects the expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

histocompatibility 2, class II, locus DMa

affects expression

Omeprazole affects the expression of HLA-DMA mRNA

NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075

G

histocompatibility 2, M region locus 2

affects expression

Omeprazole affects the expression of HLA-B mRNA

NCBI chr17:37,791,742...37,794,445
Ensembl chr17:37,791,742...37,794,443

G

histocompatibility 2, M region locus 3

affects expression

Omeprazole affects the expression of HLA-G mRNA

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

H3.3 histone B

affects expression

Omeprazole affects the expression of H3F3B mRNA

NCBI chr11:115,912,787...115,921,313
Ensembl chr11:115,912,738...115,918,788

G

histidine ammonia lyase

affects expression

Omeprazole affects the expression of HAL mRNA

NCBI chr10:93,324,630...93,352,623
Ensembl chr10:93,324,630...93,355,166

G

hepcidin antimicrobial peptide

increases expression
multiple interactions
increases secretion

Omeprazole results in increased expression of HAMP mRNA; Omeprazole results in increased expression of HAMP protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]
Omeprazole results in increased secretion of HAMP protein

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

hydroxyacid oxidase 2

affects expression

Omeprazole affects the expression of HAO2 mRNA

NCBI chr 3:98,781,835...98,802,692
Ensembl chr 3:98,781,837...98,800,555

G

hemoglobin alpha, adult chain 2

affects expression

Omeprazole affects the expression of HBA-A2 mRNA

NCBI chr11:32,246,492...32,247,310
Ensembl chr11:32,246,489...32,247,298

G

hemoglobin, beta adult major chain

affects expression

Omeprazole affects the expression of HBB mRNA

G

histidine decarboxylase

affects expression
increases stability
increases expression
multiple interactions

Omeprazole affects the expression of HDC mRNA
Omeprazole results in increased stability of HDC protein
Omeprazole results in increased expression of HDC mRNA
Omeprazole results in increased expression of and results in increased activity of HDC protein

PMID:12763636 PMID:19483382

NCBI chr 2:126,435,579...126,465,942
Ensembl chr 2:126,435,587...126,461,219

G

homogentisate 1, 2-dioxygenase

affects expression

Omeprazole affects the expression of HGD mRNA

NCBI chr16:37,400,104...37,452,388
Ensembl chr16:37,400,515...37,452,382

G

high mobility group nucleosomal binding domain 1

affects expression

Omeprazole affects the expression of HMGN1 mRNA

NCBI chr16:95,922,788...95,928,925
Ensembl chr16:95,921,818...95,928,929

G

heme oxygenase 1

multiple interactions
increases expression

Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]; Omeprazole results in increased expression of and results in increased activity of HMOX1 protein
Omeprazole results in increased expression of HMOX1 mRNA; Omeprazole results in increased expression of HMOX1 protein

PMID:16712795 PMID:27725188

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

hypoxanthine phosphoribosyltransferase 1

affects expression

Omeprazole affects the expression of HPRT1 mRNA

NCBI chr X:52,076,955...52,110,537
Ensembl chr X:52,077,014...52,110,536

G

HPS5, biogenesis of lysosomal organelles complex 2 subunit 2

affects expression

Omeprazole affects the expression of HPS5 mRNA

NCBI chr 7:46,409,890...46,445,501
Ensembl chr 7:46,409,890...46,445,488

G

hydroxysteroid (17-beta) dehydrogenase 4

affects expression

Omeprazole affects the expression of HSD17B4 mRNA

NCBI chr18:50,261,268...50,329,337
Ensembl chr18:50,261,268...50,329,336

G

hydroxysteroid dehydrogenase like 2

affects expression

Omeprazole affects the expression of HSDL2 mRNA

NCBI chr 4:59,581,515...59,618,694
Ensembl chr 4:59,581,563...59,618,689

G

heat shock protein 1A

multiple interactions
decreases expression

Zinc Compounds analog inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]
Omeprazole results in decreased expression of HSPA1A mRNA; Omeprazole results in decreased expression of HSPA1A protein

PMID:15223672 PMID:16945336

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1-like

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA]

NCBI chr17:35,191,679...35,198,204
Ensembl chr17:35,191,679...35,198,261

G

HtrA serine peptidase 1

affects expression

Omeprazole affects the expression of HTRA1 mRNA

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

immediate early response 3

multiple interactions

[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

interferon gamma

multiple interactions

Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

insulin-like growth factor 1

affects expression

Omeprazole affects the expression of IGF1 mRNA

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor binding protein, acid labile subunit

affects expression

Omeprazole affects the expression of IGFALS mRNA

NCBI chr17:25,096,818...25,100,985
Ensembl chr17:25,084,971...25,100,984

G

insulin-like growth factor binding protein 2

affects expression

Omeprazole affects the expression of IGFBP2 mRNA

NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633

G

interleukin 10

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL6 protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL6 protein]

PMID:25637687 PMID:32418911

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

inositol (myo)-1(or 4)-monophosphatase 1

affects expression

Omeprazole affects the expression of IMPA1 mRNA

NCBI chr 3:10,377,016...10,396,499
Ensembl chr 3:10,377,016...10,396,499

G

inhibin beta-E

affects expression

Omeprazole affects the expression of INHBE mRNA

NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280

G

myo-inositol 1-phosphate synthase A1

affects expression

Omeprazole affects the expression of ISYNA1 mRNA

NCBI chr 8:71,047,131...71,049,940
Ensembl chr 8:71,047,023...71,049,940

G

inter alpha-trypsin inhibitor, heavy chain 4

affects expression

Omeprazole affects the expression of ITIH4 mRNA

NCBI chr14:30,608,433...30,623,943
Ensembl chr14:30,608,433...30,624,310

G

Janus kinase 1

affects expression

Omeprazole affects the expression of JAK1 mRNA

NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479

G

KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2

affects expression

Omeprazole affects the expression of KDELR2 mRNA

NCBI chr 5:143,389,575...143,407,659
Ensembl chr 5:143,389,593...143,407,656

G

kinase insert domain protein receptor

affects expression
multiple interactions

Omeprazole affects the expression of KDR mRNA
Omeprazole promotes the reaction [Oxygen results in decreased expression of KDR protein]

PMID:19483382 PMID:26272953

NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118

G

keratin 8

affects expression

Omeprazole affects the expression of KRT8 mRNA

NCBI chr15:101,905,146...101,912,777
Ensembl chr15:101,905,133...101,912,917

G

lecithin cholesterol acyltransferase

affects expression

Omeprazole affects the expression of LCAT mRNA

NCBI chr 8:106,666,183...106,670,034
Ensembl chr 8:106,666,183...106,670,014

G

leucine carboxyl methyltransferase 1

affects expression

Omeprazole affects the expression of LCMT1 mRNA

NCBI chr 7:122,977,026...123,029,581
Ensembl chr 7:122,969,007...123,029,581

G

lipase, hepatic

affects expression

Omeprazole affects the expression of LIPC mRNA

NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508

G

lysyl oxidase

affects expression

Omeprazole affects the expression of LOX mRNA

NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939

G

low density lipoprotein receptor-related protein 3

affects expression

Omeprazole affects the expression of LRP3 mRNA

NCBI chr 7:34,900,303...34,914,770
Ensembl chr 7:34,899,452...34,914,923

G

mannosidase 2, alpha B1

affects expression

Omeprazole affects the expression of MAN2B1 mRNA

NCBI chr 8:85,809,941...85,824,215
Ensembl chr 8:85,809,899...85,824,911

G

mitogen-activated protein kinase kinase 2

affects expression

Omeprazole affects the expression of MAP2K2 mRNA

NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809

G

mitogen-activated protein kinase 14

multiple interactions

Omeprazole inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of MAPK14 protein]

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

MBL associated serine protease 2

affects expression

Omeprazole affects the expression of MASP2 mRNA

NCBI chr 4:148,679,079...148,699,939
Ensembl chr 4:148,687,011...148,699,956

G

malic enzyme 1, NADP(+)-dependent, cytosolic

affects expression
multiple interactions

Omeprazole affects the expression of ME1 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA

PMID:19483382 PMID:22687989

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

matrix metallopeptidase 14 (membrane-inserted)

multiple interactions

Omeprazole inhibits the reaction [Indomethacin results in decreased expression of MMP14 protein]

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 2

multiple interactions

Omeprazole inhibits the reaction [Hydrogen Peroxide results in decreased activity of MMP2 protein]

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

methylmalonyl-Coenzyme A mutase

affects expression

Omeprazole affects the expression of MMUT mRNA

NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879

G

myeloperoxidase

multiple interactions
decreases activity

Omeprazole inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Acids results in increased activity of MPO protein]
Omeprazole results in decreased activity of MPO protein
Omeprazole inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Cysteamine results in increased expression of MPO protein]; Omeprazole inhibits the reaction [Ethanol results in increased activity of MPO protein]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:16091555 PMID:17151854 PMID:20165931 PMID:25637687 PMID:27780710 More...

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

maestro

affects expression

Omeprazole affects the expression of MRO mRNA

NCBI chr18:73,992,465...74,014,405
Ensembl chr18:73,992,456...74,014,404

G

mitochondrial ribosomal protein L2

affects expression

Omeprazole affects the expression of MRPL2 mRNA

NCBI chr17:46,957,094...46,961,058
Ensembl chr17:46,957,155...46,961,065

G

mitochondrial ribosomal protein L9

affects expression

Omeprazole affects the expression of MRPL9 mRNA

NCBI chr 3:94,350,631...94,355,831
Ensembl chr 3:94,350,625...94,358,437

G

murinoglobulin 2

affects expression

Omeprazole affects the expression of PZP mRNA

NCBI chr 6:121,983,688...122,062,927
Ensembl chr 6:121,983,720...122,062,924

G

myeloid-associated differentiation marker

affects expression

Omeprazole affects the expression of MYADM mRNA

NCBI chr 7:3,337,563...3,347,871
Ensembl chr 7:3,337,605...3,348,958

G

MYC binding protein 2, E3 ubiquitin protein ligase

affects expression

Omeprazole affects the expression of MYCBP2 mRNA

NCBI chr14:103,350,847...103,584,276
Ensembl chr14:103,350,847...103,584,250

G

myosin ID

affects expression

Omeprazole affects the expression of MYO1D mRNA

NCBI chr11:80,372,945...80,670,881
Ensembl chr11:80,372,952...80,670,851

G

N(alpha)-acetyltransferase 38, NatC auxiliary subunit

affects expression

Omeprazole affects the expression of NAA38 mRNA

NCBI chr11:69,286,617...69,287,497
Ensembl chr11:69,286,313...69,287,506

G

nucleosome assembly protein 1-like 1

affects expression

Omeprazole affects the expression of NAP1L1 mRNA

NCBI chr10:111,308,754...111,334,011
Ensembl chr10:111,309,084...111,334,011

G

N-acetyltransferase 8 (GCN5-related)

affects expression

Omeprazole affects the expression of NAT8 mRNA

NCBI chr 6:85,807,369...85,813,839
Ensembl chr 6:85,807,370...85,809,064

G

nuclear receptor coactivator 1

multiple interactions

Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter]

NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182

G

N-myc downstream regulated gene 2

affects expression

Omeprazole affects the expression of NDRG2 mRNA

NCBI chr14:52,142,738...52,151,463
Ensembl chr14:52,142,728...52,151,615

G

NADH:ubiquinone oxidoreductase core subunit S5

affects expression

Omeprazole affects the expression of NDUFS5 mRNA

NCBI chr 4:123,606,503...123,611,979
Ensembl chr 4:123,606,503...123,611,995

G

NADH:ubiquinone oxidoreductase core subunit V3

affects expression

Omeprazole affects the expression of NDUFV3 mRNA

NCBI chr17:31,739,089...31,750,300
Ensembl chr17:31,739,089...31,750,305

G

neuraminidase 2

affects expression

Omeprazole affects the expression of NEU2 mRNA

NCBI chr 1:87,501,749...87,525,567
Ensembl chr 1:87,437,611...87,525,567

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in decreased expression of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nuclear transcription factor, X-box binding 1

affects expression

Omeprazole affects the expression of NFX1 mRNA

NCBI chr 4:40,970,906...41,025,992
Ensembl chr 4:40,970,906...41,025,993

G

NIPA-like domain containing 2

affects expression

Omeprazole affects the expression of NIPAL2 mRNA

NCBI chr15:34,572,942...34,679,739
Ensembl chr15:34,572,945...34,679,358

G

nitrilase 1

affects expression

Omeprazole affects the expression of NIT1 mRNA

NCBI chr 1:171,168,145...171,173,209
Ensembl chr 1:171,165,576...171,173,214

G

NLR family, pyrin domain containing 3

multiple interactions

Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

NME/NM23 nucleoside diphosphate kinase 2

affects expression

Omeprazole affects the expression of NME2 mRNA

NCBI chr11:93,840,640...93,847,082
Ensembl chr11:93,840,640...93,847,085

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

Omeprazole results in increased expression of NQO1 mRNA
Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 mRNA]; Omeprazole inhibits the reaction [Oxygen results in increased expression of NQO1 protein]
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA

PMID:17202759 PMID:22687989 PMID:26272953

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity

[Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]

PMID:12695340 PMID:17041008 PMID:25680588 PMID:26187274 PMID:27732639

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 1, group I, member 3

affects expression
decreases metabolic processing
increases expression

Omeprazole affects the expression of NR1I3 mRNA
NR1I3 gene mutant form results in decreased metabolism of Omeprazole
Omeprazole results in increased expression of NR1I3 mRNA

PMID:19118567 PMID:19483382 PMID:27434302

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

nuclear receptor subfamily 3, group C, member 1

affects expression

Omeprazole affects the expression of NR3C1 mRNA

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

out at first homolog

affects expression

Omeprazole affects the expression of OAF mRNA

NCBI chr 9:43,132,575...43,151,113
Ensembl chr 9:43,132,532...43,151,208

G

oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

affects expression

Omeprazole affects the expression of OGDH mRNA

NCBI chr11:6,241,597...6,309,094
Ensembl chr11:6,241,633...6,306,642

G

olfactory receptor family 51 subfamily E member 2

affects expression

Omeprazole affects the expression of OLR59 mRNA

NCBI chr 7:102,389,928...102,408,678
Ensembl chr 7:102,387,718...102,408,678

G

oligosaccharyltransferase complex subunit (non-catalytic)

affects expression

Omeprazole affects the expression of OSTC mRNA

NCBI chr 3:130,489,566...130,503,093
Ensembl chr 3:130,489,561...130,503,093

G

ornithine transcarbamylase

affects expression

Omeprazole affects the expression of OTC mRNA

NCBI chr X:10,118,584...10,187,275
Ensembl chr X:10,118,544...10,187,263

G

poly(A) binding protein, cytoplasmic 4

affects expression

Omeprazole affects the expression of PABPC4 mRNA

NCBI chr 4:123,172,722...123,192,718
Ensembl chr 4:123,156,144...123,192,718

G

phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoribosylaminoimidazole, succinocarboxamide synthetase

affects expression

Omeprazole affects the expression of PAICS mRNA

NCBI chr 5:77,099,149...77,115,356
Ensembl chr 5:77,099,154...77,115,356

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage

Omeprazole results in increased cleavage of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

propionyl Coenzyme A carboxylase, beta polypeptide

affects expression

Omeprazole affects the expression of PCCB mRNA

NCBI chr 9:100,864,085...100,916,993
Ensembl chr 9:100,864,085...100,916,951

G

proliferating cell nuclear antigen

multiple interactions

[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Omeprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein]
Omeprazole inhibits the reaction [Ethanol results in decreased expression of PCNA protein]

PMID:19251492 PMID:26970604

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

proprotein convertase subtilisin/kexin type 6

affects expression

Omeprazole affects the expression of PCSK6 mRNA

NCBI chr 7:65,511,884...65,700,134
Ensembl chr 7:65,511,482...65,700,134

G

phosphatidylcholine transfer protein

affects expression

Omeprazole affects the expression of PCTP mRNA

NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720

G

pyruvate carboxylase

affects expression

Omeprazole affects the expression of PCX mRNA

NCBI chr19:4,560,500...4,671,780
Ensembl chr19:4,560,500...4,671,780

G

phosducin-like 3

affects expression

Omeprazole affects the expression of PDCL3 mRNA

NCBI chr 1:39,026,895...39,036,317
Ensembl chr 1:39,024,689...39,036,319

G

protein disulfide isomerase associated 3

affects expression

Omeprazole affects the expression of PDIA3 mRNA

NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168

G

protein disulfide isomerase associated 6

affects expression

Omeprazole affects the expression of PDIA6 mRNA

NCBI chr12:17,316,590...17,334,786
Ensembl chr12:17,316,546...17,334,771

G

peroxisomal biogenesis factor 19

affects expression

Omeprazole affects the expression of PEX19 mRNA

NCBI chr 1:171,954,322...171,964,064
Ensembl chr 1:171,954,322...171,964,060

G

phosphoglycerate mutase 1

affects expression

Omeprazole affects the expression of PGAM1 mRNA

NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099

G

progesterone receptor membrane component 1

affects expression

Omeprazole affects the expression of PGRMC1 mRNA

NCBI chr X:35,861,846...35,869,732
Ensembl chr X:35,861,859...35,869,732

G

phytanoyl-CoA hydroxylase

affects expression

Omeprazole affects the expression of PHYH mRNA

NCBI chr 2:4,923,807...4,943,554
Ensembl chr 2:4,923,830...4,943,541

G

phosphatidylinositol glycan anchor biosynthesis, class P

affects expression

Omeprazole affects the expression of PIGP mRNA

NCBI chr16:94,159,622...94,171,874
Ensembl chr16:94,159,622...94,172,701

G

pyruvate kinase liver and red blood cell

affects expression

Omeprazole affects the expression of PKLR mRNA

NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091

G

phospholipase A2, group IVA (cytosolic, calcium-dependent)

increases phosphorylation
multiple interactions

Omeprazole results in increased phosphorylation of PLA2G4A protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Omeprazole results in increased phosphorylation of PLA2G4A protein]

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

G

phospholipase B domain containing 1

affects expression

Omeprazole affects the expression of PLBD1 mRNA

NCBI chr 6:136,589,069...136,639,301
Ensembl chr 6:136,589,068...136,638,926

G

plasminogen

affects expression

Omeprazole affects the expression of PLG mRNA

NCBI chr17:12,597,496...12,638,271
Ensembl chr17:12,597,495...12,638,272

G

plastin 3 (T-isoform)

affects expression

Omeprazole affects the expression of PLS3 mRNA

NCBI chr X:74,829,259...74,918,788
Ensembl chr X:74,829,260...74,918,788

G

paraoxonase 2

affects expression

Omeprazole affects the expression of PON2 mRNA

NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455

G

POU domain, class 2, transcription factor 2

multiple interactions

Omeprazole inhibits the reaction [Cisplatin results in increased expression of POU2F2 protein]

NCBI chr 7:24,790,111...24,879,292
Ensembl chr 7:24,786,769...24,879,151

G

pancreatic progenitor cell differentiation and proliferation factor

affects expression

Omeprazole affects the expression of PPDPF mRNA

NCBI chr 2:180,828,615...180,830,297
Ensembl chr 2:180,829,040...180,830,564

G

peroxiredoxin 2

affects expression

Omeprazole affects the expression of PRDX2 mRNA

NCBI chr 8:85,696,251...85,701,440
Ensembl chr 8:85,696,216...85,701,463

G

peroxiredoxin 6

affects expression

Omeprazole affects the expression of PRDX6 mRNA

NCBI chr 1:161,067,682...161,078,780
Ensembl chr 1:161,067,682...161,078,789

G

prolactin

increases expression

Omeprazole results in increased expression of PRL protein

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

protein C

affects expression

Omeprazole affects the expression of PROC mRNA

NCBI chr18:32,256,179...32,272,623
Ensembl chr18:32,256,179...32,272,623

G

phosphoribosyl pyrophosphate synthetase-associated protein 1

affects expression

Omeprazole affects the expression of PRPSAP1 mRNA

NCBI chr11:116,361,641...116,385,739
Ensembl chr11:116,361,671...116,385,461

G

proteasome subunit alpha 6

affects expression

Omeprazole affects the expression of PSMA6 mRNA

NCBI chr12:55,431,007...55,465,244
Ensembl chr12:55,431,007...55,465,239

G

proteasome (prosome, macropain) subunit, beta type 1

affects expression

Omeprazole affects the expression of PSMB1 mRNA

NCBI chr17:15,695,983...15,718,538
Ensembl chr17:15,695,283...15,720,013

G

proteasome (prosome, macropain) subunit, beta type 3

affects expression

Omeprazole affects the expression of PSMB3 mRNA

NCBI chr11:97,594,260...97,604,326
Ensembl chr11:97,594,225...97,604,326

G

protease (prosome, macropain) 26S subunit, ATPase 1

affects expression

Omeprazole affects the expression of PSMC1 mRNA

NCBI chr12:100,076,461...100,089,623
Ensembl chr12:100,076,413...100,089,664

G

proteasome (prosome, macropain) 26S subunit, ATPase 3

affects expression

Omeprazole affects the expression of PSMC3 mRNA

NCBI chr 2:90,884,361...90,889,783
Ensembl chr 2:90,884,354...90,896,714

G

protease (prosome, macropain) 26S subunit, ATPase 5

affects expression

Omeprazole affects the expression of PSMC5 mRNA

NCBI chr11:106,147,011...106,153,938
Ensembl chr11:106,146,980...106,153,946

G

proteasome (prosome, macropain) 26S subunit, non-ATPase, 1

affects expression

Omeprazole affects the expression of PSMD1 mRNA

NCBI chr 1:85,992,341...86,067,017
Ensembl chr 1:85,992,109...86,066,873

G

proteasome (prosome, macropain) 26S subunit, non-ATPase, 4

affects expression

Omeprazole affects the expression of PSMD4 mRNA

NCBI chr 3:94,939,999...94,949,880
Ensembl chr 3:94,940,005...94,949,925

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 mRNA; [Omeprazole co-treated with beta-Naphthoflavone] results in increased expression of PTGS2 protein
Omeprazole inhibits the reaction [Ethanol results in increased expression of PTGS2 protein]

PMID:23038005 PMID:26970604

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathymosin

affects expression

Omeprazole affects the expression of PTMS mRNA

NCBI chr 6:124,890,638...124,894,909
Ensembl chr 6:124,890,644...124,897,066

G

protein tyrosine phosphatase receptor type F

affects expression

Omeprazole affects the expression of PTPRF mRNA

NCBI chr 4:118,065,410...118,148,602
Ensembl chr 4:118,065,410...118,148,602

G

pituitary tumor-transforming 1 interacting protein

affects expression

Omeprazole affects the expression of PTTG1IP mRNA

NCBI chr10:77,417,489...77,434,566
Ensembl chr10:77,417,554...77,434,566

G

liver glycogen phosphorylase

affects expression

Omeprazole affects the expression of PYGL mRNA

NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262

G

RAB5 interacting factor

affects expression

Omeprazole affects the expression of RAB5IF mRNA

NCBI chr 2:156,705,042...156,715,483
Ensembl chr 2:156,705,048...156,715,483

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[Omeprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of RELA protein]; Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]
Omeprazole inhibits the reaction [Cisplatin affects the localization of RELA protein]

PMID:19251492 PMID:30452898 PMID:32418911

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

retinol saturase (all trans retinol 13,14 reductase)

increases expression

Omeprazole results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

reactive intermediate imine deaminase A homolog

affects expression

Omeprazole affects the expression of RIDA mRNA

NCBI chr15:34,484,168...34,495,392
Ensembl chr15:34,484,167...34,495,401

G

ribonuclease, RNase A family 4

affects expression

Omeprazole affects the expression of RNASE4 mRNA

NCBI chr14:51,328,534...51,343,608
Ensembl chr14:51,328,534...51,343,608

G

ring finger protein 103

affects expression

Omeprazole affects the expression of RNF103 mRNA

NCBI chr 6:71,470,828...71,487,864
Ensembl chr 6:71,470,878...71,487,865

G

RNA binding protein with serine rich domain 1

affects expression

Omeprazole affects the expression of RNPS1 mRNA

NCBI chr17:24,633,620...24,644,872
Ensembl chr17:24,633,539...24,644,875

G

ribosomal protein L11

affects expression

Omeprazole affects the expression of RPL11 mRNA

NCBI chr 4:135,776,665...135,780,704
Ensembl chr 4:135,755,576...135,780,739

G

ribosomal protein L13

affects expression

Omeprazole affects the expression of RPL13 mRNA

NCBI chr 8:123,829,089...123,831,983
Ensembl chr 8:123,829,089...123,831,983

G

ribosomal protein L15

affects expression

Omeprazole affects the expression of RPL15 mRNA

NCBI chr14:4,198,710...4,201,873
Ensembl chr14:4,198,305...4,201,873

G

ribosomal protein L17

affects expression

Omeprazole affects the expression of RPL17 mRNA

NCBI chr18:75,132,049...75,136,455
Ensembl chr18:75,131,629...75,136,452

G

ribosomal protein L23

affects expression

Omeprazole affects the expression of RPL23 mRNA

NCBI chr11:97,668,352...97,673,265
Ensembl chr11:97,668,353...97,673,263

G

ribosomal protein L3

affects expression

Omeprazole affects the expression of RPL3 mRNA

NCBI chr15:79,961,993...79,967,553
Ensembl chr15:79,961,992...79,976,069

G

ribosomal protein L32

affects expression

Omeprazole affects the expression of RPL32 mRNA

NCBI chr 6:115,782,475...115,785,704
Ensembl chr 6:115,782,466...115,785,708

G

ribosomal protein L4

affects expression

Omeprazole affects the expression of RPL4 mRNA

NCBI chr 9:64,080,159...64,085,805
Ensembl chr 9:64,080,657...64,085,948

G

ribophorin II

affects expression

Omeprazole affects the expression of RPN2 mRNA

NCBI chr 2:157,121,018...157,168,238
Ensembl chr 2:157,120,937...157,168,239

G

ribosomal protein S14

affects expression

Omeprazole affects the expression of RPS14 mRNA

NCBI chr18:60,907,668...60,911,618
Ensembl chr18:60,880,170...60,911,618

G

ribosomal protein S18

affects expression

Omeprazole affects the expression of RPS18 mRNA

NCBI chr17:34,170,972...34,174,639
Ensembl chr17:34,170,973...34,174,975

G

ribosomal protein S19

affects expression

Omeprazole affects the expression of RPS19 mRNA

NCBI chr 7:24,584,013...24,589,236
Ensembl chr 7:24,583,796...24,589,231

G

ribosomal protein S20

affects expression

Omeprazole affects the expression of RPS20 mRNA

NCBI chr 4:3,831,334...3,835,600
Ensembl chr 4:3,831,334...3,835,665

G

ribosomal protein S3A1

affects expression

Omeprazole affects the expression of RPS3A mRNA

NCBI chr 3:86,045,247...86,049,975
Ensembl chr 3:86,045,247...86,050,009

G

ribosomal protein S6

affects expression

Omeprazole affects the expression of RPS6 mRNA

NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649

G

ribosomal protein S8

affects expression

Omeprazole affects the expression of RPS8 mRNA

NCBI chr 4:117,011,033...117,013,329
Ensembl chr 4:117,011,024...117,013,440

G

related RAS viral (r-ras) oncogene 2

affects expression

Omeprazole affects the expression of RRAS2 mRNA

NCBI chr 7:113,646,017...113,717,016
Ensembl chr 7:113,646,017...113,717,016

G

sphingosine-1-phosphate receptor 1

affects expression

Omeprazole affects the expression of S1PR1 mRNA

NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721

G

somatomedin B and thrombospondin, type 1 domain containing

affects expression

Omeprazole affects the expression of SBSPON mRNA

NCBI chr 1:15,924,086...15,962,946
Ensembl chr 1:15,924,086...15,962,946

G

syndecan 2

affects expression

Omeprazole affects the expression of SDC2 mRNA

NCBI chr15:32,920,869...33,034,867
Ensembl chr15:32,920,869...33,035,081

G

succinate dehydrogenase complex, subunit C, integral membrane protein

affects expression

Omeprazole affects the expression of SDHC mRNA

NCBI chr 1:170,956,726...170,978,209
Ensembl chr 1:170,954,734...170,978,172

G

succinate dehydrogenase complex, subunit D, integral membrane protein

affects expression

Omeprazole affects the expression of SDHD mRNA

NCBI chr 9:50,507,640...50,515,149
Ensembl chr 9:50,507,657...50,515,112

G

selectin, lymphocyte

decreases expression

Omeprazole results in decreased expression of SELL protein

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

serine incorporator 3

affects expression

Omeprazole affects the expression of SERINC3 mRNA

NCBI chr 2:163,466,577...163,487,767
Ensembl chr 2:163,465,192...163,487,051

G

serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10

affects expression

Omeprazole affects the expression of SERPINA10 mRNA

NCBI chr12:103,582,934...103,597,681
Ensembl chr12:103,581,045...103,597,703

G

serine (or cysteine) peptidase inhibitor, clade A, member 4, pseudogene 1

affects expression

Omeprazole affects the expression of SERPINA4 mRNA

NCBI chr12:104,044,218...104,053,179
Ensembl chr12:104,046,908...104,052,983

G

serine (or cysteine) peptidase inhibitor, clade F, member 2

affects expression

Omeprazole affects the expression of SERPINF2 mRNA

NCBI chr11:75,322,562...75,330,327
Ensembl chr11:75,322,558...75,330,417

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

decreases expression

Omeprazole results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

sideroflexin 1

affects expression

Omeprazole affects the expression of SFXN1 mRNA

NCBI chr13:54,225,675...54,262,365
Ensembl chr13:54,225,888...54,262,361

G

serine hydroxymethyltransferase 2 (mitochondrial)

affects expression

Omeprazole affects the expression of SHMT2 mRNA

NCBI chr10:127,352,992...127,358,313
Ensembl chr10:127,352,992...127,358,313

G

solute carrier family 22 (organic cation transporter), member 1

affects expression

Omeprazole affects the expression of SLC22A1 mRNA

NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Omeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 22 (organic cation transporter), member 5

multiple interactions

Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions

[Omeprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

solute carrier family 23 (nucleobase transporters), member 1

affects expression

Omeprazole affects the expression of SLC23A1 mRNA

NCBI chr18:35,747,657...35,762,900
Ensembl chr18:35,747,657...35,760,297

G

solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 13

affects expression

Omeprazole affects the expression of SLC25A13 mRNA

NCBI chr 6:6,041,218...6,217,304
Ensembl chr 6:6,041,218...6,217,173

G

solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3

affects expression

Omeprazole affects the expression of SLC25A3 mRNA

NCBI chr10:90,952,436...90,959,902
Ensembl chr10:90,952,436...90,959,921

G

solute carrier family 27 (fatty acid transporter), member 2

affects expression

Omeprazole affects the expression of SLC27A2 mRNA

NCBI chr 2:126,394,944...126,430,163
Ensembl chr 2:126,394,327...126,430,163

G

solute carrier family 39 (metal ion transporter), member 8

affects expression

Omeprazole affects the expression of SLC39A8 mRNA

NCBI chr 3:135,522,644...135,594,333
Ensembl chr 3:135,531,040...135,594,333

G

solute carrier family 40 (iron-regulated transporter), member 1

decreases expression

Omeprazole results in decreased expression of SLC40A1 protein

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

solute carrier family 46, member 1

affects expression

Omeprazole affects the expression of SLC46A1 mRNA

NCBI chr11:78,356,527...78,362,771
Ensembl chr11:78,356,523...78,362,885

G

solute carrier family 66 member 2

affects expression

Omeprazole affects the expression of SLC66A2 mRNA

NCBI chr18:80,298,458...80,335,940
Ensembl chr18:80,296,507...80,335,940

G

solute carrier family 6 (neurotransmitter transporter, taurine), member 6

affects expression

Omeprazole affects the expression of SLC6A6 mRNA

NCBI chr 6:91,661,031...91,736,044
Ensembl chr 6:91,661,034...91,736,047

G

solute carrier organic anion transporter family, member 1a5

increases expression

Omeprazole results in increased expression of SLCO1A2 mRNA

NCBI chr 6:142,179,953...142,268,707
Ensembl chr 6:142,179,953...142,268,707

G

superoxide dismutase 1, soluble

multiple interactions

Omeprazole inhibits the reaction [Ethanol results in decreased activity of SOD1 protein]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

signal peptide peptidase like 2A

affects expression

Omeprazole affects the expression of SPPL2A mRNA

NCBI chr 2:126,732,311...126,775,706
Ensembl chr 2:126,732,311...126,775,155

G

spermidine synthase

affects expression

Omeprazole affects the expression of SRM mRNA

NCBI chr 4:148,675,970...148,679,076
Ensembl chr 4:148,675,960...148,679,450

G

signal recognition particle receptor, B subunit

affects expression

Omeprazole affects the expression of SRPRB mRNA

NCBI chr 9:103,065,232...103,079,264
Ensembl chr 9:103,065,231...103,079,336

G

SSX family member 2 interacting protein

affects expression

Omeprazole affects the expression of SSX2IP mRNA

NCBI chr 3:146,110,397...146,145,899
Ensembl chr 3:146,110,397...146,145,899

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

affects expression

Omeprazole affects the expression of ST3GAL6 mRNA

NCBI chr16:58,290,105...58,344,614
Ensembl chr16:58,288,488...58,344,606

G

beta galactoside alpha 2,6 sialyltransferase 1

affects expression

Omeprazole affects the expression of ST6GAL1 mRNA

NCBI chr16:23,043,478...23,179,100
Ensembl chr16:23,043,490...23,179,100

G

succinate-CoA ligase, GDP-forming, alpha subunit

affects expression

Omeprazole affects the expression of SUCLG1 mRNA

NCBI chr 6:73,225,488...73,253,890
Ensembl chr 6:73,225,365...73,253,894

G

surfeit gene 4

affects expression

Omeprazole affects the expression of SURF4 mRNA

NCBI chr 2:26,810,052...26,823,801
Ensembl chr 2:26,810,052...26,823,940

G

synaptojanin 2 binding protein

affects expression

Omeprazole affects the expression of SYNJ2BP mRNA

NCBI chr12:81,538,968...81,579,685
Ensembl chr12:81,544,715...81,579,685

G

tachykinin receptor 1

multiple interactions

Omeprazole inhibits the reaction [Acids affects the localization of TACR1 protein]

NCBI chr 6:82,378,990...82,537,085
Ensembl chr 6:82,379,315...82,537,085

G

transforming growth factor, beta 1

increases expression

Omeprazole results in increased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta induced

affects expression

Omeprazole affects the expression of TGFBI mRNA

NCBI chr13:56,757,399...56,787,172
Ensembl chr13:56,757,336...56,787,375

G

threonine synthase-like 2 (bacterial)

affects expression

Omeprazole affects the expression of THNSL2 mRNA

NCBI chr 6:71,105,150...71,121,364
Ensembl chr 6:71,105,150...71,121,423

G

translocase of inner mitochondrial membrane 21

affects expression

Omeprazole affects the expression of TIMM21 mRNA

NCBI chr18:84,964,316...84,970,168
Ensembl chr18:84,964,316...84,969,649

G

tissue inhibitor of metalloproteinase 2

multiple interactions

Omeprazole inhibits the reaction [Indomethacin results in increased expression of TIMP2 protein]

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

triokinase, FMN cyclase

affects expression

Omeprazole affects the expression of TKFC mRNA

NCBI chr19:10,565,153...10,583,257
Ensembl chr19:10,565,155...10,583,018

G

toll-like receptor 4

multiple interactions

Lipopolysaccharides inhibits the reaction [Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]]; Omeprazole inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

transmembrane BAX inhibitor motif containing 1

affects expression

Omeprazole affects the expression of TMBIM1 mRNA

NCBI chr 1:74,327,406...74,343,495
Ensembl chr 1:74,327,406...74,344,781

G

transmembrane and coiled-coil domains 1

affects expression

Omeprazole affects the expression of TMCO1 mRNA

NCBI chr 1:167,136,239...167,161,547
Ensembl chr 1:167,135,947...167,161,547

G

transmembrane p24 trafficking protein 2

affects expression

Omeprazole affects the expression of TMED2 mRNA

NCBI chr 5:124,678,835...124,688,566
Ensembl chr 5:124,678,758...124,688,569

G

transmembrane p24 trafficking protein 7

affects expression

Omeprazole affects the expression of TMED7 mRNA

NCBI chr18:46,718,995...46,730,602
Ensembl chr18:46,693,302...46,730,602

G

transmembrane protein 123

affects expression

Omeprazole affects the expression of TMEM123 mRNA

NCBI chr 9:7,764,078...7,794,334
Ensembl chr 9:7,764,042...7,794,334

G

transmembrane protein 97

affects expression

Omeprazole affects the expression of TMEM97 mRNA

NCBI chr11:78,432,643...78,441,561
Ensembl chr11:78,432,643...78,441,603

G

tumor necrosis factor

multiple interactions

Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]
Omeprazole inhibits the reaction [Ethanol results in increased expression of TNF protein]
Omeprazole inhibits the reaction [Cisplatin results in increased expression of TNF protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of TNF protein]

PMID:19232345 PMID:25637687 PMID:26970604 PMID:30452898 PMID:32418911

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

thioredoxin 1

affects expression

Omeprazole affects the expression of TXN1 mRNA

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

G

thioredoxin-like 1

affects expression

Omeprazole affects the expression of TXNL1 mRNA

NCBI chr18:63,795,872...63,825,535
Ensembl chr18:63,794,165...63,841,872

G

tyrosinase

multiple interactions
decreases expression

Omeprazole affects the N-linked glycosylation of and results in increased degradation of TYR protein; Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein]
Omeprazole results in decreased expression of TYR protein

NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720

G

ubiquitin A-52 residue ribosomal protein fusion product 1

affects expression

Omeprazole affects the expression of UBA52 mRNA

NCBI chr 8:70,960,913...70,963,067
Ensembl chr 8:70,960,913...70,963,451

G

ubiquitin-conjugating enzyme E2N

affects expression

Omeprazole affects the expression of UBE2N mRNA

NCBI chr10:95,351,024...95,381,520
Ensembl chr10:95,351,007...95,381,519

G

ubiquitin recognition factor in ER-associated degradation 1

affects expression

Omeprazole affects the expression of UFD1 mRNA

NCBI chr16:18,630,486...18,654,011
Ensembl chr16:18,630,529...18,654,011

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression
affects expression

Omeprazole results in increased expression of UGT1A1 mRNA
Omeprazole affects the expression of UGT1A1 mRNA

PMID:19118567 PMID:19483382 PMID:25626140

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glycosyltransferase 1 family, polypeptide A10

increases expression

Omeprazole results in increased expression of UGT1A10 mRNA

NCBI chr 1:87,983,133...88,147,724
Ensembl chr 1:87,983,110...88,146,726

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Omeprazole results in increased expression of UGT1A2 mRNA; Omeprazole results in increased expression of UGT1A3 mRNA

NCBI chr 1:88,128,333...88,147,724
Ensembl chr 1:88,128,323...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A5

increases expression

Omeprazole results in increased expression of UGT1A4 mRNA

NCBI chr 1:88,093,734...88,147,724
Ensembl chr 1:88,093,734...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

increases expression
multiple interactions

Omeprazole results in increased expression of UGT1A6 mRNA
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of UGT1A6 mRNA

PMID:19118567 PMID:22687989

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UDP glucuronosyltransferase 1 family, polypeptide A9

increases expression

Omeprazole results in increased expression of UGT1A9 mRNA

NCBI chr 1:87,998,501...88,147,724
Ensembl chr 1:87,998,522...88,146,719

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

Omeprazole results in increased expression of UGT2B1 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

ubiquinol-cytochrome c reductase, complex III subunit XI

affects expression

Omeprazole affects the expression of UQCR11 mRNA

NCBI chr10:80,238,831...80,242,655
Ensembl chr10:80,238,831...80,242,664

G

vanin 1

affects expression

Omeprazole affects the expression of VNN1 mRNA

NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241

G

WD repeat domain 26

affects expression

Omeprazole affects the expression of WDR26 mRNA

NCBI chr 1:181,000,791...181,046,211
Ensembl chr 1:181,000,793...181,039,566

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide

affects expression

Omeprazole affects the expression of YWHAG mRNA

NCBI chr 5:135,937,233...135,963,495
Ensembl chr 5:135,937,263...135,963,470

G

zinc finger, DHHC domain containing 23

affects expression

Omeprazole affects the expression of ZDHHC23 mRNA

NCBI chr16:43,785,396...43,800,295
Ensembl chr16:43,785,396...43,800,154

G

zona pellucida 3 receptor

decreases expression
affects expression

Omeprazole results in decreased expression of C4BPA mRNA
Omeprazole affects the expression of C4BPA mRNA

PMID:19483382 PMID:25626140

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

G

ZW10 interactor

affects expression

Omeprazole affects the expression of ZWINT mRNA

NCBI chr10:72,490,678...72,510,796
Ensembl chr10:72,490,677...72,510,796

Omeprazole sulfide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl-hydrocarbon receptor

multiple interactions

omeprazole sulfide binds to and affects the folding of AHR protein; omeprazole sulfide binds to and results in decreased activity of AHR protein; omeprazole sulfide inhibits the reaction [Methylcholanthrene results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]
omeprazole sulfide inhibits the reaction [Methylcholanthrene results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; omeprazole sulfide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
omeprazole sulfide results in increased expression of CYP1A1 mRNA

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

oxatomide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 22

decreases activity

oxatomide results in decreased activity of CYP2D6 protein

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

hexosaminidase B

affects secretion

oxatomide affects the secretion of HEXB protein

NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

oxatomide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

oxfendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2 (Junior blood group)

affects transport
decreases activity
multiple interactions

ABCG2 protein affects the transport of oxfendazole
oxfendazole results in decreased activity of ABCG2 protein
oxfendazole inhibits the reaction [ABCG2 protein affects the transport of Mitoxantrone]

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

caspase 3

increases cleavage

oxfendazole results in increased cleavage of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

cyclin dependent kinase inhibitor 1A

increases expression

oxfendazole results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

checkpoint kinase 1

affects expression

oxfendazole affects the expression of CHEK1 mRNA

NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 protein; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA]

PMID:18754104 PMID:20033131

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA

PMID:18754104 PMID:20033131

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 13

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

glutathione peroxidase 2

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GPX2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA

PMID:18754104 PMID:20033131

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

glutathione S-transferase, alpha 1 (Ya)

multiple interactions

[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [Melatonin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA

PMID:18754104 PMID:20033131

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, mu 1

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GSTM1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTM1 mRNA

PMID:18754104 PMID:20033131

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

MAD2 mitotic arrest deficient-like 1

decreases expression

oxfendazole results in decreased expression of MAD2L1 mRNA

NCBI chr 6:66,512,205...66,518,091
Ensembl chr 6:66,512,374...66,524,204

G

transformed mouse 3T3 cell double minute 2

decreases phosphorylation
increases expression

oxfendazole results in decreased phosphorylation of MDM2 protein
oxfendazole results in increased expression of MDM2 mRNA

NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663

G

malic enzyme 1, NADP(+)-dependent, cytosolic

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]

PMID:18754104 PMID:20033131

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

antigen identified by monoclonal antibody Ki 67

decreases expression

oxfendazole results in decreased expression of MKI67 protein

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions

[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of NQO1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA

PMID:18754104 PMID:20033131

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

oxfendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

topoisomerase (DNA) II alpha

decreases expression

oxfendazole results in decreased expression of TOP2A protein

NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015

G

transformation related protein 53

decreases expression

oxfendazole results in decreased expression of TP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

pantoprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

increases expression

pantoprazole results in increased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family member 2

multiple interactions

pantoprazole promotes the reaction [ABCC2 protein affects the transport of estradiol-17 beta-glucuronide]

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP binding cassette subfamily G member 2 (Junior blood group)

multiple interactions

pantoprazole inhibits the reaction [ABCG2 protein affects the transport of 7-hydroxymethotrexate]

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

pantoprazole results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, C chain

decreases expression

pantoprazole results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

caspase 3

multiple interactions

pantoprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

complement component factor i

decreases expression

pantoprazole results in decreased expression of CFI mRNA

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
decreases expression

pantoprazole results in increased expression of CYP1A1 protein
pantoprazole results in decreased expression of CYP1A1 mRNA

PMID:9152597 PMID:25626140

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

pantoprazole results in increased expression of CYP1A2 mRNA; pantoprazole results in increased expression of CYP1A2 protein

PMID:9152597 PMID:25626140

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 13

increases expression

pantoprazole results in increased expression of CYP2B2 protein

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 38

increases metabolic processing
multiple interactions
decreases activity
affects response to substance

CYP2C19 protein results in increased metabolism of pantoprazole
pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]
pantoprazole results in decreased activity of CYP2C19 protein
CYP2C19 gene polymorphism affects the susceptibility to pantoprazole

PMID:8930576 PMID:15258107 PMID:20223877 PMID:21795468

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions

pantoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac]

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Pantoprazole results in increased expression of and results in increased activity of CYP2E1 protein

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

hepcidin antimicrobial peptide

increases expression

Pantoprazole results in increased expression of HAMP mRNA

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

Janus kinase 2

multiple interactions

pantoprazole decreases expression of JAK2 mRNA and decreases phosphorylation of JAK2 protein in gastrocnemius

RGD

NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480

G

myeloperoxidase

multiple interactions

pantoprazole inhibits the reaction [Indomethacin results in increased expression of MPO protein]; pantoprazole inhibits the reaction [Ketoprofen results in increased expression of MPO protein]; pantoprazole inhibits the reaction [Piroxicam results in increased expression of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

proliferating cell nuclear antigen

multiple interactions

[pantoprazole co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; pantoprazole promotes the reaction [Acetic Acid results in increased expression of PCNA protein]

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

retinol saturase (all trans retinol 13,14 reductase)

increases expression

pantoprazole results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

decreases expression

pantoprazole results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions

[Pantoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

transforming growth factor, beta 1

increases expression

Pantoprazole results in increased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression

pantoprazole results in increased expression of UGT1A1 mRNA

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

pantoprazole results in increased expression of UGT2B1 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

zona pellucida 3 receptor

decreases expression

pantoprazole results in decreased expression of C4BPA mRNA

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

parbendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

parbendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

pimobendan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases methylation

CYP1A2 protein results in decreased methylation of pimobendan

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

interleukin 1 beta

multiple interactions
decreases expression

pimobendan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
pimobendan results in decreased expression of IL1B protein

PMID:9004165 PMID:10193745

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

decreases expression
multiple interactions

pimobendan results in decreased expression of IL6 protein
pimobendan inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:9004165 PMID:10193745

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

pimobendan promotes the reaction [Glucose results in increased secretion of INS1 protein]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity

pimobendan results in decreased activity of KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

nitric oxide synthase 2, inducible

decreases expression
multiple interactions

pimobendan results in decreased expression of NOS2 mRNA
[pimobendan results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

tumor necrosis factor

multiple interactions
decreases expression

pimobendan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
pimobendan results in decreased expression of TNF protein

PMID:9004165 PMID:10193745

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

pimozide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

B cell leukemia/lymphoma 2

decreases expression

Pimozide results in decreased expression of BCL2 mRNA

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

FBJ osteosarcoma oncogene

multiple interactions
increases expression

istradefylline inhibits the reaction [Pimozide results in increased expression of FOS protein]; Tropicamide promotes the reaction [Pimozide results in increased expression of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

potassium voltage-gated channel, shaker-related subfamily, member 10

multiple interactions

Pimozide inhibits the reaction [KCNA10 protein results in increased transport of Potassium]

NCBI chr 3:107,090,459...107,103,037
Ensembl chr 3:107,090,372...107,103,037

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions
decreases activity

Pimozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Pimozide results in decreased activity of KCNH2 protein

PMID:15671647 PMID:19583963 PMID:21158687 PMID:24052561

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

luteinizing hormone beta

multiple interactions

Pimozide results in decreased secretion of and results in decreased glycosylation of LHB protein

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

prolactin

increases expression

Pimozide results in increased expression of PRL protein

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

rabeprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

Rabeprazole results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, C chain

decreases expression

Rabeprazole results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

complement component factor i

decreases expression

Rabeprazole results in decreased expression of CFI mRNA

NCBI chr 3:129,630,432...129,668,978
Ensembl chr 3:129,629,533...129,668,981

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
decreases activity

Rabeprazole results in increased expression of CYP1A1 mRNA; Rabeprazole results in increased expression of CYP1A1 protein
Rabeprazole results in decreased activity of CYP1A1 protein

PMID:9041675 PMID:12623754 PMID:25626140 PMID:33814510

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Rabeprazole results in increased expression of CYP1A2 mRNA

PMID:12623754 PMID:25626140

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Rabeprazole results in decreased activity of CYP1B1 protein

NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions
affects response to substance

CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]
CYP2C19 gene affects the susceptibility to Rabeprazole

PMID:15903128 PMID:17377957

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 3, subfamily a, polypeptide 13

multiple interactions

CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

hepcidin antimicrobial peptide

increases expression

Rabeprazole results in increased expression of HAMP mRNA

NCBI chr 7:30,641,793...30,643,454
Ensembl chr 7:30,641,793...30,643,457

G

pro-opiomelanocortin-alpha

increases expression

Rabeprazole results in increased expression of POMC protein

NCBI chr12:4,004,945...4,010,643
Ensembl chr12:4,004,951...4,010,642

G

retinol saturase (all trans retinol 13,14 reductase)

increases expression

Rabeprazole results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

decreases expression

Rabeprazole results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

solute carrier family 18 (vesicular monoamine), member 2

multiple interactions

Rabeprazole promotes the reaction [SLC18A2 protein results in increased secretion of Histamine]

NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Rabeprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression

Rabeprazole results in increased expression of UGT1A1 mRNA

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

Rabeprazole results in increased expression of UGT2B1 mRNA

NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389

G

zona pellucida 3 receptor

decreases expression

Rabeprazole results in decreased expression of C4BPA mRNA

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

selumetinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 like 11

increases expression

AZD 6244 results in increased expression of BCL2L11 protein

NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467

G

cathelicidin antimicrobial peptide

multiple interactions

AZD 6244 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; AZD 6244 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]]

NCBI chr 9:109,676,445...109,678,524
Ensembl chr 9:109,676,447...109,678,685

G

caspase 3

multiple interactions
increases cleavage

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP3 protein]

PMID:17876044 PMID:27222248

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 7

increases cleavage
multiple interactions

AZD 6244 results in increased cleavage of CASP7 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP7 protein]

NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776

G

caspase 8

multiple interactions

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

cyclin B1

decreases expression
multiple interactions

AZD 6244 results in decreased expression of CCNB1 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CCNB1 protein]

NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078

G

cyclin D1

multiple interactions

AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein]

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin dependent kinase 2

multiple interactions
decreases expression

Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK2 protein]

NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900

G

cyclin dependent kinase 4

decreases expression
multiple interactions

AZD 6244 results in decreased expression of CDK4 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK4 protein]

NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789

G

cyclin dependent kinase inhibitor 1A

multiple interactions

AZD 6244 promotes the reaction [decitabine results in increased expression of CDKN1A]

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

chromodomain helicase DNA binding protein 4

multiple interactions

AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]

NCBI chr 6:125,073,144...125,107,554
Ensembl chr 6:125,072,944...125,107,554

G

cAMP responsive element binding protein 1

decreases phosphorylation

AZD 6244 results in decreased phosphorylation of CREB1 protein

NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

[Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702

G

FBJ osteosarcoma oncogene

decreases phosphorylation

AZD 6244 results in decreased phosphorylation of FOS protein

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

Janus kinase 2

increases phosphorylation

selumetinib increases phosphorylation of JAK2 protein in colonic epithelium

RGD

NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480

G

Kirsten rat sarcoma viral oncogene homolog

multiple interactions

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]

NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965

G

mitogen-activated protein kinase 1

multiple interactions
decreases phosphorylation

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]
AZD 6244 results in decreased phosphorylation of MAPK1 protein

PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
decreases phosphorylation

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]
AZD 6244 results in decreased phosphorylation of MAPK3 protein

PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

matrix metallopeptidase 1b (interstitial collagenase)

decreases activity

AZD 6244 results in decreased activity of MMP1 protein

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

G

matrix metallopeptidase 2

decreases activity

AZD 6244 results in decreased activity of MMP2 protein

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

decreases activity

AZD 6244 results in decreased activity of MMP9 protein

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myelocytomatosis oncogene

multiple interactions
decreases expression

Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of MYC protein]

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage
multiple interactions

AZD 6244 results in increased cleavage of PARP1 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of PARP1 protein]
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]

PMID:17876044 PMID:27222248

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

ribosomal protein S6 kinase polypeptide 1

multiple interactions
decreases phosphorylation

Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of RPS6KA1 protein]

NCBI chr 4:133,574,601...133,615,466
Ensembl chr 4:133,574,601...133,615,108

G

suppressor of cytokine signaling 3

multiple interactions

AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 mRNA]; AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 protein]

NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873

G

uncoupling protein 1 (mitochondrial, proton carrier)

multiple interactions

AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

telmisartan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

decreases activity
multiple interactions

telmisartan results in decreased activity of ABCB11 protein
telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

PMID:20829430 PMID:23956101 PMID:24014644

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP binding cassette subfamily G member 1

multiple interactions
increases expression

PPARG mutant form inhibits the reaction [telmisartan results in increased expression of ABCG1 mRNA]

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

angiotensin I converting enzyme

decreases expression
multiple interactions

Telmisartan results in decreased expression of ACE mRNA; Telmisartan results in decreased expression of ACE protein
Telmisartan inhibits the reaction [Pregabalin results in increased expression of ACE protein]

PMID:19171132 PMID:25973029 PMID:29909460 PMID:31629013

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

multiple interactions
increases expression
decreases expression
decreases expression

telmisartan inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]
Telmisartan results in increased expression of ACE2 mRNA; Telmisartan results in increased expression of ACE2 protein
Telmisartan results in decreased expression of ACE2 mRNA; Telmisartan results in decreased expression of ACE2 protein
Telmisartan inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein]
telmisartan decreases expression of mRNA in mandible of rats with periodontal disease

CTD
RGD

PMID:21381899 PMID:25973029 PMID:28656296 PMID:29909460 PMID:31629013 More...

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

acetylcholinesterase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [telmisartan inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; telmisartan inhibits the reaction [Streptozocin results in increased activity of ACHE protein]

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

acid phosphatase 5, tartrate resistant

decreases activity

telmisartan decreases enzyme activity of Trap, Acp5 in serum of rats with periodontal disease

RGD

NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007

G

adiponectin, C1Q and collagen domain containing

increases expression

telmisartan results in increased expression of ADIPOQ mRNA
telmisartan results in increased expression of ADIPOQ protein

PMID:19730415 PMID:20555330

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

angiotensinogen

multiple interactions
decreases expression

telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]
Telmisartan inhibits the reaction [AGT protein results in decreased expression of PLAU mRNA]; Telmisartan inhibits the reaction [AGT protein results in decreased expression of SYP protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of AGTR1A mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1G mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1H mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CRH protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of FOS protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL1B protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; Telmisartan inhibits the reaction [AGT protein results in increased ubiquitination of SYP protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Diatrizoate results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Iohexol results in increased expression of AGT protein]; Telmisartan inhibits the reaction [Pregabalin results in decreased expression of AGT protein]
telmisartan results in decreased expression of AGT mRNA; telmisartan results in decreased expression of AGT protein

PMID:9533614 PMID:17620961 PMID:18487452 PMID:19171132 PMID:19289654 More...

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

angiotensin II receptor, type 1a

multiple interactions
decreases expression
affects binding
increases expression
decreases expression

telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; telmisartan inhibits the reaction [Streptozocin results in increased expression of AGTR1A protein]
telmisartan results in decreased expression of AGTR1A mRNA
telmisartan binds to and results in decreased activity of AGTR1 protein
telmisartan binds to AGTR1 protein
Telmisartan binds to and results in decreased activity of AGTR1 protein; Telmisartan inhibits the reaction [AGT protein results in increased expression of AGTR1A mRNA]; Telmisartan inhibits the reaction [Daunorubicin results in increased expression of AGTR1A protein]; Telmisartan inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein]
telmisartan results in increased expression of AGTR1 mRNA
telmisartan decreases expression of mRNA in mandible of rats with periodontal disease

CTD
RGD

PMID:8220885 PMID:9533614 PMID:9728324 PMID:17620961 PMID:19171132 More...

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

angiotensin II receptor, type 1b

multiple interactions

telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]

NCBI chr 3:20,368,637...20,421,341
Ensembl chr 3:20,368,637...20,421,341

G

angiotensin II receptor, type 2

increases expression

telmisartan increases expression of mRNA in mandible of rats with periodontal disease

RGD

NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403

G

aryl-hydrocarbon receptor

increases activity

Telmisartan results in increased activity of AHR protein

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

albumin

affects expression
multiple interactions

telmisartan affects the expression of ALB protein modified form
Telmisartan affects the reaction [LEPR protein affects the abundance of ALB protein]

PMID:16671338 PMID:34464088

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

alkaline phosphatase, liver/bone/kidney

increases activity
multiple interactions

telmisartan increases enzyme activity of Alpl in serum of rats with periodontal disease
Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of ALPL protein]

CTD
RGD

PMID:27269004 PMID:33364953

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

angiogenin, ribonuclease A family, member 2

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of ANG2 protein]

NCBI chr14:51,432,781...51,436,400
Ensembl chr14:51,432,781...51,436,605

G

BCL2-associated X protein

multiple interactions

telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BAX mRNA]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

brain derived neurotrophic factor

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]

NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352

G

calcium channel, voltage-dependent, T type, alpha 1G subunit

multiple interactions
decreases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Telmisartan results in decreased expression of CACNA1G mRNA]; SB 203580 inhibits the reaction [Telmisartan results in decreased expression of CACNA1G mRNA]; Telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1G mRNA]
telmisartan results in decreased expression of CACNA1G mRNA

NCBI chr11:94,299,217...94,365,226
Ensembl chr11:94,299,217...94,365,024

G

calcium channel, voltage-dependent, T type, alpha 1H subunit

multiple interactions
decreases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA]; SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of CACNA1H mRNA]

NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759

G

caspase 3

multiple interactions
decreases expression

telmisartan inhibits the reaction [Pyruvaldehyde results in increased cleavage of CASP3 protein]
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]
Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]; Telmisartan inhibits the reaction [Diatrizoate results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Iohexol results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of CASP3]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of CASP3 protein]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CASP3 mRNA]
Telmisartan results in decreased expression of CASP3 protein

PMID:18565324 PMID:19452295 PMID:21620867 PMID:21819444 PMID:22750630 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

Telmisartan inhibits the reaction [arsenite results in decreased activity of CAT protein]; Telmisartan inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]

PMID:23750309 PMID:26929000 PMID:34339004

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

C-C motif chemokine ligand 2

multiple interactions
decreases expression

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
telmisartan results in decreased expression of CCL2 protein

PMID:17922026 PMID:22124178

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 5

decreases response to substance

telmisartan results in decreased susceptibility to CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine receptor 2

decreases expression

telmisartan results in decreased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

CD36 molecule

increases expression
multiple interactions

telmisartan results in increased expression of CD36 mRNA
PPARG mutant form inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]; T 0070907 inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

CCAAT/enhancer binding protein beta

multiple interactions

telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]

NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338

G

corticotropin releasing hormone

multiple interactions

Telmisartan inhibits the reaction [AGT protein results in increased expression of CRH protein]

NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560

G

C-reactive protein, pentraxin-related

decreases expression

telmisartan results in decreased expression of CRP protein

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

cathepsin K

decreases expression

telmisartan decreases expression of mRNA in mandible of rats with periodontal disease

RGD

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

G

C-X-C motif chemokine ligand 12

multiple interactions
decreases response to substance

PPARG protein promotes the reaction [telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein]]; telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein]
telmisartan results in decreased susceptibility to CXCL12 protein

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 15

decreases expression

telmisartan metabolite results in decreased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 3

decreases expression

telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease

RGD

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

cytochrome b-245, alpha polypeptide

decreases expression
multiple interactions

telmisartan results in decreased expression of CYBA mRNA; telmisartan results in decreased expression of CYBA protein
telmisartan inhibits the reaction [Daunorubicin results in increased expression of CYBA protein]

PMID:16141465 PMID:19171132 PMID:21054405

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

multiple interactions
decreases expression

telmisartan inhibits the reaction [Streptozocin results in increased expression of CYBB protein]
telmisartan results in decreased expression of CYBB mRNA
Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of CYBB protein]
Telmisartan inhibits the reaction [arsenite results in increased expression of CYBB mRNA]

PMID:19171132 PMID:21381899 PMID:34339004 PMID:34464088

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome c, somatic

multiple interactions

telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CYCS mRNA]

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

G

cytochrome P450, family 2, subfamily j, polypeptide 9

decreases activity

Telmisartan results in decreased activity of CYP2J2 protein

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

DNA-damage inducible transcript 3

decreases expression

telmisartan results in decreased expression of DDIT3 protein

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

endothelin 1

multiple interactions

telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDN1 protein]

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin receptor type A

multiple interactions

telmisartan inhibits the reaction [Daunorubicin results in increased expression of EDNRA protein]

NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093

G

endothelin receptor type B

multiple interactions

telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein]

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

Fas ligand

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of FASL protein]
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of FASLG protein]

PMID:21620867 PMID:21819444

NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064

G

fibronectin 1

multiple interactions

telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of FN1 protein]

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

FBJ osteosarcoma oncogene

multiple interactions

Telmisartan inhibits the reaction [AGT protein results in increased expression of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

glial cell line derived neurotrophic factor

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]

NCBI chr15:7,839,529...7,867,061
Ensembl chr15:7,840,327...7,867,056

G

glial fibrillary acidic protein

multiple interactions
decreases expression

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]
Telmisartan results in decreased expression of GFAP protein

PMID:23747572 PMID:29909460

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

gamma-glutamyltransferase 1

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of GGT1 protein]

NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034

G

gap junction protein, alpha 1

multiple interactions

Telmisartan inhibits the reaction [Dibutyl Phthalate results in increased expression of GJA1 protein]

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions

Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glutamic pyruvic transaminase, soluble

multiple interactions

Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GPT protein]

PMID:26929000 PMID:27269004

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione reductase

decreases activity
multiple interactions

Telmisartan results in decreased activity of GSR protein
Telmisartan inhibits the reaction [arsenite results in decreased activity of GSR protein]

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

hepatocyte growth factor

increases expression

telmisartan results in increased expression of HGF mRNA

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

heat shock protein 5

decreases expression

telmisartan results in decreased expression of HSPA5 protein

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

intercellular adhesion molecule 1

multiple interactions

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]
telmisartan inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]
telmisartan inhibits the reaction [Daunorubicin results in increased expression of ICAM1 protein]

PMID:17724226 PMID:20888384 PMID:22124178

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

interleukin 10

multiple interactions
increases expression
decreases expression

telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL10 protein]
Telmisartan results in increased expression of IL10 protein
telmisartan decreases expression of protein in mandible of WKY rats with periodontal disease

CTD
RGD

PMID:24831514 PMID:29909460 PMID:33364953

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

multiple interactions
decreases expression

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
Telmisartan inhibits the reaction [AGT protein results in increased expression of IL1B protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of IL1B protein]
telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease

CTD
RGD

PMID:22124178 PMID:33872574 PMID:34339004 PMID:33364953

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions
decreases expression

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; Telmisartan inhibits the reaction [AGT protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein]
telmisartan results in decreased expression of IL6 mRNA
Telmisartan results in decreased expression of IL6 protein

PMID:19289654 PMID:21479465 PMID:22124178 PMID:29909460 PMID:34339004

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

increases expression

Telmisartan results in increased expression of INS1 protein

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

insulin II

decreases expression

telmisartan results in decreased expression of INS protein

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

interleukin-1 receptor-associated kinase 1

multiple interactions

[Atorvastatin co-treated with Telmisartan] results in decreased expression of IRAK1 mRNA

NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524

G

potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4

decreases expression

telmisartan decreases expression of KCNN4 mRNA and protein in CD4-positive alpha-beta T cell

RGD

NCBI chr 7:24,069,750...24,084,635
Ensembl chr 7:24,069,688...24,086,115

G

leptin receptor

multiple interactions

Telmisartan affects the reaction [LEPR protein affects the abundance of ALB protein]; Telmisartan affects the reaction [LEPR protein affects the expression of OCLN mRNA]

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

lipase, hormone sensitive

multiple interactions
increases expression

PPARD promotes the reaction [telmisartan results in increased expression of LIPE protein]

NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135

G

mitogen-activated protein kinase 1

multiple interactions

telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]
Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]

PMID:22124178 PMID:33872574

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 14

multiple interactions
decreases phosphorylation

telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]
telmisartan results in decreased phosphorylation of MAPK14 protein

PMID:19292980 PMID:22124178

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

mitogen-activated protein kinase 3

multiple interactions

telmisartan inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]
Telmisartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]

PMID:22124178 PMID:33872574

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

MAP kinase-activated protein kinase 2

multiple interactions

telmisartan inhibits the reaction [Streptozocin results in increased expression of MAPKAPK2 protein modified form]

NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563

G

MAS1 oncogene

multiple interactions
increases expression

telmisartan inhibits the reaction [Streptozocin results in decreased expression of MAS1 protein]
Telmisartan results in increased expression of MAS1 protein
Telmisartan inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein]

PMID:21381899 PMID:28656296 PMID:31629013

NCBI chr17:13,056,981...13,087,037
Ensembl chr17:13,059,966...13,087,030

G

microRNA 146

multiple interactions

[Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146A
telmisartan inhibits the reaction [ischemia-reperfusion injury increases expression of Mir146a miRNA in kidney]

CTD
RGD

PMID:20524934 PMID:27760486

NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288

G

microRNA 146b

multiple interactions

[Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146B

NCBI chr19:46,331,201...46,331,309
Ensembl chr19:46,331,201...46,331,309

G

microRNA 320

multiple interactions

telmisartan inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in kidney]

RGD

NCBI chr14:70,680,950...70,681,031
Ensembl chr14:70,680,950...70,681,031

G

matrix metallopeptidase 2

decreases expression
decreases expression

telmisartan results in decreased expression of MMP2 protein
telmisartan decreases expression of mRNA in mandible of WKY rats with periodontal disease

CTD
RGD

PMID:21054405 PMID:33364953

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

decreases expression

telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease

RGD

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [telmisartan inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; telmisartan inhibits the reaction [Streptozocin results in increased activity of MPO protein]
telmisartan inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein]; telmisartan inhibits the reaction [sodium arsenite results in increased activity of MPO protein]; telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

PMID:23060470 PMID:24831514 PMID:26439596 PMID:26929000

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

myosin, light polypeptide kinase

multiple interactions

MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK mRNA]; Telmisartan inhibits the reaction [Glucose results in increased expression of MYLK protein]

NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790

G

neutrophil cytosolic factor 1

multiple interactions
decreases expression

telmisartan inhibits the reaction [Streptozocin results in increased expression of NCF1 protein]
telmisartan results in decreased expression of NCF1 mRNA; telmisartan results in decreased expression of NCF1 protein
telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF1 protein]

PMID:16141465 PMID:19171132 PMID:21054405 PMID:21381899

NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479

G

neutrophil cytosolic factor 2

multiple interactions
decreases expression

telmisartan inhibits the reaction [Streptozocin results in increased expression of NCF2 protein]
telmisartan results in decreased expression of NCF2 mRNA; telmisartan results in decreased expression of NCF2 protein
telmisartan inhibits the reaction [Daunorubicin results in increased expression of NCF2 protein]

PMID:16141465 PMID:21054405 PMID:21381899

NCBI chr 1:152,675,904...152,712,743
Ensembl chr 1:152,675,945...152,712,742

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NFKB1 protein]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nitric oxide synthase 2, inducible

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NOS2 protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein]
Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of NOS2 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of NOS2]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]

PMID:21620867 PMID:21819444 PMID:22750630 PMID:24831514 PMID:26439596 More...

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

multiple interactions
increases expression
increases phosphorylation

2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan results in increased expression of NOS3 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan results in increased phosphorylation of NOS3 protein]
telmisartan results in increased expression of NOS3 protein
telmisartan results in increased phosphorylation of NOS3 protein

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

NADPH oxidase 4

multiple interactions

telmisartan inhibits the reaction [Daunorubicin results in increased expression of NOX4 protein]

NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918

G

natriuretic peptide type B

affects expression
decreases expression
multiple interactions

telmisartan affects the expression of NPPB protein
telmisartan results in decreased expression of NPPB protein
Telmisartan inhibits the reaction [Pregabalin results in increased expression of NPPB protein]

PMID:16671338 PMID:18712048 PMID:31629013

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

occludin

multiple interactions

Telmisartan affects the reaction [LEPR protein affects the expression of OCLN mRNA]
MYLK protein inhibits the reaction [Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN mRNA]; Telmisartan inhibits the reaction [Glucose results in decreased expression of OCLN protein]

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

oxidized low density lipoprotein (lectin-like) receptor 1

multiple interactions

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of OLR1 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of OLR1 protein]

NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128

G

plasminogen activator, urokinase

multiple interactions

telmisartan inhibits the reaction [AGT protein results in decreased expression of PLAU mRNA]

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

peroxisome proliferator activator receptor delta

multiple interactions
increases expression

PPARD promotes the reaction [Telmisartan results in increased expression of LIPE protein]; PPARD promotes the reaction [Telmisartan results in increased expression of UCP1 protein]; PPARD promotes the reaction [Telmisartan results in increased expression of UCP2 protein]; PPARD promotes the reaction [Telmisartan results in increased expression of UCP3 protein]
telmisartan results in increased expression of PPARD protein

NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448

G

peroxisome proliferator activated receptor gamma

multiple interactions
increases activity
increases expression

PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of NFKBIA mRNA]]; PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; PPARG mutant form inhibits the reaction [telmisartan results in increased expression of ABCG1 mRNA]; PPARG mutant form inhibits the reaction [telmisartan results in increased expression of CD36 mRNA]; PPARG protein promotes the reaction [telmisartan inhibits the reaction [CXCL12 protein affects the localization of ICAM3 protein]]
Telmisartan results in increased activity of PPARG protein
telmisartan inhibits the reaction [Streptozocin results in decreased expression of PPARG protein]
telmisartan results in increased expression of PPARG protein
telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of PPARG mRNA]; telmisartan promotes the reaction [Daunorubicin results in increased expression of PPARG protein]

PMID:18158351 PMID:20176998 PMID:20888384 PMID:21381899 PMID:22124178 More...

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

multiple interactions

telmisartan inhibits the reaction [Streptozocin results in decreased expression of PPARGC1A protein]

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

protein kinase, AMP-activated, alpha 2 catalytic subunit

multiple interactions

Telmisartan inhibits the reaction [Dibutyl Phthalate results in increased expression of PRKAA2 protein]

NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087

G

protein kinase, cAMP dependent, catalytic, alpha

multiple interactions

Telmisartan inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein]

NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases activity

telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
[Telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [arsenite results in increased activity of PTGS2 protein]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [Daunorubicin results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of PTGS2]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA]
telmisartan inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]
Telmisartan results in increased activity of PTGS2 protein

PMID:20223228 PMID:20888384 PMID:22124178 PMID:22750630 PMID:24831514 More...

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathyroid hormone 1 receptor

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of PTH1R protein]

NCBI chr 9:110,551,132...110,576,213
Ensembl chr 9:110,551,153...110,576,213

G

parathyroid hormone-like peptide

multiple interactions

telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of PTHLH protein]

NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

[telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of RELA protein]; telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of RELA mRNA]; telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of RELA protein]
telmisartan inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]

PMID:20223228 PMID:22124178 PMID:24831514 PMID:26929000

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

renin 1 structural

increases expression

telmisartan results in increased expression of REN mRNA; telmisartan results in increased expression of REN protein

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

G

runt related transcription factor 2

increases expression

telmisartan increases expression of mRNA in mandible of rats with periodontal disease

RGD

NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684

G

sodium channel, voltage-gated, type V, alpha

increases activity

telmisartan results in increased activity of SCN5A protein

NCBI chr 9:119,312,470...119,408,096
Ensembl chr 9:119,312,474...119,408,082

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B

multiple interactions

telmisartan inhibits the reaction [Calcitriol results in increased expression of SEMA3B protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3B protein]

NCBI chr 9:107,474,868...107,486,440
Ensembl chr 9:107,474,873...107,486,428

G

sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F

multiple interactions

telmisartan inhibits the reaction [Calcitriol results in increased expression of SEMA3F protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3F protein]

NCBI chr 9:107,558,698...107,587,674
Ensembl chr 9:107,558,699...107,587,674

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

multiple interactions

Telmisartan inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; Telmisartan inhibits the reaction [Hydrogen Peroxide results in increased expression of SERPINE1 mRNA]
telmisartan inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]

PMID:17620961 PMID:19706694

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

solute carrier family 18 (vesicular monoamine), member 2

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]

NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

telmisartan inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 6 (neurotransmitter transporter, dopamine), member 3

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]

NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791

G

synuclein, alpha

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

superoxide dismutase 1, soluble

multiple interactions

Telmisartan inhibits the reaction [Methotrexate results in decreased expression of and results in decreased activity of SOD1 protein]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

sperm microtubule inner protein 11

multiple interactions

Telmisartan inhibits the reaction [Daunorubicin results in decreased expression of NPHS1 protein]

NCBI chr15:98,468,885...98,487,469
Ensembl chr15:98,468,885...98,487,461

G

secreted phosphoprotein 1

increases expression

telmisartan increases expression of mRNA in mandible of WKY rats with periodontal disease

RGD

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

synaptophysin

multiple interactions

telmisartan inhibits the reaction [Streptozocin results in decreased expression of SYP protein]
telmisartan inhibits the reaction [AGT protein results in decreased expression of SYP protein]; telmisartan inhibits the reaction [AGT protein results in increased ubiquitination of SYP protein]

NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495

G

transforming growth factor, beta 1

multiple interactions
decreases expression

telmisartan inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]
telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; telmisartan inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; telmisartan inhibits the reaction [Daunorubicin results in increased expression of TGFB1 protein]
telmisartan results in decreased expression of TGFB1 mRNA

PMID:19171132 PMID:19706694 PMID:20888384 PMID:21381899

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tyrosine hydroxylase

multiple interactions

telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]

NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865

G

tight junction protein 1

multiple interactions
affects localization
decreases expression

2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan affects the localization of TJP1 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in decreased expression of TJP1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [telmisartan results in decreased expression of TJP1 protein]; wortmannin inhibits the reaction [telmisartan affects the localization of TJP1 protein]; wortmannin inhibits the reaction [telmisartan results in decreased expression of TJP1 mRNA]; wortmannin inhibits the reaction [telmisartan results in decreased expression of TJP1 protein]
telmisartan results in decreased expression of TJP1 mRNA; telmisartan results in decreased expression of TJP1 protein

NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529

G

toll-like receptor 4

multiple interactions

[Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 protein

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

multiple interactions
decreases expression
decreases expression

PPARG mutant form inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; T 0070907 inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; T 0070907 inhibits the reaction [telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; telmisartan inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
2-chloro-5-nitrobenzanilide inhibits the reaction [Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; [Telmisartan co-treated with Aspirin] inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Telmisartan inhibits the reaction [arsenite results in increased expression of TNF protein]; Telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Telmisartan inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Telmisartan inhibits the reaction [sodium arsenite results in increased expression of TNF]; Telmisartan inhibits the reaction [TNF protein promotes the reaction [CEBPB protein binds to IL6 promoter]]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein]; Telmisartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
telmisartan inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; telmisartan inhibits the reaction [sodium arsenite results in increased expression of TNF protein]; telmisartan inhibits the reaction [TNF protein results in increased expression of IL6 protein]
Telmisartan results in decreased expression of TNF protein
telmisartan decreases expression of protein in mandible of SHR rats with periodontal disease

CTD
RGD

PMID:19289654 PMID:20223228 PMID:21620867 PMID:21819444 PMID:22124178 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)

increases expression

telmisartan increases expression of mRNA in mandible of WKY rats with periodontal disease

RGD

NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880

G

tumor necrosis factor (ligand) superfamily, member 11

decreases expression

telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease

RGD

NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483

G

TNF receptor-associated factor 6

multiple interactions

[Atorvastatin co-treated with Telmisartan] results in decreased expression of TRAF6 mRNA

NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014

G

uncoupling protein 1 (mitochondrial, proton carrier)

multiple interactions
increases expression

PPARD promotes the reaction [telmisartan results in increased expression of UCP1 protein]

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

G

uncoupling protein 2 (mitochondrial, proton carrier)

multiple interactions
increases expression

PPARD promotes the reaction [telmisartan results in increased expression of UCP2 protein]

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

uncoupling protein 3 (mitochondrial, proton carrier)

multiple interactions
increases expression

PPARD promotes the reaction [telmisartan results in increased expression of UCP3 protein]

NCBI chr 7:100,122,198...100,135,639
Ensembl chr 7:100,122,197...100,135,639

G

vascular cell adhesion molecule 1

multiple interactions

telmisartan inhibits the reaction [Daunorubicin results in increased expression of VCAM1 protein]

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

vascular endothelial growth factor A

multiple interactions
decreases expression

telmisartan inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]
telmisartan results in decreased expression of VEGFA mRNA
telmisartan inhibits the reaction [sodium arsenite results in increased expression of VEGFA]

PMID:17724226 PMID:19171132 PMID:26439596

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vitronectin

decreases expression

telmisartan decreases expression of mRNA in mandible of SHR rats with periodontal disease

RGD

NCBI chr11:78,389,946...78,393,151
Ensembl chr11:78,389,917...78,393,150

thiabendazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 4931406C07 gene

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA

NCBI chr 9:15,194,633...15,217,836
Ensembl chr 9:15,194,633...15,217,744

G

acyl-CoA thioesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene

NCBI chr12:84,034,635...84,040,651
Ensembl chr12:84,034,635...84,040,647

G

acyl-CoA thioesterase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA

NCBI chr12:84,084,028...84,091,497
Ensembl chr12:84,085,153...84,095,375

G

aminoacylase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA

NCBI chr 9:106,310,180...106,315,594
Ensembl chr 9:106,310,180...106,315,518

G

ADAM metallopeptidase domain 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene

NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303

G

ADAMTS-like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene

NCBI chr 7:81,984,612...82,263,658
Ensembl chr 7:81,984,902...82,263,658

G

adenylate cyclase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA

NCBI chr15:98,484,982...98,508,119
Ensembl chr15:98,487,854...98,507,957

G

adhesion regulating molecule 1 26S proteasome ubiquitin receptor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA

NCBI chr 2:179,813,381...179,818,076
Ensembl chr 2:179,813,278...179,818,079

G

alpha fetoprotein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA

NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766

G

angiotensinogen

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

androgen-induced 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene

NCBI chr10:13,522,798...13,744,980
Ensembl chr10:13,522,798...13,744,724

G

A kinase anchor protein 8

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA

NCBI chr17:32,522,646...32,540,212
Ensembl chr17:32,522,646...32,540,212

G

A kinase anchor protein 8-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA

NCBI chr17:32,540,398...32,569,589
Ensembl chr17:32,540,398...32,569,581

G

albumin

decreases expression

Thiabendazole results in decreased expression of ALB mRNA

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase 9, subfamily A1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA

NCBI chr 1:167,177,560...167,196,100
Ensembl chr 1:167,177,560...167,196,101

G

ALG2 alpha-1,3/1,6-mannosyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA

NCBI chr 4:47,469,833...47,474,367
Ensembl chr 4:47,465,067...47,474,333

G

angiopoietin-like 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

ankyrin repeat and sterile alpha motif domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA

NCBI chr16:4,759,290...4,783,362
Ensembl chr16:4,759,300...4,782,069

G

annexin A11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA

NCBI chr14:25,842,575...25,887,228
Ensembl chr14:25,842,580...25,887,228

G

aprataxin and PNKP like factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA

NCBI chr 6:87,605,407...87,649,244
Ensembl chr 6:87,605,406...87,649,175

G

apolipoprotein F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA

NCBI chr10:128,104,568...128,107,119
Ensembl chr10:128,103,866...128,106,022

G

ARF GTPase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA

NCBI chr11:103,857,551...103,876,176
Ensembl chr11:103,857,565...103,876,163

G

actin related protein 2/3 complex, subunit 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene

NCBI chr 5:145,020,679...145,045,566
Ensembl chr 5:145,020,640...145,045,571

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA

NCBI chr 7:66,294,220...66,339,601
Ensembl chr 7:66,294,313...66,339,344

G

argininosuccinate synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA

NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684

G

atos homolog A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA

NCBI chr 9:74,860,162...74,939,750
Ensembl chr 9:74,860,151...74,939,746

G

ATP synthase membrane subunit c locus 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA

NCBI chr11:95,963,619...95,966,520
Ensembl chr11:95,959,678...95,966,496

G

ATPase, H+ transporting, lysosomal V0 subunit D1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA

NCBI chr 8:106,251,093...106,292,696
Ensembl chr 8:106,251,097...106,292,679

G

BCL2-associated athanogene 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA

NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705

G

BTG3 associated nuclear protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA

NCBI chr 8:122,674,711...122,755,999
Ensembl chr 8:122,676,489...122,755,997

G

B cell CLL/lymphoma 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA

NCBI chr 3:97,110,974...97,205,718
Ensembl chr 3:97,110,978...97,205,233

G

basic helix-loop-helix domain containing, class B9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA

NCBI chr X:134,742,388...134,791,828
Ensembl chr X:134,698,343...134,791,830

G

betaine-homocysteine methyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA

NCBI chr13:93,753,399...93,774,266
Ensembl chr13:93,753,183...93,774,469

G

complement component 1, q subcomponent, C chain

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA

NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156

G

cyclase associated actin cytoskeleton regulatory protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA

NCBI chr 4:122,752,841...122,779,869
Ensembl chr 4:122,752,840...122,779,849

G

calcyphosphine 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA

NCBI chr10:111,999,254...112,052,466
Ensembl chr10:111,999,526...112,052,460

G

caspase 3

increases activity

Thiabendazole results in increased activity of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

increases activity

Thiabendazole results in increased activity of CASP8 protein

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

increases activity

Thiabendazole results in increased activity of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

cystathionine beta-synthase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA

NCBI chr17:31,831,602...31,856,170
Ensembl chr17:31,827,868...31,856,212

G

coiled-coil domain containing 125

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA

NCBI chr13:100,805,442...100,833,748
Ensembl chr13:100,806,225...100,833,748

G

cyclin L1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA

NCBI chr 3:65,853,333...65,869,451
Ensembl chr 3:65,853,572...65,865,670

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

CCAAT/enhancer binding protein delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

centrosomal protein 85

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA

NCBI chr 4:133,857,169...133,914,420
Ensembl chr 4:133,857,169...133,914,423

G

ceramide kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA

NCBI chr15:86,023,302...86,070,537
Ensembl chr15:86,023,329...86,070,342

G

complement factor B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

cofilin 1, non-muscle

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

coiled-coil-helix-coiled-coil-helix domain containing 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA

NCBI chr10:75,768,964...75,773,584
Ensembl chr10:75,768,964...75,773,581

G

checkpoint kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA

NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011

G

charged multivesicular body protein 5

affects expression

Thiabendazole affects the expression of CHMP5 mRNA

NCBI chr 4:40,948,553...40,965,302
Ensembl chr 4:40,948,407...40,965,303

G

cold inducible RNA binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA

NCBI chr10:80,001,824...80,008,620
Ensembl chr10:80,001,819...80,008,620

G

cardiotrophin-like cytokine factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA

NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544

G

clusterin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

CNDP dipeptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA

NCBI chr18:84,685,590...84,703,827
Ensembl chr18:84,685,590...84,703,827

G

carnitine palmitoyltransferase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA

NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807

G

cryptochrome circadian regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA

NCBI chr10:84,967,564...85,020,918
Ensembl chr10:84,967,564...85,020,928

G

centrosome and spindle pole associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA

NCBI chr 1:10,108,194...10,206,996
Ensembl chr 1:10,108,212...10,206,993

G

cysteine-serine-rich nuclear protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA

NCBI chr 9:119,800,229...119,813,808
Ensembl chr 9:119,800,229...119,813,724

G

cystathionine gamma lyase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene

NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714

G

catenin alpha like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA

NCBI chr 4:56,810,935...56,865,370
Ensembl chr 4:56,810,935...56,865,188

G

cut-like homeobox 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA

NCBI chr 5:121,996,025...122,188,522
Ensembl chr 5:121,994,429...122,188,165

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

herbimycin inhibits the reaction [Thiabendazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Thiabendazole results in increased expression of CYP1A1 protein]
Thiabendazole results in increased expression of CYP1A1 mRNA; Thiabendazole results in increased expression of CYP1A1 protein

PMID:8900397 PMID:10103034 PMID:11226373 PMID:14987951 PMID:15110098

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression
affects metabolic processing
decreases activity

beta-Naphthoflavone promotes the reaction [CYP1A2 protein affects the metabolism of Thiabendazole]
Thiabendazole results in increased expression of CYP1A2 mRNA; Thiabendazole results in increased expression of CYP1A2 protein
Thiabendazole results in decreased activity of CYP1A2 protein

PMID:10936227 PMID:11124226 PMID:12920490 PMID:15110098 PMID:16261361 More...

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily b, polypeptide 10

increases expression

Thiabendazole results in increased expression of CYP2B6 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

increases expression

Thiabendazole results in increased expression of CYP2B2 mRNA; Thiabendazole results in increased expression of CYP2B2 protein

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 65

decreases activity

Thiabendazole results in decreased activity of CYP2C9 protein

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 4, subfamily a, polypeptide 12B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA

NCBI chr 4:115,268,821...115,296,231
Ensembl chr 4:115,268,821...115,296,231

G

cytochrome P450, family 4, subfamily f, polypeptide 14

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA

NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316

G

cytohesin 1 interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA

NCBI chr 2:58,019,151...58,085,559
Ensembl chr 2:58,019,149...58,085,544

G

D site albumin promoter binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA

NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627

G

DNA cross-link repair 1C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA

NCBI chr 2:3,425,112...3,475,248
Ensembl chr 2:3,425,168...3,465,167

G

DEAD box helicase 20

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA

NCBI chr 3:105,585,586...105,595,104
Ensembl chr 3:105,585,586...105,594,890

G

DEAD box helicase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA

NCBI chr11:106,671,181...106,680,011
Ensembl chr11:106,671,181...106,680,011

G

DNA fragmentation factor, beta subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA

NCBI chr 4:154,048,904...154,059,578
Ensembl chr 4:154,048,906...154,059,583

G

discs large MAGUK scaffold protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene

NCBI chr 7:90,125,399...92,098,454
Ensembl chr 7:90,125,880...92,098,455

G

delta like canonical Notch ligand 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA

NCBI chr17:15,587,616...15,597,275
Ensembl chr17:15,587,616...15,597,134

G

doublesex and mab-3 related transcription factor 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene

NCBI chr19:25,587,609...25,601,285
Ensembl chr19:25,587,665...25,601,285

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA

NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA

NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109

G

dipeptidylpeptidase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA

NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575

G

dual specificity phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene

NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862

G

dual specificity phosphatase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA

NCBI chr10:99,098,676...99,103,351
Ensembl chr10:99,099,093...99,103,351

G

DAZ interacting protein 1-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene

NCBI chr 9:99,511,448...99,552,128
Ensembl chr 9:99,511,549...99,551,309

G

elastin microfibril interfacer 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA

NCBI chr 5:31,070,729...31,078,623
Ensembl chr 5:31,070,746...31,078,621

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA

NCBI chr10:24,649,712...24,712,093
Ensembl chr10:24,648,304...24,718,721

G

erythrocyte membrane protein band 4.1 like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene

NCBI chr17:69,382,642...69,596,986
Ensembl chr17:69,382,678...69,596,984

G

EPM2A interacting protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA

NCBI chr 9:111,100,913...111,108,161
Ensembl chr 9:111,100,997...111,108,161

G

Ets2 repressor factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA

NCBI chr 7:24,941,985...24,950,522
Ensembl chr 7:24,941,986...24,950,186

G

esterase D/formylglutathione hydrolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA

NCBI chr14:74,969,591...74,988,205
Ensembl chr14:74,969,737...74,988,205

G

family with sequence similarity 135, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA

NCBI chr 1:24,049,824...24,139,444
Ensembl chr 1:24,050,174...24,139,422

G

family with sequence similarity 177, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene

NCBI chr12:55,171,313...55,188,889
Ensembl chr12:55,171,254...55,188,889

G

family with sequence similarity 204, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA

NCBI chr19:60,187,018...60,215,137
Ensembl chr19:60,187,018...60,215,133

G

family with sequence similarity 53, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene

NCBI chr 5:33,757,695...33,787,007
Ensembl chr 5:33,757,691...33,786,979

G

FIC domain containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA

NCBI chr 5:113,873,821...113,878,670
Ensembl chr 5:113,873,864...113,878,661

G

FK506 binding protein 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA

NCBI chr 6:128,407,066...128,415,619
Ensembl chr 6:128,406,698...128,415,640

G

FK506 binding protein 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene

NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501

G

formin 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA

NCBI chr 2:113,158,029...113,547,113
Ensembl chr 2:113,158,081...113,547,112

G

FERM domain containing 4B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA

NCBI chr 6:97,263,828...97,594,618
Ensembl chr 6:97,263,828...97,594,502

G

frizzled class receptor 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA

NCBI chr15:38,869,673...38,901,587
Ensembl chr15:38,869,429...38,901,583

G

growth arrest and DNA-damage-inducible 45 alpha

increases expression

Thiabendazole results in increased expression of GADD45A mRNA

NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441

G

growth arrest and DNA-damage-inducible 45 gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA

NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504

G

glutamine amidotransferase like class 1 domain containing 3A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA

NCBI chr10:77,997,900...78,005,589
Ensembl chr10:77,997,900...78,005,616

G

glutamate-cysteine ligase, catalytic subunit

increases activity
multiple interactions

Thiabendazole results in increased activity of GCLC protein
[Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

growth differentiation factor 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

gypsy retrotransposon integrase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA

NCBI chr 1:97,697,894...97,721,435
Ensembl chr 1:97,697,897...97,721,434

G

GIT ArfGAP 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA

NCBI chr 5:114,865,469...114,912,647
Ensembl chr 5:114,865,468...114,913,578

G

galactosidase, beta 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA

NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966

G

predicted gene 715

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene

NCBI chr X:59,591,614...59,592,823
Ensembl chr X:59,591,614...59,592,823

G

glucosamine-6-phosphate deaminase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA

NCBI chr 5:69,732,344...69,749,684
Ensembl chr 5:69,730,451...69,749,683

G

GRAM domain containing 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA

NCBI chr 7:30,829,552...30,855,374
Ensembl chr 7:30,829,552...30,855,321

G

glutamate receptor, ionotropic, AMPA1 (alpha 1)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene

NCBI chr11:56,902,342...57,221,070
Ensembl chr11:56,902,213...57,221,070

G

glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA

NCBI chr15:76,130,917...76,134,109
Ensembl chr15:76,130,964...76,134,104

G

gasdermin A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene

NCBI chr11:98,555,163...98,568,534
Ensembl chr11:98,555,177...98,568,534

G

glutathione S-transferase kappa 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA

NCBI chr 6:42,222,869...42,227,375
Ensembl chr 6:42,222,869...42,227,381

G

glutathione S-transferase, pi 1

increases expression

Thiabendazole results in increased expression of GSTP1 mRNA

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase, theta 1

increases expression

Thiabendazole results in increased expression of GSTT1 mRNA

NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418

G

histidyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA

NCBI chr18:36,899,581...36,916,258
Ensembl chr18:36,899,581...36,916,258

G

heme binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA

NCBI chr 6:135,114,517...135,145,213
Ensembl chr 6:135,114,520...135,175,020

G

hes family bHLH transcription factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA

NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614

G

heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA

NCBI chr11:63,775,519...63,813,110
Ensembl chr11:63,776,618...63,813,116

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA

NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620

G

hydroxysteroid (17-beta) dehydrogenase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA

NCBI chr X:150,784,892...150,787,438
Ensembl chr X:150,784,841...150,787,438

G

hydroxysteroid (17-beta) dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA

NCBI chr 8:118,427,752...118,485,767
Ensembl chr 8:118,428,643...118,485,766

G

heat shock protein 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA

NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214

G

HSPA (heat shock 70kDa) binding protein, cytoplasmic cochaperone 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA

NCBI chr 7:4,663,514...4,688,218
Ensembl chr 7:4,663,520...4,688,067

G

immediate early response 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

insulin-like growth factor binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA

NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546

G

inositol polyphosphate-5-phosphatase F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA

NCBI chr 7:128,212,905...128,298,161
Ensembl chr 7:128,213,052...128,298,149

G

IQ calmodulin-binding motif containing 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA

NCBI chr16:36,648,722...36,694,044
Ensembl chr16:36,648,747...36,693,083

G

interferon regulatory factor 2 binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA

NCBI chr 8:127,315,035...127,320,725
Ensembl chr 8:127,315,035...127,320,725

G

inositol 1,4,5-triphosphate receptor interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA

NCBI chr19:47,883,029...47,907,738
Ensembl chr19:47,883,041...47,907,738

G

jun B proto-oncogene

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA

NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347

G

katanin interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene

NCBI chr 7:125,307,027...125,473,967
Ensembl chr 7:125,307,060...125,473,965

G

KH domain containing 4, pre-mRNA splicing factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA

NCBI chr 3:88,593,087...88,620,240
Ensembl chr 3:88,593,110...88,620,231

G

Kruppel-like transcription factor 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA

NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950

G

Kruppel-like transcription factor 2 (lung)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA

NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500

G

kelch-like 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene

NCBI chr11:100,331,954...100,347,853
Ensembl chr11:100,332,743...100,347,848

G

galectin like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA

NCBI chr11:20,773,355...20,781,916
Ensembl chr11:20,773,576...20,781,056

G

LIM homeobox protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene

NCBI chr 2:38,229,282...38,259,747
Ensembl chr 2:38,229,293...38,259,745

G

LPS-induced TN factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA

NCBI chr16:10,777,137...10,810,985
Ensembl chr16:10,777,139...10,884,021

G

ligand of numb-protein X 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA

NCBI chr 5:146,953,471...147,013,364
Ensembl chr 5:146,953,465...147,013,396

G

lysyl oxidase-like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene

NCBI chr 6:83,011,186...83,029,547
Ensembl chr 6:83,011,154...83,029,543

G

lysophosphatidylcholine acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene

NCBI chr13:73,615,332...73,664,539
Ensembl chr13:73,615,316...73,664,541

G

lysophosphatidylglycerol acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene

NCBI chr 1:191,449,682...191,516,367
Ensembl chr 1:191,449,946...191,516,367

G

lipin 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA

NCBI chr 2:160,722,590...160,747,920
Ensembl chr 2:160,722,590...160,747,922

G

leukotriene A4 hydrolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA

NCBI chr10:93,289,258...93,320,758
Ensembl chr10:93,289,273...93,320,737

G

leucine rich adaptor protein 1-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene

NCBI chr 4:80,828,923...80,872,538
Ensembl chr 4:80,828,883...80,873,865

G

MAP kinase-activated protein kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA

NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563

G

meiosis regulator and mRNA stability 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA

NCBI chr16:13,927,030...13,977,157
Ensembl chr16:13,927,037...13,981,215

G

mediator complex subunit 12-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA

NCBI chr 3:58,912,820...59,225,867
Ensembl chr 3:58,913,246...59,226,103

G

methyltransferase 14, N6-adenosine-methyltransferase subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA

NCBI chr 3:123,161,944...123,179,639
Ensembl chr 3:123,161,946...123,179,757

G

microfibrillar associated protein 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene

NCBI chr 6:122,490,543...122,506,249
Ensembl chr 6:122,482,804...122,506,249

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

microRNA 122

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA

NCBI chr18:65,381,932...65,381,997
Ensembl chr18:65,381,932...65,381,997

G

microRNA 130a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA

NCBI chr 2:84,571,459...84,571,522
Ensembl chr 2:84,571,459...84,571,522

G

microRNA 146

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA

NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288

G

microRNA 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA

NCBI chr11:75,354,542...75,354,636
Ensembl chr11:75,354,542...75,354,636

G

microRNA 32

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA

NCBI chr 4:56,895,229...56,895,298
Ensembl chr 4:56,895,229...56,895,298

G

microRNA 33

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA

NCBI chr15:82,082,323...82,082,391
Ensembl chr15:82,082,323...82,082,391

G

microRNA 486

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA

NCBI chr 8:23,632,571...23,632,698
Ensembl chr 8:23,632,571...23,632,698

G

malonyl-CoA decarboxylase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA

NCBI chr 8:120,121,591...120,148,577
Ensembl chr 8:120,121,617...120,137,841

G

molybdenum cofactor synthesis 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA

NCBI chr13:114,954,707...114,965,960
Ensembl chr13:114,954,772...114,968,811

G

microrchidia 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA

NCBI chr16:93,629,009...93,672,964
Ensembl chr16:93,629,009...93,672,961

G

myeloperoxidase

increases metabolic processing

MPO protein results in increased metabolism of Thiabendazole metabolite

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

MRG/MORF4L binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA

NCBI chr 2:180,222,990...180,228,097
Ensembl chr 2:180,223,097...180,228,097

G

MRN complex interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA

NCBI chr11:50,065,678...50,090,943
Ensembl chr11:50,065,271...50,090,942

G

mitochondrial ribosomal protein L44

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA

NCBI chr 1:79,753,735...79,759,162
Ensembl chr 1:79,753,735...79,759,162

G

mitochondrial ribosomal protein S18B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA

NCBI chr17:36,221,272...36,227,332
Ensembl chr17:36,221,271...36,227,281

G

mitochondrial amidoxime reducing component 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA

NCBI chr 1:184,518,964...184,543,622
Ensembl chr 1:184,518,964...184,543,394

G

myosin X

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA

NCBI chr15:25,622,636...25,813,759
Ensembl chr15:25,622,611...25,813,759

G

NEDD4 binding protein 2-like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA

NCBI chr 5:150,515,310...150,589,213
Ensembl chr 5:150,531,472...150,589,648

G

NEDD8 activating enzyme E1 subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA

NCBI chr 8:105,237,660...105,261,269
Ensembl chr 8:105,237,660...105,261,269

G

NADH:ubiquinone oxidoreductase subunit B11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene

NCBI chr X:20,481,565...20,483,858
Ensembl chr X:20,481,565...20,483,858

G

nuclear factor, erythroid derived 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA

NCBI chr15:103,156,640...103,166,809
Ensembl chr15:103,156,639...103,166,830

G

nuclear factor, interleukin 3, regulated

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA

NCBI chr13:53,121,245...53,136,914
Ensembl chr13:53,121,245...53,135,109

G

natriuretic peptide type B

increases expression

Thiabendazole results in increased expression of NPPB mRNA

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA

NCBI chr11:98,658,758...98,666,233
Ensembl chr11:98,658,758...98,666,159

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA

NCBI chr14:4,230,549...4,265,639
Ensembl chr14:4,230,569...4,265,642

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Thiabendazole results in increased activity of NR1I2 protein

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA

NCBI chr 1:131,838,196...131,864,059
Ensembl chr 1:131,838,272...131,864,059

G

5-oxoprolinase (ATP-hydrolysing)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA

NCBI chr15:76,180,803...76,215,381
Ensembl chr15:76,180,801...76,212,215

G

ORAI calcium release-activated calcium modulator 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene

NCBI chr 7:127,368,987...127,374,322
Ensembl chr 7:127,368,987...127,374,322

G

3-oxoacid CoA transferase 1

affects expression

Thiabendazole affects the expression of OXCT1 mRNA

NCBI chr15:4,055,910...4,184,826
Ensembl chr15:4,055,865...4,184,826

G

PP2A A alpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene

NCBI chr19:24,451,270...24,454,819
Ensembl chr19:24,453,866...24,454,720

G

PARP1 binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene

NCBI chr10:87,927,260...87,982,831
Ensembl chr10:87,927,294...87,982,803

G

PDZ and LIM domain 1 (elfin)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA

NCBI chr19:40,210,683...40,260,060
Ensembl chr19:40,209,617...40,260,286

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA

NCBI chr 4:11,958,183...11,966,450
Ensembl chr 4:11,958,184...11,966,452

G

PDZ domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene

NCBI chr15:12,359,797...12,740,052
Ensembl chr15:12,359,797...12,740,010

G

period circadian clock 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA

NCBI chr11:68,985,934...69,000,791
Ensembl chr11:68,986,043...69,000,786

G

period circadian clock 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA

NCBI chr 4:151,081,475...151,129,167
Ensembl chr 4:151,088,109...151,129,122

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1

increases expression

Thiabendazole results in increased expression of PFKFB1 mRNA

NCBI chr X:149,370,441...149,426,874
Ensembl chr X:149,371,225...149,426,874

G

phosphoglycerate kinase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA

NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305

G

protein inhibitor of activated STAT 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA

NCBI chr 3:96,603,679...96,613,386
Ensembl chr 3:96,603,700...96,613,386

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA

NCBI chr14:51,164,672...51,168,306
Ensembl chr14:51,163,525...51,168,313

G

paired Ig-like receptor B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA

NCBI chr 7:3,715,504...3,723,381
Ensembl chr 7:3,714,408...3,723,390

G

pleckstrin homology domain containing, family G (with RhoGef domain) member 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA

NCBI chr 4:152,156,890...152,199,855
Ensembl chr 4:152,156,955...152,199,857

G

polo like kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

phospholipid phosphatase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene

NCBI chr 7:128,858,114...128,993,138
Ensembl chr 7:128,858,755...128,993,136

G

phosphomevalonate kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA

NCBI chr 3:89,361,848...89,376,321
Ensembl chr 3:89,361,848...89,376,320

G

paroxysmal nonkinesiogenic dyskinesia

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA

NCBI chr 1:74,323,757...74,392,851
Ensembl chr 1:74,324,089...74,392,853

G

proline-rich nuclear receptor coactivator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA

NCBI chr 4:33,245,423...33,248,787
Ensembl chr 4:33,245,423...33,290,163

G

cytochrome p450 oxidoreductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene

NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180

G

peroxisome proliferator activator receptor delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA

NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448

G

PR domain containing 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA

NCBI chr16:97,592,720...97,653,076
Ensembl chr16:97,592,667...97,653,050

G

PRELI domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA

NCBI chr18:42,008,761...42,084,259
Ensembl chr18:42,008,665...42,084,307

G

proline arginine-rich end leucine-rich repeat

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA

NCBI chr 1:133,838,042...133,857,820
Ensembl chr 1:133,838,042...133,849,152

G

protein kinase C, beta

increases expression

Thiabendazole results in increased expression of PRKCB mRNA

NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625

G

proline and serine rich 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA

NCBI chr 2:6,103,304...6,135,100
Ensembl chr 2:6,102,418...6,135,022

G

pre-mRNA processing factor 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA

NCBI chr12:65,083,094...65,110,160
Ensembl chr12:65,083,107...65,110,160

G

proteasome (prosome, macropain) 26S subunit, ATPase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA

NCBI chr 5:21,990,273...22,008,785
Ensembl chr 5:21,990,281...22,008,785

G

proteasome (prosome, macropain) 26S subunit, ATPase, 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA

NCBI chr 7:27,741,127...27,749,517
Ensembl chr 7:27,741,132...27,749,526

G

protease (prosome, macropain) 26S subunit, ATPase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA

NCBI chr11:106,147,011...106,153,938
Ensembl chr11:106,146,980...106,153,946

G

protein phosphatase 2 protein activator

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA

NCBI chr 2:30,306,062...30,337,819
Ensembl chr 2:30,306,051...30,337,818

G

pseudouridylate synthase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA

NCBI chr11:23,608,588...23,682,876
Ensembl chr11:23,615,674...23,682,876

G

rabaptin, RAB GTPase binding effector protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA

NCBI chr11:70,735,553...70,833,931
Ensembl chr11:70,735,604...70,833,931

G

RAB, member RAS oncogene family-like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA

NCBI chr15:89,466,730...89,476,126
Ensembl chr15:89,466,736...89,476,126

G

RNA guanine-7 methyltransferase activating subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene

NCBI chr 7:81,412,701...81,419,238
Ensembl chr 7:81,412,673...81,419,239

G

RAN GTPase activating protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA

NCBI chr15:81,588,449...81,614,120
Ensembl chr15:81,588,449...81,629,731

G

arginyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA

NCBI chr11:35,699,207...35,725,355
Ensembl chr11:35,699,208...35,725,333

G

RNA binding motif protein 14

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA

NCBI chr19:4,850,594...4,861,662
Ensembl chr19:4,850,597...4,861,662

G

RNA binding motif (RNP1, RRM) protein 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA

NCBI chr X:8,005,214...8,012,119
Ensembl chr X:8,005,214...8,012,119

G

RNA binding protein gene with multiple splicing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene

NCBI chr 8:34,272,671...34,419,925
Ensembl chr 8:34,272,671...34,419,891

G

retroelement silencing factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA

NCBI chr 6:149,210,907...149,237,161
Ensembl chr 6:149,210,912...149,237,161

G

REV1, DNA directed polymerase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA

NCBI chr 1:38,091,867...38,169,191
Ensembl chr 1:38,091,867...38,168,882

G

regulatory factor X, 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA

NCBI chr 9:72,439,346...72,530,231
Ensembl chr 9:72,439,522...72,530,111

G

regulator of cell cycle

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene

NCBI chr14:79,526,190...79,539,075
Ensembl chr14:79,526,196...79,539,085

G

regulator of G-protein signaling 16

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA

NCBI chr 1:153,616,099...153,621,212
Ensembl chr 1:153,616,095...153,621,214

G

Rho-related BTB domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA

NCBI chr13:76,017,656...76,092,054
Ensembl chr13:76,017,656...76,092,044

G

ribonuclease, RNase A family, 10 (non-active)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene

NCBI chr14:51,245,208...51,248,218
Ensembl chr14:51,245,208...51,248,215

G

Rho family GTPase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA

NCBI chr 2:51,020,451...51,039,123
Ensembl chr 2:51,020,450...51,039,123

G

RAR-related orphan receptor gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA

NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583

G

ribitol xylosyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene

NCBI chr10:121,916,844...121,933,271
Ensembl chr10:121,914,019...121,933,276

G

spalt like transcription factor 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene

NCBI chr 2:168,590,252...168,609,121
Ensembl chr 2:168,590,252...168,609,863

G

sarcosine dehydrogenase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA

NCBI chr 2:27,078,405...27,138,344
Ensembl chr 2:27,078,405...27,138,349

G

sodium channel, nonvoltage-gated 1 alpha

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA

NCBI chr 6:125,286,657...125,321,906
Ensembl chr 6:125,297,622...125,321,906

G

short chain dehydrogenase/reductase family 42E, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA

NCBI chr 8:118,388,138...118,400,428
Ensembl chr 8:118,388,138...118,400,428

G

sestrin 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

SET domain containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA

NCBI chr 8:96,442,211...96,448,135
Ensembl chr 8:96,442,509...96,445,638

G

secreted frizzled-related protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene

NCBI chr 3:83,673,628...83,681,621
Ensembl chr 3:83,673,628...83,681,623

G

SH3-domain binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA

NCBI chr 5:34,683,128...34,720,983
Ensembl chr 5:34,683,182...34,720,985

G

single immunoglobulin and toll-interleukin 1 receptor (TIR) domain

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA

NCBI chr 7:140,671,088...140,680,493
Ensembl chr 7:140,671,088...140,680,485

G

salt inducible kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA

NCBI chr 9:50,800,944...50,920,432
Ensembl chr 9:50,804,101...50,920,373

G

solute carrier family 12, member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA

NCBI chr 2:112,096,659...112,193,508
Ensembl chr 2:112,096,170...112,193,508

G

solute carrier family 20, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA

NCBI chr 2:129,038,662...129,053,535
Ensembl chr 2:129,040,684...129,053,536

G

solute carrier family 25, member 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA

NCBI chr11:102,293,795...102,299,501
Ensembl chr11:102,293,811...102,298,772

G

solute carrier family 26, member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA

NCBI chr 9:108,731,239...108,742,117
Ensembl chr 9:108,730,482...108,742,117

G

solute carrier family 37 (glycerol-3-phosphate transporter), member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA

NCBI chr 9:37,140,445...37,166,709
Ensembl chr 9:37,138,881...37,167,034

G

STE20-like kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene

NCBI chr19:47,568,458...47,633,685
Ensembl chr19:47,568,117...47,633,685

G

SMAD family member 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA

NCBI chr18:75,500,436...75,529,006
Ensembl chr18:75,500,600...75,529,006

G

small muscle protein, X-linked

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene

NCBI chr X:156,481,969...156,535,587
Ensembl chr X:156,481,906...156,535,587

G

small nuclear ribonucleoprotein 200 (U5)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA

NCBI chr 2:127,050,306...127,082,373
Ensembl chr 2:127,050,306...127,082,371

G

sorting nexin 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA

NCBI chr16:33,071,826...33,119,932
Ensembl chr16:33,071,812...33,120,639

G

suppressor of cytokine signaling 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA

NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873

G

superoxide dismutase 3, extracellular

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA

NCBI chr 5:52,521,146...52,527,080
Ensembl chr 5:52,521,133...52,528,760

G

spermatogenesis and oogenesis specific basic helix-loop-helix 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene

NCBI chr 2:25,733,007...25,737,347
Ensembl chr 2:25,733,007...25,737,260

G

sperm associated antigen 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA

NCBI chr15:36,175,629...36,235,767
Ensembl chr15:36,178,245...36,235,767

G

steroid 5 alpha-reductase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene

NCBI chr17:74,321,886...74,354,855
Ensembl chr17:74,323,950...74,354,911

G

serine/arginine repetitive matrix 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA

NCBI chr17:24,009,501...24,043,715
Ensembl chr17:24,009,506...24,043,715

G

serine and arginine-rich splicing factor 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA

NCBI chr12:80,992,308...80,997,277
Ensembl chr12:80,992,278...80,997,281

G

StAR related lipid transfer domain containing 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA

NCBI chr 2:120,459,567...120,562,371
Ensembl chr 2:120,459,602...120,562,376

G

sushi domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA

NCBI chr10:75,472,453...75,479,842
Ensembl chr10:75,472,540...75,479,842

G

symplekin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA

NCBI chr 7:18,758,321...18,788,542
Ensembl chr 7:18,758,302...18,788,543

G

TATA-box binding protein associated factor 9B

affects expression

Thiabendazole affects the expression of TAF9B mRNA

NCBI chr X:105,250,480...105,264,764
Ensembl chr X:105,250,489...105,264,764

G

tyrosine aminotransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA

NCBI chr 8:110,712,710...110,726,436
Ensembl chr 8:110,717,069...110,726,435

G

tyrosyl-DNA phosphodiesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA

NCBI chr13:25,015,642...25,026,136
Ensembl chr13:25,015,662...25,026,136

G

TEA domain family member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA

NCBI chr 7:44,865,216...44,882,892
Ensembl chr 7:44,865,177...44,883,068

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA

NCBI chr 8:84,298,327...84,321,120
Ensembl chr 8:84,298,327...84,334,600

G

TDP-glucose 4,6-dehydratase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA

NCBI chr14:118,349,323...118,370,177
Ensembl chr14:118,349,323...118,370,167

G

transforming growth factor, beta induced

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA

NCBI chr13:56,757,399...56,787,172
Ensembl chr13:56,757,336...56,787,375

G

tight junction associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA

NCBI chr17:46,568,777...46,593,991
Ensembl chr17:46,568,777...46,593,952

G

transketolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA

NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677

G

transmembrane BAX inhibitor motif containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA

NCBI chr15:99,290,828...99,307,930
Ensembl chr15:99,290,763...99,307,930

G

transmembrane protein 268

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA

NCBI chr 4:63,472,410...63,504,594
Ensembl chr 4:63,477,018...63,504,594

G

thiol methyltransferase 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMT1B mRNA

NCBI chr10:128,794,146...128,796,857
Ensembl chr10:128,794,143...128,796,857

G

tumor necrosis factor, alpha-induced protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA

NCBI chr12:111,408,898...111,421,452
Ensembl chr12:111,408,903...111,421,452

G

torsin family 3, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA

NCBI chr 1:156,481,187...156,501,909
Ensembl chr 1:156,481,187...156,501,926

G

TRAF3 interacting protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA

NCBI chr10:39,488,930...39,531,303
Ensembl chr10:39,488,930...39,531,303

G

TRAF type zinc finger domain containing 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA

NCBI chr 5:121,509,788...121,524,543
Ensembl chr 5:121,509,788...121,523,695

G

tripartite motif-containing 3

increases expression

Thiabendazole results in increased expression of TRIM3 mRNA

NCBI chr 7:105,253,670...105,282,805
Ensembl chr 7:105,253,670...105,282,778

G

tripartite motif-containing 34A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA

NCBI chr 7:103,893,657...103,911,446
Ensembl chr 7:103,893,664...103,911,441

G

transformation related protein 53

increases expression

Thiabendazole results in increased expression of TP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

TSC22 domain family, member 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA

NCBI chr X:139,440,277...139,501,257
Ensembl chr X:139,440,277...139,501,408

G

ubiquitin-like modifier activating enzyme 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA

NCBI chr 6:97,160,593...97,182,608
Ensembl chr 6:97,160,631...97,182,608

G

ubiquitin B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA

NCBI chr11:62,442,329...62,444,037
Ensembl chr11:62,441,997...62,444,039

G

ubiquitin C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA

NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266

G

uridine-cytidine kinase 1-like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA

NCBI chr 2:181,210,942...181,223,820
Ensembl chr 2:181,210,942...181,226,685

G

UDP-glucose dehydrogenase

increases expression

Thiabendazole results in increased expression of UGDH mRNA

NCBI chr 5:65,570,550...65,593,185
Ensembl chr 5:65,570,564...65,593,292

G

unc-45 myosin chaperone A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA

NCBI chr 7:79,975,040...79,990,748
Ensembl chr 7:79,975,040...79,997,741

G

ubiquitin specific peptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA

NCBI chr 9:43,978,318...44,006,924
Ensembl chr 9:43,978,318...44,006,924

G

ubiquitin specific peptidase 40

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA

NCBI chr 1:87,872,841...87,936,308
Ensembl chr 1:87,872,841...87,936,273

G

utrophin

increases expression

Thiabendazole results in increased expression of UTRN mRNA

NCBI chr10:12,257,931...12,745,632
Ensembl chr10:12,257,932...12,745,109

G

vascular endothelial growth factor A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vanin 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA

NCBI chr10:23,727,360...23,745,741
Ensembl chr10:23,727,360...23,745,741

G

vitronectin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA

NCBI chr11:78,389,946...78,393,151
Ensembl chr11:78,389,917...78,393,150

G

WD repeat domain 11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene

NCBI chr 7:129,193,373...129,237,462
Ensembl chr 7:129,193,587...129,237,462

G

WEE 1 homolog 1 (S. pombe)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA

NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493

G

WAP four-disulfide core domain 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene

NCBI chr 2:164,491,547...164,499,263
Ensembl chr 2:164,491,551...164,498,503

G

YOD1 deubiquitinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene

NCBI chr 1:130,645,064...130,652,093
Ensembl chr 1:130,645,064...130,652,095

G

zinc finger, C3H1-type containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA

NCBI chr10:115,220,691...115,268,677
Ensembl chr10:115,220,864...115,268,677

G

zinc finger protein 280D

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA

NCBI chr 9:72,181,900...72,271,061
Ensembl chr 9:72,182,142...72,271,059

G

zinc finger protein 36, C3H type-like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA

NCBI chr17:84,491,352...84,495,375
Ensembl chr17:84,491,359...84,495,375

G

zinc finger protein 422

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA

NCBI chr 6:116,600,977...116,605,960
Ensembl chr 6:116,600,977...116,605,960

G

zinc finger protein 598

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA

NCBI chr17:24,888,661...24,900,997
Ensembl chr17:24,888,661...24,900,990

G

zinc finger, MYM-type 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA

NCBI chr X:100,447,990...100,464,986
Ensembl chr X:100,447,990...100,464,455

G

zinc finger, MYM-type 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA

NCBI chr 4:126,971,176...127,018,167
Ensembl chr 4:126,971,176...127,018,165

G

zinc finger, RAN-binding domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA

NCBI chr 3:157,239,749...157,254,029
Ensembl chr 3:157,239,797...157,254,047

veliparib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

increases transport

ABCB1 protein results in increased transport of veliparib

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

thymoma viral proto-oncogene 1

multiple interactions

veliparib promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein]; veliparib promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

ataxia telangiectasia mutated

multiple interactions
increases activity

veliparib results in increased phosphorylation of and results in increased activity of ATM protein
veliparib results in increased activity of ATM protein

NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040

G

BCL2-antagonist/killer 1

multiple interactions

BAK1 protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983

G

BCL2-associated X protein

multiple interactions

BAX protein results in increased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

BCL2-like 1

multiple interactions

BCL2L1 protein results in decreased susceptibility to [Methylnitronitrosoguanidine co-treated with veliparib]

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

breast cancer 1, early onset

affects response to substance
decreases response to substance

BRCA1 affects the susceptibility to veliparib
BRCA1 protein results in decreased susceptibility to veliparib

PMID:21633166 PMID:21707865

NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781

G

breast cancer 2, early onset

affects response to substance

BRCA2 affects the susceptibility to veliparib

NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794

G

cyclin dependent kinase 12

affects response to substance

CDK12 protein affects the susceptibility to veliparib

NCBI chr11:98,093,259...98,171,941
Ensembl chr11:98,093,885...98,169,330

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing

CYP1A2 protein results in increased metabolism of veliparib

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 2, subfamily c, polypeptide 38

increases metabolic processing

CYP2C19 protein results in increased metabolism of veliparib

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily d, polypeptide 22

increases metabolic processing

CYP2D6 protein results in increased metabolism of veliparib

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

G

epidermal growth factor receptor

decreases response to substance
affects localization

EGFR protein results in decreased susceptibility to veliparib
veliparib affects the localization of EGFR protein

PMID:21719137 PMID:21912620

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

excision repair cross-complementing rodent repair deficiency, complementation group 1

multiple interactions

ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr 7:19,079,016...19,090,449
Ensembl chr 7:19,078,703...19,090,449

G

excision repair cross-complementing rodent repair deficiency, complementation group 4

multiple interactions

ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr16:12,927,600...12,969,873
Ensembl chr16:12,927,548...12,968,481

G

excision repair cross-complementing rodent repair deficiency, complementation group 6

multiple interactions

veliparib promotes the reaction [ERCC6 protein affects the susceptibility to potassium bromate]

NCBI chr14:32,235,248...32,302,947
Ensembl chr14:32,235,478...32,302,947

G

H2A.X variant histone

multiple interactions
increases expression

[veliparib co-treated with Topotecan] results in increased expression of H2AX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein; veliparib results in increased expression of H2AX protein modified form

PMID:17505006 PMID:21227924 PMID:21795476 PMID:21917757 PMID:27694308

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

interleukin 1 beta

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

N-methylpurine-DNA glycosylase

multiple interactions

MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide]

NCBI chr11:32,176,505...32,182,702
Ensembl chr11:32,176,505...32,182,700

G

MRE11A homolog A, double strand break repair nuclease

decreases response to substance

MRE11 protein results in decreased susceptibility to veliparib

NCBI chr 9:14,695,971...14,748,421
Ensembl chr 9:14,695,950...14,748,419

G

nitric oxide synthase 2, inducible

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions
decreases activity
increases expression

PARP1 protein affects the susceptibility to [Temozolomide co-treated with veliparib]; veliparib binds to and results in decreased activity of PARP1 protein; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of H2AX protein modified form]; veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]
veliparib results in decreased activity of PARP1 protein
[veliparib results in increased expression of PARP1 protein] which results in increased expression of H2AX protein; veliparib results in increased expression of PARP1 protein; veliparib results in increased expression of PARP1 protein mutant form
[veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin

PMID:17505006 PMID:19143569 PMID:19823047 PMID:19825992 PMID:21300766 More...

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

poly (ADP-ribose) polymerase family, member 10

affects binding

veliparib binds to PARP10 protein

NCBI chr15:76,117,195...76,127,640
Ensembl chr15:76,115,374...76,127,641

G

poly (ADP-ribose) polymerase family, member 2

affects binding
multiple interactions
decreases activity

PARP2 protein binds to veliparib
veliparib binds to and results in decreased activity of PARP2 protein
veliparib results in decreased activity of PARP2 protein

PMID:19143569 PMID:20092359 PMID:21917757 PMID:28001384

NCBI chr14:51,045,347...51,058,758
Ensembl chr14:51,045,298...51,058,758

G

phosphatase and tensin homolog

decreases response to substance

PTEN protein results in decreased susceptibility to veliparib

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

replication protein A2

multiple interactions

veliparib inhibits the reaction [PARP1 protein mutant form results in increased expression of RPA2 protein modified form]

NCBI chr 4:132,495,671...132,506,057
Ensembl chr 4:132,495,643...132,506,063

G

S100 protein, beta polypeptide, neural

multiple interactions

veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA]; veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]

NCBI chr10:76,089,670...76,097,153
Ensembl chr10:76,089,687...76,096,993

G

tyrosyl-DNA phosphodiesterase 1

multiple interactions

TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]

NCBI chr12:99,850,767...99,921,482
Ensembl chr12:99,850,776...99,921,478

G

X-ray repair complementing defective repair in Chinese hamster cells 1

multiple interactions

veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]

NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22307
chemical entity	22306
atom	22302
nonmetal atom	22132
nitrogen atom	20045
nitrogen molecular entity	20045
organonitrogen compound	19855
organonitrogen heterocyclic compound	19105
benzimidazoles	1182
(2R,4S)-N-\{(1R,2R)-4-[(1H-benzimidazol-2-ylmethyl)amino]-1-benzyl-2-hydroxy-4-oxobutyl\}-2-\{(1R)-2-(benzylamino)-2-oxo-1-[(phenylacetyl)amino]ethyl\}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide	0
(2S,4R)-N-(1H-benzimidazol-2-ylmethyl)-4-cyclohexyl-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-carboxamide	0
(5S)-5-\{4-[(2S)-2-(1H-benzimidazol-2-yl)-2-(1,3-benzothiazol-2-ylamino)ethyl]phenyl\}isothiazolidin-3-one 1,1-dioxide	0
(6-chloro-1H-benzimidazol-2-yl)-(4-methyl-1-piperazinyl)methanone	0
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol	0
1-(1H-benzimidazol-2-yl)-3-cyclohexylurea	0
1-(2,4-dichlorobenzoyl)-1H-benzimidazole	0
1-(2,4-difluorophenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-5-benzimidazolecarboxamide	0
1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol	0
1-(2-chlorophenyl)-3-[[(1-ethyl-2-methyl-5-benzimidazolyl)-oxomethyl]amino]thiourea	0
1-(2-deoxyribosyl)benzimidazole +	0
1-(2-furanyl)-2-(3-heptyl-2-imino-1-benzimidazolyl)ethanol	0
1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]benzimidazole	0
1-(2-methoxyethyl)-2-[(4-methylphenoxy)methyl]benzimidazole	0
1-(2-methylpropyl)-2-thiophen-2-ylbenzimidazole	0
1-(4-ethylphenyl)-2-methyl-N-(3-pyridinylmethyl)-5-benzimidazolecarboxamide	0
1-(4-morpholinyl)-2-[2-(phenylmethylthio)-1-benzimidazolyl]ethanone	0
1-(5-\{[3-(1H-benzimidazol-2-yl)propanoyl]amino\}-5-deoxy-alpha-L-lyxofuranosyl)cytosine	0
1-(5-bromo-2-thiophenyl)-2-[(5-ethoxy-1-methyl-2-benzimidazolyl)thio]ethanone	0
1-(5-bromo-2-thiophenyl)-2-[(5-methoxy-1-methyl-2-benzimidazolyl)thio]ethanone	0
1-(Piperidinomethyl)-1H-benzo[d]imidazole	0
1-(phenylmethyl)benzimidazole	0
1-[(3,4-difluorophenyl)methyl]-2-oxo-N-[(1R)-2-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)oxy]-1-phenylethyl]-3-pyridinecarboxamide	0
1-[(3-methylphenyl)methyl]benzimidazole	0
1-[1-(cyclooctylmethyl)-5-(hydroxymethyl)-3,6-dihydro-2H-pyridin-4-yl]-3-ethyl-2-benzimidazolone	0
1-[2-(2-chlorophenoxy)ethyl]benzimidazole	0
1-[2-imino-3-[2-(1-piperidinyl)ethyl]-1-benzimidazolyl]-3-(3-methylphenoxy)-2-propanol	0
1-[3-[2-(diethylamino)ethyl]-2-imino-1-benzimidazolyl]-3-(3-methylphenoxy)-2-propanol	0
1-[4-(1H-benzimidazol-2-yl)phenyl]-3-[3-(4-morpholinyl)propyl]thiourea	0
1-[[2-(1H-benzimidazol-2-ylthio)-1-oxoethyl]amino]-3-ethylthiourea	0
1-azepanyl-[2-(phenylmethyl)-1-benzimidazolyl]methanone	0
1-butyl-2-(2-methylphenyl)-7-propan-2-yl-5H-imidazo[4,5-g]quinoxalin-6-one	0
1-cyclohexyl-N-(3-methylbutyl)-5-benzimidazolecarboxamide	0
1-cyclopentyl-1-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-3-(2-oxolanylmethyl)thiourea	0
1-cyclopropyl-3-[3-[5-(4-morpholinylmethyl)-2-benzimidazolylidene]-1,2-dihydropyrazol-4-yl]urea	0
1-erythrosylbenzimidazole +	0
1-ethyl-2-[(4-methylphenoxy)methyl]benzimidazole	0
1-ethyl-2-[[(1-methyl-2-benzimidazolyl)thio]methyl]benzimidazole	0
1-ethyl-2-methyl-N-[(phenylmethylene)amino]-5-benzimidazolecarboxamide	0
1-ethyl-3-[[2-[(1-methyl-2-benzimidazolyl)thio]-1-oxoethyl]amino]thiourea	0
1-ethyl-N-[(4-methoxyphenyl)methyl]-5-benzimidazolamine	0
1-ethyl-N-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine	0
1-methyl-3-phenylpyrazino[1,2-a]benzimidazole	0
1-ribosylbenzimidazole +	37
11-[2-(4-morpholinyl)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile	0
11-[2-(diethylamino)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile	0
1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]-	0
1H-benzimidazol-5-ylmethanol	0
1H-benzimidazole-5,6-diamine	0
1H-benzo[d]imidazole-2-thiol	1
2''-(4-methoxyphenyl)-5-(3-aminopyrrolidin-1-yl)-2,5',2',5''-ter(benzimidazole)	0
2,2'-[3-(2-methoxyphenyl)-1,2-propanediyl]bis(1H-benzimidazole)	0
2-(1-benzimidazolylmethyl)-5-[(4-chlorophenyl)methylthio]-1,3,4-oxadiazole	0
2-(1H-Benzimidazol-2-yl)-N-(4-phenylmethoxyphenyl)benzamide	0
2-(1H-benzimidazol-2-yl)-1-(4-chlorophenyl)ethanamine	0
2-(1H-benzimidazol-2-yl)-3-(2-furanyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-(3-nitrophenyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-oxo-4-[(5-oxo-4-propyl-1H-1,2,4-triazol-3-yl)thio]butanenitrile	0
2-(1H-benzimidazol-2-yl)-5-methyl-4-(phenylmethyl)-4H-pyrazol-3-one	0
2-(1H-benzimidazol-2-yl)aniline	0
2-(1H-benzimidazol-2-ylmethoxymethyl)-1H-benzimidazole	0
2-(1H-benzimidazol-2-ylmethoxymethyl)-6-nitro-1H-benzimidazole	0
2-(1H-benzimidazol-2-ylmethyl)benzene-1,4-diol	0
2-(1H-benzimidazol-2-ylthio)-1-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)ethanone	0
2-(1H-benzimidazol-2-ylthio)-1-[2,5-dimethyl-1-(2-oxolanylmethyl)-3-pyrrolyl]ethanone	0
2-(1H-benzimidazol-2-ylthio)-1-thiophen-2-ylethanone	0
2-(1H-benzimidazol-2-ylthio)-N-(5-propyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-(1H-benzimidazol-2-ylthio)acetic acid methyl ester	0
2-(2,3,3-trichloro-1-nitroprop-2-enylidene)-1,3-dihydrobenzimidazole	0
2-(2,5-dimethylphenyl)-3H-benzimidazol-5-amine	0
2-(2-chloro-3-pyridinyl)-1-prop-2-enylbenzimidazole	0
2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide	0
2-(2-phenoxyethylsulfonyl)-1H-benzimidazole	0
2-(3-methyl-2-oxo-1-benzimidazolyl)acetonitrile	0
2-(4-\{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl\}-1,3-thiazol-2-yl)guanidine	0
2-(4-cyanophenoxy)-N-(2-methyl-1-phenyl-5-benzimidazolyl)acetamide	0
2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole	0
2-(4-methyl-1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(5-methyl-1,3-dihydrobenzimidazol-2-ylidene)-2-nitrosoacetonitrile	0
2-(6-chloro-3-pyridinyl)-1H-benzimidazole	0
2-(6-methyl-1H-benzimidazol-2-yl)-3-(5-methyl-2-furanyl)-2-propenenitrile	0
2-(6-methyl-1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(Methoxymethyl)-1-methyl-1H-benzimidazole	0
2-(beta-D-glucosyl)benzimidazole	0
2-(trifluoromethyl)-1H-benzo[d]imidazole	0
2-Amino-1-methylbenzimidazole	0
2-Butyl-1H-benzimidazole	0
2-Isopropyl-1H-benzo[d]imidazole	0
2-Methyl-1H-benzo[d]imidazole	0
2-[(1,5-dimethyl-2-benzimidazolyl)amino]ethanol	0
2-[(1-acetyl-2-benzimidazolyl)thio]-N-(2-methoxyphenyl)acetamide	0
2-[(2,2-dichloro-3,3-dimethylcyclopropyl)methylthio]-1H-benzimidazole	0
2-[(2,5-dimethylphenyl)thio]acetic acid [3-(1H-benzimidazol-2-yl)-3-cyano-2-oxopropyl] ester	0
2-[(2-ethoxy-2-oxoethyl)thio]-1-benzimidazolecarboxylic acid ethyl ester	0
2-[(2-methoxyphenoxy)methyl]-1H-benzimidazole	0
2-[(3S)-1-(1-Methyl-4-piperidinyl)-3-pyrrolidinyl]-1H-benzimidazole	0
2-[(3S)-1-(3,4-Difluorobenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
2-[(3S)-1-(4-Chlorobenzyl)-3-pyrrolidinyl]-1-methyl-1H-benzimidazole	0
2-[(3S)-1-(Cyclohexylmethyl)-3-pyrrolidinyl]-5-methyl-1H-benzimidazole	0
2-[(3s)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-5-fluoro-1h-benzimidazole	0
2-[(4-cyano-1-oxo-5H-pyrido[1,2-a]benzimidazol-3-yl)methylthio]propanoic acid	0
2-[(6-chloro-1H-benzimidazol-2-yl)thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[(6-chloro-2-phenyl-1-benzimidazolyl)oxy]acetic acid	0
2-[(6-methyl-1H-benzimidazol-2-yl)thio]-1-(2-methyl-1H-indol-3-yl)ethanone	0
2-[2-(2-chlorophenyl)-1-benzimidazolyl]-N-(2,6-diethylphenyl)acetamide	0
2-[2-(2-chlorophenyl)-1-benzimidazolyl]-N-(2-propan-2-ylphenyl)acetamide	0
2-[2-(4-aminophenyl)-3H-benzimidazol-5-yl]-3H-benzimidazol-5-amine	0
2-[2-(ethylthio)-1-benzimidazolyl]-1-(1-piperidinyl)ethanone	0
2-[2-[2-[(1,3-dimethyl-2-oxo-5-benzimidazolyl)methylidene]hydrazinyl]-4-oxo-5-thiazolyl]acetic acid	0
2-[5-(4-carbamimidoylphenyl)furan-2-yl]-1H-benzimidazole-5-carboximidamide	0
2-[5-[(5,7-dimethyl-1-oxo-2-thiazolo[3,2-a]benzimidazolylidene)methyl]-2-furanyl]benzoic acid	0
2-[5-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-furanyl]benzoic acid	0
2-[8-(6-amino-1H-benzimidazol-2-yl)octyl]-3H-benzimidazol-5-amine	0
2-[[(1-butyl-2-benzimidazolyl)amino]methyl]phenol	0
2-[[(1-propan-2-yl-2-benzimidazolyl)amino]methyl]-6-prop-2-enylphenol	0
2-[[(6-bromo-1H-benzimidazol-2-yl)thio]methyl]-1-methylbenzimidazole	0
2-[[2-(2-methylphenoxy)ethylthio]methyl]-1H-benzimidazole	0
2-[[3-(1H-benzimidazol-2-yl)-2-pyridinyl]thio]acetic acid methyl ester	0
2-[[5-(1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(4-methyl-2-thiazolyl)acetamide	0
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide	0
2-[[5-[2-(1H-benzimidazol-2-yl)ethyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-[[5-[2-(1H-benzimidazol-2-yl)ethyl]-4-methyl-1,2,4-triazol-3-yl]thio]acetonitrile	0
2-[[6-(butylsulfamoyl)-1H-benzimidazol-2-yl]thio]-N-(2-chlorophenyl)acetamide	0
2-[[6-(dimethylsulfamoyl)-1H-benzimidazol-2-yl]methoxymethyl]-N,N-dimethyl-3H-benzimidazole-5-sulfonamide	0
2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol	0
2-[[[5-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]methyl]benzonitrile	0
2-[fluoro(trifluoromethoxy)methyl]-6-methyl-1H-benzimidazole	0
2-aminobenzimidazole +	86
2-benzamido-1-(3-phenylpropyl)-5-benzimidazolecarboxylic acid methyl ester	0
2-ethyl-1-[(2-methoxyphenyl)methyl]benzimidazole	0
2-ethyl-N-[1-[2-(1-piperidinyl)ethyl]-2-benzimidazolyl]-3-pyrazolecarboxamide	0
2-methoxy-1-(1-methyl-2-benzimidazolyl)-1-phenylethanamine	0
2-methoxy-N-[(1-methyl-2-benzimidazolyl)methyl]aniline	0
2-methyl-1-phenyl-5-benzimidazolecarboxylic acid [2-(2-methoxyanilino)-2-oxoethyl] ester	0
2-methyl-1-phenyl-5-benzimidazolecarboxylic acid [2-(3-methylbutan-2-ylamino)-2-oxoethyl] ester	0
2-methyl-1H-benzimidazole-5-carboxylic acid	0
2-methyl-1H-pyrimido[1,2-a]benzimidazol-4-one	0
2-methyl-N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]propanamide	0
2-methylpropanoic acid [3-(1H-benzimidazol-2-yl)-3-cyano-2-oxopropyl] ester	0
2-phenyl-2,3-dihydro-[1,3]thiazino[3,2-a]benzimidazol-4-one	0
3,4,5-trimethoxy-N-[2-(1-methyl-2-benzimidazolyl)ethyl]benzamide	0
3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol	0
3,4-dimethyl-N-[[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]-sulfanylidenemethyl]benzamide	0
3-(1-benzimidazolylmethyl)-6-[(4-methoxyphenoxy)methyl]-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	0
3-(1H-benzimidazol-2-yl)-N-(3-pyridinylmethyl)aniline	0
3-(1H-benzimidazol-2-ylthio)-5,5-dimethyl-3-(1-oxopropyl)-2-oxolanone	0
3-(2-phenoxyethyl)-1H-benzimidazole-2-thione	0
3-(6-amino-1H-benzimidazol-2-yl)-1-propanol	0
3-(6-amino-1H-benzimidazol-2-yl)propanoic acid	0
3-Hydroxyomeprazole	0
3-[(7-carbamimidoylnaphthalen-2-yl)methyl]-5-(\{1-[(1Z)-ethanimidoyl]piperidin-4-yl\}oxy)-2-methyl-1H-3,1-benzimidazol-3-ium	0
3-[1-(2-carboxyethyl)-1H-benzo[d]imidazol-2-yl]propanoic acid	0
3-[1-[(4-methyl-6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)methyl]-4-piperidinyl]-1H-benzimidazol-2-one	0
3-[1-butyl-5-(diethylsulfamoyl)-2-benzimidazolyl]propanoic acid	0
3-[2-(4-methyl-2-propan-2-ylphenoxy)ethyl]-1H-benzimidazole-2-thione	0
3-[3-[[2-oxo-2-(1,2,5-trimethyl-3-pyrrolyl)ethyl]thio]propyl]-1H-benzimidazol-2-one	0
3-[5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl]propan-1-ol	0
3-[5-(diethylsulfamoyl)-1-methyl-2-benzimidazolyl]propanoic acid [2-(3,5-dichloroanilino)-2-oxoethyl] ester	0
3-[5-(dimethylsulfamoyl)-1-ethyl-2-benzimidazolyl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide	0
3-[5-(dimethylsulfamoyl)-1-ethyl-2-benzimidazolyl]propanoic acid	0
3-\{[2-(1H-benzimidazol-1-yl)-6-\{[2-(diethylamino)ethyl]amino\}pyrimidin-4-yl]amino\}-4-methylphenol	0
4-(1-ethyl-2-benzimidazolyl)aniline	0
4-(1H-benzimidazol-2-ylmethylthio)-2-methylbenzofuro[3,2-d]pyrimidine	0
4-(4-chloro-3-nitrophenyl)-N-[2-(5,6-dichloro-1-propyl-2-benzimidazolyl)ethyl]-2-thiazolamine	0
4-(5,6-Dichloro-1H-benzimidazol-1-yl)butan-1-ol	0
4-[(1H-benzimidazol-2-ylhydrazinylidene)methyl]benzoic acid	0
4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine	0
4-[(6-chloro-1H-benzimidazol-2-yl)amino]benzoic acid	0
4-[1-[(3-methoxy-4-methylphenyl)methyl]-2-benzimidazolyl]-1,2,5-oxadiazol-3-amine	0
4-[1-[(3-methoxyphenyl)methyl]-2-benzimidazolyl]-1,2,5-oxadiazol-3-amine	0
4-[2-(1-methyl-2-benzimidazolyl)ethyl]aniline	0
4-[2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]-1-oxoethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester	0
4-[2-[[1-(phenylmethyl)-2-benzimidazolyl]thio]ethyl]morpholine	0
4-[5-[(1-oxo-2-thiazolo[3,2-a]benzimidazolylidene)methyl]-2-furanyl]benzoic acid	0
4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-pyridinone	0
4-[[2-(phenylmethyl)-1-benzimidazolyl]sulfonyl]morpholine	0
4-ethyl-3-hydroxy-6-[5-methyl-4-(1-methyl-2-benzimidazolyl)-1,2-dihydropyrazol-3-ylidene]-1-cyclohexa-2,4-dienone	0
4-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-2-benzimidazolyl]benzamide	0
4-oxo-10H-pyrimido[1,2-a]benzimidazole-3-carboxylic acid ethyl ester	0
4H-[1,3]thiazino[3,2-a]benzimidazol-4-ol	0
5'-O-Desmethyl omeprazole	0
5'-hydroxyomeprazole	2
5,6-dimethyl-1-octyl-4-benzimidazolamine	0
5,6-dimethyl-2-[1-[[1-(phenylmethyl)-5-tetrazolyl]methyl]-4-piperidinyl]-1H-benzimidazole	0
5,6-dimethyl-2-[2-(1-pyrrolidinyl)ethylthio]-1H-benzimidazole	0
5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde	0
5-(1H-benzimidazol-2-ylmethylidene)-3-(4-fluorophenyl)-2-sulfanylidene-4-thiazolidinone	0
5-(2,3-dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(4-methylsulfonylphenyl)methoxy]-2-thiophenecarboxamide	0
5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one	0
5-Fluoro-2-[(3S)-1-(2-fluorobenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
5-Fluoro-2-[(3S)-1-(2-methylbenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
5-Hydroxyemedastine	0
5-Hydroxymebendazole	0
5-Hydroxythiabendazole	0
5-[(2-aminobenzimidazol-6-yl)amino]-5-oxopentanoic acid	0
5-[[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[3-bromo-4-[(2-fluorophenyl)methoxy]-5-methoxyphenyl]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[3-methyl-1-(4-methylphenyl)-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[4-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-ethoxyphenoxy]methyl]-2-furancarboxylic acid	0
5-[[4-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-methoxyphenoxy]methyl]-2-furancarboxylic acid	0
5-amino-4-(1H-benzimidazol-2-yl)-1-pentyl-2H-pyrrol-3-one	0
5-amino-4-(1H-benzimidazol-2-yl)-1-propan-2-yl-2H-pyrrol-3-one	0
5-chloro-6-(trifluoromethyl)-1,3-dihydro-2H-benzimidazole-2-thione	0
5-ethoxy-2-[(2,3,4,5,6-pentafluorobenzyl)thio]-1H-benzo[d]imidazole	0
5-hydroxybenzimidazole	0
5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole +	400
6-(1H-benzimidazol-2-yl)-2-methyl-1H-benzimidazole	0
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole	0
6-Hydroxyemedastine	0
6-[3-[(2-hydroxyphenyl)methyl]-1H-benzimidazol-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-fluoro-2-[(6-fluoro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole	0
6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole	0
6-methyl-2-(trifluoromethyl)-3,5-dihydroimidazo[4,5-f]benzimidazole	0
6-methyl-2-[(4-nitrophenyl)methylthio]-1H-benzimidazole	0
6-nitro-3-phenyl-1H-benzimidazole-2-thione	0
6-nitro-8-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine	0
7-[[[1-(3-methylphenyl)-2-benzimidazolyl]thio]methyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-amino-N-cyclohexyl-1-methyl-2-thiazolo[3,2-a]benzimidazolecarboxamide	0
7-amino-N-cyclohexyl-N,1-dimethyl-2-thiazolo[3,2-a]benzimidazolecarboxamide	0
AZ3451	0
Allyl 2-(1H-benzimidazoL-2-yl)-2-cyano-n-phenylethanimidothioate	0
CGP 12177	10
CHIR-265	0
CHZ868	0
Clemizole hydrochloride	0
FIPI	0
GSK461364	0
GW843682X	0
L-779976	0
LSM-19079	0
LSM-1988	0
LSM-23645	0
LSM-25679	0
LSM-28507	0
LSM-33057	0
ML240	0
Mizolastine	2
N,N,1-triethyl-2-sulfanylidene-3H-benzimidazole-5-sulfonamide	0
N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide	0
N-(1,1-dioxo-3-thiolanyl)-N-methyl-2-[[1-(2-phenylethyl)-2-benzimidazolyl]thio]acetamide	0
N-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-2-benzofurancarboxamide	0
N-(1-benzimidazolyl)-1-(6-chloro-5-imidazo[2,1-b]thiazolyl)methanimine	0
N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide	0
N-(1-methyl-2-benzimidazolyl)-1-thiophen-2-ylmethanimine	0
N-(1-propyl-5-benzimidazolyl)-2-thiophenecarboxamide	0
N-(1-tert-butyl-5-benzimidazolyl)-2-thiophenecarboxamide	0
N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide	0
N-(1H-1,3-benzodiazol-2-yl)carbamate	0
N-(1H-benzimidazol-2-yl)-2-methylsulfonylbenzamide	0
N-(1H-benzimidazol-2-yl)-2-nitrobenzamide	0
N-(1H-benzimidazol-2-yl)-3-(1-imidazolyl)propanamide	0
N-(1H-benzimidazol-2-yl)-3-[(3-\{3-[(1H-benzimidazol-2-ylamino)carbonyl]benzyl\}-4,7-dibenzyl-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl)methyl]benzamide	0
N-(1H-benzimidazol-2-yl)-3-phenylbutanamide	0
N-(1H-benzimidazol-2-yl)-4-(3-methylphenoxy)butanamide	0
N-(1H-benzimidazol-2-yl)carbamic acid ethyl ester	0
N-(2-benzimidazolylidenemethyl)-1,2,4-triazol-4-amine	0
N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide	0
N-(2-ethoxyphenyl)-1H-benzimidazol-2-amine	0
N-(2-fluorophenyl)-2-[2-(4-thiazolyl)-1-benzimidazolyl]acetamide	0
N-(2-furanylmethyl)-1-(4-methoxyphenyl)-5-benzimidazolamine	0
N-(2-methyl-1-benzimidazolyl)-1-(5-nitro-2-thiophenyl)methanimine	0
N-(3,4-dihydro-1H-[1,4]thiazino[4,3-a]benzimidazol-8-yl)butanamide	0
N-(3,4-dihydro-1H-[1,4]thiazino[4,3-a]benzimidazol-8-yl)pentanamide	0
N-(3,5-dichloro-2-pyridinyl)-2-[(1-phenyl-2-benzimidazolyl)thio]acetamide	0
N-(3,5-dichloro-2-pyridinyl)-2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]propanamide	0
N-(3H-benzimidazol-5-yl)-2-furancarboxamide	0
N-(4-methylphenyl)-5-nitro-4-spiro[benzimidazole-2,1'-cyclohexane]amine	0
N-(5,6-dimethyl-1-benzimidazolyl)-1-(5-nitro-2-furanyl)methanimine	0
N-(5-chloro-2-pyridinyl)-2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]acetamide	0
N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester	0
N-(cyclohexylmethylideneamino)-1H-benzimidazol-2-amine	0
N-[(1S)-1-(1H-benzimidazol-2-yl)-2-\{4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}ethyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide	0
N-[(1S)-1-(1H-benzimidazol-2-yl)-3-(methylthio)propyl]-2-(4-chlorophenoxy)-2-methylpropanamide	0
N-[(3-methoxyphenyl)methyl]-1-propyl-5-benzimidazolamine	0
N-[1-(1-hexyl-2-benzimidazolyl)ethyl]-2-furancarboxamide	0
N-[1-(1H-benzimidazol-2-yl)-3-(methylthio)propyl]-3,5-dinitrobenzamide	0
N-[1-(2-methoxyphenyl)-5-benzimidazolyl]benzenesulfonamide	0
N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide	0
N-[1-[(4-methylphenyl)methyl]-2-benzimidazolyl]-2-furancarboxamide	0
N-[1-[1-[(3-chlorophenyl)methyl]-2-benzimidazolyl]ethyl]-3-(2-furanyl)-2-propenamide	0
N-[1-[1-[2-[4-(diethylamino)anilino]-2-oxoethyl]-2-benzimidazolyl]ethyl]-4-methylbenzamide	0
N-[1-[2-(1-piperidinyl)ethyl]-2-benzimidazolyl]-1-thiophen-2-ylmethanimine	0
N-[1-[2-(2-chlorophenoxy)ethyl]-2-benzimidazolyl]acetamide	0
N-[2-(1H-benzimidazol-2-yl)ethyl]-2-(2-bromophenoxy)acetamide	0
N-[2-(1H-benzimidazol-2-yl)ethyl]-3,5-dinitrobenzamide	0
N-[2-(1H-benzimidazol-2-yl)phenyl]-2-thiophen-2-ylacetamide	0
N-[2-(2-benzamidoethyl)-1-methyl-5-benzimidazolyl]-2-furancarboxamide	0
N-[2-(2-benzamidoethyl)-1-methyl-5-benzimidazolyl]-2-methoxybenzamide	0
N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide	0
N-[2-(3-acetamidophenyl)-3H-benzimidazol-5-yl]acetamide	0
N-[2-(3-pyridinyl)-3H-benzimidazol-5-yl]-2-furancarboxamide	0
N-[2-(4-fluorophenyl)ethyl]-2-[2-(2-hydroxyethylamino)-1-benzimidazolyl]acetamide	0
N-[2-(4-phenoxybenzyl)benzimidazol-5-yl]methanesulfonamide	0
N-[2-[1-(3-phenylprop-2-enyl)-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-[2-(2,5-difluorophenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cycloheptanecarboxamide	0
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-methyl-5-[[(4-methylphenyl)-oxomethyl]amino]-2-benzimidazolyl]ethyl]-2-furancarboxamide	0
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline	0
N-[3-(1H-benzimidazol-2-yl)-5-(1-piperazinylmethyl)phenyl]-2-quinoxalinecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-1-[(5-methyl-1H-pyrazol-3-yl)methyl]-3-piperidinecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,3,4,5,6-pentafluorobenzamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-2-methyl-4-nitro-3-pyrazolecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(2,5-dioxo-1-pyrrolidinyl)benzamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-4-ethoxy-3-nitrobenzamide	0
N-[4-(6-chloro-5-nitro-1H-benzimidazol-2-yl)phenyl]acetamide	0
N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-2-(2-nitrophenoxy)acetamide	0
N-[6-(propan-2-ylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester	0
N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-2-[(1-ethyl-2-benzimidazolyl)thio]-N-methylacetamide	0
N-[[1-(2-phenoxyethyl)-2-benzimidazolyl]methyl]aniline	0
N-[[4-(diethylamino)phenyl]methyl]-1-[2-(1-piperidinyl)ethyl]-2-benzimidazolamine	0
N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-5-benzimidazolamine	0
N-[[5-(1H-benzimidazol-2-yl)-2-chloroanilino]-sulfanylidenemethyl]-2,6-dimethoxybenzamide	0
N-[[5-(1H-benzimidazol-2-yl)-2-methylanilino]-sulfanylidenemethyl]-5-chloro-2-methoxybenzamide	0
N-\{(1S)-2-\{4-[(5R)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl\}-2,2,2-trifluoroacetamide	0
N-\{2-[(4-benzylpiperidin-1-yl)methyl]benzimidazol-5-yl\}methanesulfonamide	0
N-butyl-1H-benzimidazol-2-amine	0
N-cycloheptyl-2-[(6-nitro-1H-benzimidazol-2-yl)thio]acetamide	0
N-methyl-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]amine	0
N-phenyl-1-propan-2-yl-2-benzimidazolamine	0
N2-(1H-benzimidazol-2-yl)benzene-1,2-diamine	0
NNC 55-0396 (free base) +	0
NS 1619	4
Omeprazole sodium	0
Omeprazole sulfide	2
Omeprazole sulfone	0
Ro 18-5364	0
ZSTK-474	0
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone	0
[1-[3-(4-methylphenoxy)propyl]-2-benzimidazolyl]methanol	0
[4-(2-benzimidazolylidene)-3-imino-2-phenyl-1H-pyridazin-6-yl]-thiophen-2-ylmethanone	0
albendazole +	48
astemizole	86
azilsartan medoxomil	0
bendamustine	0
bendazol	0
benomyl	56
benzimidazole +	372
benzimidazole fungicide +	424
benzimidazolecarbaldehyde +	0
benzimidazolecarboxylic acid +	78
benzimidazolequinone +	0
benzimidazolylcarbamate fungicide +	164
bibenzimidazole +	6
bilastine	0
binimetinib	1
carbendazim	86
chlormidazole	6
ciclobendazole	1
clemizole	15
crenolanib	0
dabigatran +	28
dabigatran etexilate	0
desmethylastemizole	2
dexlansoprazole	0
dexrabeprazole	0
dimethylbenzimidazole +	0
domperidone +	19
droperidol	2
emedastine +	1
ensulizole	0
fabomotizole	0
fenbendazole +	60
flibanserin	0
flubendazole	15
fuberidazole	0
glasdegib	0
hydroxyalbendazole	0
hydroxyfenbendazole	0
ilaprazole	0
lansoprazole	63
liarozole	1
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide	0
mebendazole	51
methyl 4-oxo-4H-benzo[4,5]imidazo[2,1-b][1,3]thiazine-2-carboxylate	0
nocodazole	73
oxatomide	3
oxfendazole	18
pantoprazole	24
pantoprazole(1-) +	0
parbendazole	1
pimobendan	7
pimozide	6
procodazole	0
rabeprazole	17
selumetinib	26
tarocin B	0
tcmdc-123507	0
telmisartan	124
thiabendazole	310
veliparib	29
Path 2
Term	Annotations
CHEBI ontology	22307
subatomic particle	22302
composite particle	22302
hadron	22302
baryon	22302
nucleon	22302
atomic nucleus	22302
atom	22302
main group element atom	22182
p-block element atom	22182
p-block molecular entity	22182
carbon group molecular entity	21984
organic molecular entity	21924
organic molecule	21750
organic cyclic compound	21366
organic heterocyclic compound	20382
organic heteropolycyclic compound	19675
organic heterobicyclic compound	18253
benzimidazoles	1182
(2R,4S)-N-\{(1R,2R)-4-[(1H-benzimidazol-2-ylmethyl)amino]-1-benzyl-2-hydroxy-4-oxobutyl\}-2-\{(1R)-2-(benzylamino)-2-oxo-1-[(phenylacetyl)amino]ethyl\}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide	0
(2S,4R)-N-(1H-benzimidazol-2-ylmethyl)-4-cyclohexyl-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-carboxamide	0
(5S)-5-\{4-[(2S)-2-(1H-benzimidazol-2-yl)-2-(1,3-benzothiazol-2-ylamino)ethyl]phenyl\}isothiazolidin-3-one 1,1-dioxide	0
(6-chloro-1H-benzimidazol-2-yl)-(4-methyl-1-piperazinyl)methanone	0
1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol	0
1-(1H-benzimidazol-2-yl)-3-cyclohexylurea	0
1-(2,4-dichlorobenzoyl)-1H-benzimidazole	0
1-(2,4-difluorophenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-5-benzimidazolecarboxamide	0
1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol	0
1-(2-chlorophenyl)-3-[[(1-ethyl-2-methyl-5-benzimidazolyl)-oxomethyl]amino]thiourea	0
1-(2-deoxyribosyl)benzimidazole +	0
1-(2-furanyl)-2-(3-heptyl-2-imino-1-benzimidazolyl)ethanol	0
1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]benzimidazole	0
1-(2-methoxyethyl)-2-[(4-methylphenoxy)methyl]benzimidazole	0
1-(2-methylpropyl)-2-thiophen-2-ylbenzimidazole	0
1-(4-ethylphenyl)-2-methyl-N-(3-pyridinylmethyl)-5-benzimidazolecarboxamide	0
1-(4-morpholinyl)-2-[2-(phenylmethylthio)-1-benzimidazolyl]ethanone	0
1-(5-\{[3-(1H-benzimidazol-2-yl)propanoyl]amino\}-5-deoxy-alpha-L-lyxofuranosyl)cytosine	0
1-(5-bromo-2-thiophenyl)-2-[(5-ethoxy-1-methyl-2-benzimidazolyl)thio]ethanone	0
1-(5-bromo-2-thiophenyl)-2-[(5-methoxy-1-methyl-2-benzimidazolyl)thio]ethanone	0
1-(Piperidinomethyl)-1H-benzo[d]imidazole	0
1-(phenylmethyl)benzimidazole	0
1-[(3,4-difluorophenyl)methyl]-2-oxo-N-[(1R)-2-[(2-oxo-1,3-dihydrobenzimidazol-5-yl)oxy]-1-phenylethyl]-3-pyridinecarboxamide	0
1-[(3-methylphenyl)methyl]benzimidazole	0
1-[1-(cyclooctylmethyl)-5-(hydroxymethyl)-3,6-dihydro-2H-pyridin-4-yl]-3-ethyl-2-benzimidazolone	0
1-[2-(2-chlorophenoxy)ethyl]benzimidazole	0
1-[2-imino-3-[2-(1-piperidinyl)ethyl]-1-benzimidazolyl]-3-(3-methylphenoxy)-2-propanol	0
1-[3-[2-(diethylamino)ethyl]-2-imino-1-benzimidazolyl]-3-(3-methylphenoxy)-2-propanol	0
1-[4-(1H-benzimidazol-2-yl)phenyl]-3-[3-(4-morpholinyl)propyl]thiourea	0
1-[[2-(1H-benzimidazol-2-ylthio)-1-oxoethyl]amino]-3-ethylthiourea	0
1-azepanyl-[2-(phenylmethyl)-1-benzimidazolyl]methanone	0
1-butyl-2-(2-methylphenyl)-7-propan-2-yl-5H-imidazo[4,5-g]quinoxalin-6-one	0
1-cyclohexyl-N-(3-methylbutyl)-5-benzimidazolecarboxamide	0
1-cyclopentyl-1-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-3-(2-oxolanylmethyl)thiourea	0
1-cyclopropyl-3-[3-[5-(4-morpholinylmethyl)-2-benzimidazolylidene]-1,2-dihydropyrazol-4-yl]urea	0
1-erythrosylbenzimidazole +	0
1-ethyl-2-[(4-methylphenoxy)methyl]benzimidazole	0
1-ethyl-2-[[(1-methyl-2-benzimidazolyl)thio]methyl]benzimidazole	0
1-ethyl-2-methyl-N-[(phenylmethylene)amino]-5-benzimidazolecarboxamide	0
1-ethyl-3-[[2-[(1-methyl-2-benzimidazolyl)thio]-1-oxoethyl]amino]thiourea	0
1-ethyl-N-[(4-methoxyphenyl)methyl]-5-benzimidazolamine	0
1-ethyl-N-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine	0
1-methyl-3-phenylpyrazino[1,2-a]benzimidazole	0
1-ribosylbenzimidazole +	37
11-[2-(4-morpholinyl)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile	0
11-[2-(diethylamino)ethylamino]-7,8,9,10-tetrahydrobenzimidazolo[1,2-b]isoquinoline-6-carbonitrile	0
1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]-	0
1H-benzimidazol-5-ylmethanol	0
1H-benzimidazole-5,6-diamine	0
1H-benzo[d]imidazole-2-thiol	1
2''-(4-methoxyphenyl)-5-(3-aminopyrrolidin-1-yl)-2,5',2',5''-ter(benzimidazole)	0
2,2'-[3-(2-methoxyphenyl)-1,2-propanediyl]bis(1H-benzimidazole)	0
2-(1-benzimidazolylmethyl)-5-[(4-chlorophenyl)methylthio]-1,3,4-oxadiazole	0
2-(1H-Benzimidazol-2-yl)-N-(4-phenylmethoxyphenyl)benzamide	0
2-(1H-benzimidazol-2-yl)-1-(4-chlorophenyl)ethanamine	0
2-(1H-benzimidazol-2-yl)-3-(2-furanyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-(3-nitrophenyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(1H-benzimidazol-2-yl)-3-oxo-4-[(5-oxo-4-propyl-1H-1,2,4-triazol-3-yl)thio]butanenitrile	0
2-(1H-benzimidazol-2-yl)-5-methyl-4-(phenylmethyl)-4H-pyrazol-3-one	0
2-(1H-benzimidazol-2-yl)aniline	0
2-(1H-benzimidazol-2-ylmethoxymethyl)-1H-benzimidazole	0
2-(1H-benzimidazol-2-ylmethoxymethyl)-6-nitro-1H-benzimidazole	0
2-(1H-benzimidazol-2-ylmethyl)benzene-1,4-diol	0
2-(1H-benzimidazol-2-ylthio)-1-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)ethanone	0
2-(1H-benzimidazol-2-ylthio)-1-[2,5-dimethyl-1-(2-oxolanylmethyl)-3-pyrrolyl]ethanone	0
2-(1H-benzimidazol-2-ylthio)-1-thiophen-2-ylethanone	0
2-(1H-benzimidazol-2-ylthio)-N-(5-propyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-(1H-benzimidazol-2-ylthio)acetic acid methyl ester	0
2-(2,3,3-trichloro-1-nitroprop-2-enylidene)-1,3-dihydrobenzimidazole	0
2-(2,5-dimethylphenyl)-3H-benzimidazol-5-amine	0
2-(2-chloro-3-pyridinyl)-1-prop-2-enylbenzimidazole	0
2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide	0
2-(2-phenoxyethylsulfonyl)-1H-benzimidazole	0
2-(3-methyl-2-oxo-1-benzimidazolyl)acetonitrile	0
2-(4-\{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl\}-1,3-thiazol-2-yl)guanidine	0
2-(4-cyanophenoxy)-N-(2-methyl-1-phenyl-5-benzimidazolyl)acetamide	0
2-(4-methoxyphenyl)-1-(2-methylprop-2-enyl)benzimidazole	0
2-(4-methyl-1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(5-methyl-1,3-dihydrobenzimidazol-2-ylidene)-2-nitrosoacetonitrile	0
2-(6-chloro-3-pyridinyl)-1H-benzimidazole	0
2-(6-methyl-1H-benzimidazol-2-yl)-3-(5-methyl-2-furanyl)-2-propenenitrile	0
2-(6-methyl-1H-benzimidazol-2-yl)-3-(5-nitro-2-furanyl)-2-propenenitrile	0
2-(Methoxymethyl)-1-methyl-1H-benzimidazole	0
2-(beta-D-glucosyl)benzimidazole	0
2-(trifluoromethyl)-1H-benzo[d]imidazole	0
2-Amino-1-methylbenzimidazole	0
2-Butyl-1H-benzimidazole	0
2-Isopropyl-1H-benzo[d]imidazole	0
2-Methyl-1H-benzo[d]imidazole	0
2-[(1,5-dimethyl-2-benzimidazolyl)amino]ethanol	0
2-[(1-acetyl-2-benzimidazolyl)thio]-N-(2-methoxyphenyl)acetamide	0
2-[(2,2-dichloro-3,3-dimethylcyclopropyl)methylthio]-1H-benzimidazole	0
2-[(2,5-dimethylphenyl)thio]acetic acid [3-(1H-benzimidazol-2-yl)-3-cyano-2-oxopropyl] ester	0
2-[(2-ethoxy-2-oxoethyl)thio]-1-benzimidazolecarboxylic acid ethyl ester	0
2-[(2-methoxyphenoxy)methyl]-1H-benzimidazole	0
2-[(3S)-1-(1-Methyl-4-piperidinyl)-3-pyrrolidinyl]-1H-benzimidazole	0
2-[(3S)-1-(3,4-Difluorobenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
2-[(3S)-1-(4-Chlorobenzyl)-3-pyrrolidinyl]-1-methyl-1H-benzimidazole	0
2-[(3S)-1-(Cyclohexylmethyl)-3-pyrrolidinyl]-5-methyl-1H-benzimidazole	0
2-[(3s)-1-(cyclohexylmethyl)-3-pyrrolidinyl]-5-fluoro-1h-benzimidazole	0
2-[(4-cyano-1-oxo-5H-pyrido[1,2-a]benzimidazol-3-yl)methylthio]propanoic acid	0
2-[(6-chloro-1H-benzimidazol-2-yl)thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide	0
2-[(6-chloro-2-phenyl-1-benzimidazolyl)oxy]acetic acid	0
2-[(6-methyl-1H-benzimidazol-2-yl)thio]-1-(2-methyl-1H-indol-3-yl)ethanone	0
2-[2-(2-chlorophenyl)-1-benzimidazolyl]-N-(2,6-diethylphenyl)acetamide	0
2-[2-(2-chlorophenyl)-1-benzimidazolyl]-N-(2-propan-2-ylphenyl)acetamide	0
2-[2-(4-aminophenyl)-3H-benzimidazol-5-yl]-3H-benzimidazol-5-amine	0
2-[2-(ethylthio)-1-benzimidazolyl]-1-(1-piperidinyl)ethanone	0
2-[2-[2-[(1,3-dimethyl-2-oxo-5-benzimidazolyl)methylidene]hydrazinyl]-4-oxo-5-thiazolyl]acetic acid	0
2-[5-(4-carbamimidoylphenyl)furan-2-yl]-1H-benzimidazole-5-carboximidamide	0
2-[5-[(5,7-dimethyl-1-oxo-2-thiazolo[3,2-a]benzimidazolylidene)methyl]-2-furanyl]benzoic acid	0
2-[5-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-furanyl]benzoic acid	0
2-[8-(6-amino-1H-benzimidazol-2-yl)octyl]-3H-benzimidazol-5-amine	0
2-[[(1-butyl-2-benzimidazolyl)amino]methyl]phenol	0
2-[[(1-propan-2-yl-2-benzimidazolyl)amino]methyl]-6-prop-2-enylphenol	0
2-[[(6-bromo-1H-benzimidazol-2-yl)thio]methyl]-1-methylbenzimidazole	0
2-[[2-(2-methylphenoxy)ethylthio]methyl]-1H-benzimidazole	0
2-[[3-(1H-benzimidazol-2-yl)-2-pyridinyl]thio]acetic acid methyl ester	0
2-[[5-(1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(4-methyl-2-thiazolyl)acetamide	0
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide	0
2-[[5-[2-(1H-benzimidazol-2-yl)ethyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide	0
2-[[5-[2-(1H-benzimidazol-2-yl)ethyl]-4-methyl-1,2,4-triazol-3-yl]thio]acetonitrile	0
2-[[6-(butylsulfamoyl)-1H-benzimidazol-2-yl]thio]-N-(2-chlorophenyl)acetamide	0
2-[[6-(dimethylsulfamoyl)-1H-benzimidazol-2-yl]methoxymethyl]-N,N-dimethyl-3H-benzimidazole-5-sulfonamide	0
2-[[[2-methyl-1-(phenylmethyl)-5-benzimidazolyl]amino]methyl]phenol	0
2-[[[5-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]methyl]benzonitrile	0
2-[fluoro(trifluoromethoxy)methyl]-6-methyl-1H-benzimidazole	0
2-aminobenzimidazole +	86
2-benzamido-1-(3-phenylpropyl)-5-benzimidazolecarboxylic acid methyl ester	0
2-ethyl-1-[(2-methoxyphenyl)methyl]benzimidazole	0
2-ethyl-N-[1-[2-(1-piperidinyl)ethyl]-2-benzimidazolyl]-3-pyrazolecarboxamide	0
2-methoxy-1-(1-methyl-2-benzimidazolyl)-1-phenylethanamine	0
2-methoxy-N-[(1-methyl-2-benzimidazolyl)methyl]aniline	0
2-methyl-1-phenyl-5-benzimidazolecarboxylic acid [2-(2-methoxyanilino)-2-oxoethyl] ester	0
2-methyl-1-phenyl-5-benzimidazolecarboxylic acid [2-(3-methylbutan-2-ylamino)-2-oxoethyl] ester	0
2-methyl-1H-benzimidazole-5-carboxylic acid	0
2-methyl-1H-pyrimido[1,2-a]benzimidazol-4-one	0
2-methyl-N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]propanamide	0
2-methylpropanoic acid [3-(1H-benzimidazol-2-yl)-3-cyano-2-oxopropyl] ester	0
2-phenyl-2,3-dihydro-[1,3]thiazino[3,2-a]benzimidazol-4-one	0
3,4,5-trimethoxy-N-[2-(1-methyl-2-benzimidazolyl)ethyl]benzamide	0
3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol	0
3,4-dimethyl-N-[[(2-oxo-1,3-dihydrobenzimidazol-5-yl)amino]-sulfanylidenemethyl]benzamide	0
3-(1-benzimidazolylmethyl)-6-[(4-methoxyphenoxy)methyl]-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	0
3-(1H-benzimidazol-2-yl)-N-(3-pyridinylmethyl)aniline	0
3-(1H-benzimidazol-2-ylthio)-5,5-dimethyl-3-(1-oxopropyl)-2-oxolanone	0
3-(2-phenoxyethyl)-1H-benzimidazole-2-thione	0
3-(6-amino-1H-benzimidazol-2-yl)-1-propanol	0
3-(6-amino-1H-benzimidazol-2-yl)propanoic acid	0
3-Hydroxyomeprazole	0
3-[(7-carbamimidoylnaphthalen-2-yl)methyl]-5-(\{1-[(1Z)-ethanimidoyl]piperidin-4-yl\}oxy)-2-methyl-1H-3,1-benzimidazol-3-ium	0
3-[1-(2-carboxyethyl)-1H-benzo[d]imidazol-2-yl]propanoic acid	0
3-[1-[(4-methyl-6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl)methyl]-4-piperidinyl]-1H-benzimidazol-2-one	0
3-[1-butyl-5-(diethylsulfamoyl)-2-benzimidazolyl]propanoic acid	0
3-[2-(4-methyl-2-propan-2-ylphenoxy)ethyl]-1H-benzimidazole-2-thione	0
3-[3-[[2-oxo-2-(1,2,5-trimethyl-3-pyrrolyl)ethyl]thio]propyl]-1H-benzimidazol-2-one	0
3-[5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl]propan-1-ol	0
3-[5-(diethylsulfamoyl)-1-methyl-2-benzimidazolyl]propanoic acid [2-(3,5-dichloroanilino)-2-oxoethyl] ester	0
3-[5-(dimethylsulfamoyl)-1-ethyl-2-benzimidazolyl]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide	0
3-[5-(dimethylsulfamoyl)-1-ethyl-2-benzimidazolyl]propanoic acid	0
3-\{[2-(1H-benzimidazol-1-yl)-6-\{[2-(diethylamino)ethyl]amino\}pyrimidin-4-yl]amino\}-4-methylphenol	0
4-(1-ethyl-2-benzimidazolyl)aniline	0
4-(1H-benzimidazol-2-ylmethylthio)-2-methylbenzofuro[3,2-d]pyrimidine	0
4-(4-chloro-3-nitrophenyl)-N-[2-(5,6-dichloro-1-propyl-2-benzimidazolyl)ethyl]-2-thiazolamine	0
4-(5,6-Dichloro-1H-benzimidazol-1-yl)butan-1-ol	0
4-[(1H-benzimidazol-2-ylhydrazinylidene)methyl]benzoic acid	0
4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine	0
4-[(6-chloro-1H-benzimidazol-2-yl)amino]benzoic acid	0
4-[1-[(3-methoxy-4-methylphenyl)methyl]-2-benzimidazolyl]-1,2,5-oxadiazol-3-amine	0
4-[1-[(3-methoxyphenyl)methyl]-2-benzimidazolyl]-1,2,5-oxadiazol-3-amine	0
4-[2-(1-methyl-2-benzimidazolyl)ethyl]aniline	0
4-[2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]-1-oxoethyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester	0
4-[2-[[1-(phenylmethyl)-2-benzimidazolyl]thio]ethyl]morpholine	0
4-[5-[(1-oxo-2-thiazolo[3,2-a]benzimidazolylidene)methyl]-2-furanyl]benzoic acid	0
4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-pyridinone	0
4-[[2-(phenylmethyl)-1-benzimidazolyl]sulfonyl]morpholine	0
4-ethyl-3-hydroxy-6-[5-methyl-4-(1-methyl-2-benzimidazolyl)-1,2-dihydropyrazol-3-ylidene]-1-cyclohexa-2,4-dienone	0
4-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-2-benzimidazolyl]benzamide	0
4-oxo-10H-pyrimido[1,2-a]benzimidazole-3-carboxylic acid ethyl ester	0
4H-[1,3]thiazino[3,2-a]benzimidazol-4-ol	0
5'-O-Desmethyl omeprazole	0
5'-hydroxyomeprazole	2
5,6-dimethyl-1-octyl-4-benzimidazolamine	0
5,6-dimethyl-2-[1-[[1-(phenylmethyl)-5-tetrazolyl]methyl]-4-piperidinyl]-1H-benzimidazole	0
5,6-dimethyl-2-[2-(1-pyrrolidinyl)ethylthio]-1H-benzimidazole	0
5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde	0
5-(1H-benzimidazol-2-ylmethylidene)-3-(4-fluorophenyl)-2-sulfanylidene-4-thiazolidinone	0
5-(2,3-dihydroindol-1-ylsulfonyl)-1,3-diethyl-2-benzimidazolone	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile	0
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(4-methylsulfonylphenyl)methoxy]-2-thiophenecarboxamide	0
5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one	0
5-Fluoro-2-[(3S)-1-(2-fluorobenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
5-Fluoro-2-[(3S)-1-(2-methylbenzyl)-3-pyrrolidinyl]-1H-benzimidazole	0
5-Hydroxyemedastine	0
5-Hydroxymebendazole	0
5-Hydroxythiabendazole	0
5-[(2-aminobenzimidazol-6-yl)amino]-5-oxopentanoic acid	0
5-[[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[3-bromo-4-[(2-fluorophenyl)methoxy]-5-methoxyphenyl]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[3-methyl-1-(4-methylphenyl)-5-oxo-4-pyrazolylidene]methylamino]-1,3-dihydrobenzimidazol-2-one	0
5-[[4-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-ethoxyphenoxy]methyl]-2-furancarboxylic acid	0
5-[[4-[2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2-methoxyphenoxy]methyl]-2-furancarboxylic acid	0
5-amino-4-(1H-benzimidazol-2-yl)-1-pentyl-2H-pyrrol-3-one	0
5-amino-4-(1H-benzimidazol-2-yl)-1-propan-2-yl-2H-pyrrol-3-one	0
5-chloro-6-(trifluoromethyl)-1,3-dihydro-2H-benzimidazole-2-thione	0
5-ethoxy-2-[(2,3,4,5,6-pentafluorobenzyl)thio]-1H-benzo[d]imidazole	0
5-hydroxybenzimidazole	0
5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole +	400
6-(1H-benzimidazol-2-yl)-2-methyl-1H-benzimidazole	0
6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole	0
6-Hydroxyemedastine	0
6-[3-[(2-hydroxyphenyl)methyl]-1H-benzimidazol-2-ylidene]-1-cyclohexa-2,4-dienone	0
6-fluoro-2-[(6-fluoro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole	0
6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole	0
6-methyl-2-(trifluoromethyl)-3,5-dihydroimidazo[4,5-f]benzimidazole	0
6-methyl-2-[(4-nitrophenyl)methylthio]-1H-benzimidazole	0
6-nitro-3-phenyl-1H-benzimidazole-2-thione	0
6-nitro-8-(trifluoromethyl)benzo[4,5]imidazo[1,2-a]pyridine	0
7-[[[1-(3-methylphenyl)-2-benzimidazolyl]thio]methyl]-5-thiazolo[3,2-a]pyrimidinone	0
7-amino-N-cyclohexyl-1-methyl-2-thiazolo[3,2-a]benzimidazolecarboxamide	0
7-amino-N-cyclohexyl-N,1-dimethyl-2-thiazolo[3,2-a]benzimidazolecarboxamide	0
AZ3451	0
Allyl 2-(1H-benzimidazoL-2-yl)-2-cyano-n-phenylethanimidothioate	0
CGP 12177	10
CHIR-265	0
CHZ868	0
Clemizole hydrochloride	0
FIPI	0
GSK461364	0
GW843682X	0
L-779976	0
LSM-19079	0
LSM-1988	0
LSM-23645	0
LSM-25679	0
LSM-28507	0
LSM-33057	0
ML240	0
Mizolastine	2
N,N,1-triethyl-2-sulfanylidene-3H-benzimidazole-5-sulfonamide	0
N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide	0
N-(1,1-dioxo-3-thiolanyl)-N-methyl-2-[[1-(2-phenylethyl)-2-benzimidazolyl]thio]acetamide	0
N-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-2-benzofurancarboxamide	0
N-(1-benzimidazolyl)-1-(6-chloro-5-imidazo[2,1-b]thiazolyl)methanimine	0
N-(1-butyl-2-benzimidazolyl)cyclohexanecarboxamide	0
N-(1-methyl-2-benzimidazolyl)-1-thiophen-2-ylmethanimine	0
N-(1-propyl-5-benzimidazolyl)-2-thiophenecarboxamide	0
N-(1-tert-butyl-5-benzimidazolyl)-2-thiophenecarboxamide	0
N-(1-tert-butyl-5-benzimidazolyl)-3,4,5-trimethoxybenzamide	0
N-(1H-1,3-benzodiazol-2-yl)carbamate	0
N-(1H-benzimidazol-2-yl)-2-methylsulfonylbenzamide	0
N-(1H-benzimidazol-2-yl)-2-nitrobenzamide	0
N-(1H-benzimidazol-2-yl)-3-(1-imidazolyl)propanamide	0
N-(1H-benzimidazol-2-yl)-3-[(3-\{3-[(1H-benzimidazol-2-ylamino)carbonyl]benzyl\}-4,7-dibenzyl-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl)methyl]benzamide	0
N-(1H-benzimidazol-2-yl)-3-phenylbutanamide	0
N-(1H-benzimidazol-2-yl)-4-(3-methylphenoxy)butanamide	0
N-(1H-benzimidazol-2-yl)carbamic acid ethyl ester	0
N-(2-benzimidazolylidenemethyl)-1,2,4-triazol-4-amine	0
N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide	0
N-(2-ethoxyphenyl)-1H-benzimidazol-2-amine	0
N-(2-fluorophenyl)-2-[2-(4-thiazolyl)-1-benzimidazolyl]acetamide	0
N-(2-furanylmethyl)-1-(4-methoxyphenyl)-5-benzimidazolamine	0
N-(2-methyl-1-benzimidazolyl)-1-(5-nitro-2-thiophenyl)methanimine	0
N-(3,4-dihydro-1H-[1,4]thiazino[4,3-a]benzimidazol-8-yl)butanamide	0
N-(3,4-dihydro-1H-[1,4]thiazino[4,3-a]benzimidazol-8-yl)pentanamide	0
N-(3,5-dichloro-2-pyridinyl)-2-[(1-phenyl-2-benzimidazolyl)thio]acetamide	0
N-(3,5-dichloro-2-pyridinyl)-2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]propanamide	0
N-(3H-benzimidazol-5-yl)-2-furancarboxamide	0
N-(4-methylphenyl)-5-nitro-4-spiro[benzimidazole-2,1'-cyclohexane]amine	0
N-(5,6-dimethyl-1-benzimidazolyl)-1-(5-nitro-2-furanyl)methanimine	0
N-(5-chloro-2-pyridinyl)-2-[[1-(2-methoxyethyl)-2-benzimidazolyl]thio]acetamide	0
N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester	0
N-(cyclohexylmethylideneamino)-1H-benzimidazol-2-amine	0
N-[(1S)-1-(1H-benzimidazol-2-yl)-2-\{4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}ethyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide	0
N-[(1S)-1-(1H-benzimidazol-2-yl)-3-(methylthio)propyl]-2-(4-chlorophenoxy)-2-methylpropanamide	0
N-[(3-methoxyphenyl)methyl]-1-propyl-5-benzimidazolamine	0
N-[1-(1-hexyl-2-benzimidazolyl)ethyl]-2-furancarboxamide	0
N-[1-(1H-benzimidazol-2-yl)-3-(methylthio)propyl]-3,5-dinitrobenzamide	0
N-[1-(2-methoxyphenyl)-5-benzimidazolyl]benzenesulfonamide	0
N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide	0
N-[1-[(4-methylphenyl)methyl]-2-benzimidazolyl]-2-furancarboxamide	0
N-[1-[1-[(3-chlorophenyl)methyl]-2-benzimidazolyl]ethyl]-3-(2-furanyl)-2-propenamide	0
N-[1-[1-[2-[4-(diethylamino)anilino]-2-oxoethyl]-2-benzimidazolyl]ethyl]-4-methylbenzamide	0
N-[1-[2-(1-piperidinyl)ethyl]-2-benzimidazolyl]-1-thiophen-2-ylmethanimine	0
N-[1-[2-(2-chlorophenoxy)ethyl]-2-benzimidazolyl]acetamide	0
N-[2-(1H-benzimidazol-2-yl)ethyl]-2-(2-bromophenoxy)acetamide	0
N-[2-(1H-benzimidazol-2-yl)ethyl]-3,5-dinitrobenzamide	0
N-[2-(1H-benzimidazol-2-yl)phenyl]-2-thiophen-2-ylacetamide	0
N-[2-(2-benzamidoethyl)-1-methyl-5-benzimidazolyl]-2-furancarboxamide	0
N-[2-(2-benzamidoethyl)-1-methyl-5-benzimidazolyl]-2-methoxybenzamide	0
N-[2-(2-pyridinyl)-3H-benzimidazol-5-yl]cyclohexanecarboxamide	0
N-[2-(3-acetamidophenyl)-3H-benzimidazol-5-yl]acetamide	0
N-[2-(3-pyridinyl)-3H-benzimidazol-5-yl]-2-furancarboxamide	0
N-[2-(4-fluorophenyl)ethyl]-2-[2-(2-hydroxyethylamino)-1-benzimidazolyl]acetamide	0
N-[2-(4-phenoxybenzyl)benzimidazol-5-yl]methanesulfonamide	0
N-[2-[1-(3-phenylprop-2-enyl)-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-[2-(2,5-difluorophenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cycloheptanecarboxamide	0
N-[2-[1-[2-(4-methylphenoxy)ethyl]-2-benzimidazolyl]ethyl]cyclohexanecarboxamide	0
N-[2-[1-methyl-5-[[(4-methylphenyl)-oxomethyl]amino]-2-benzimidazolyl]ethyl]-2-furancarboxamide	0
N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline	0
N-[3-(1H-benzimidazol-2-yl)-5-(1-piperazinylmethyl)phenyl]-2-quinoxalinecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-1-[(5-methyl-1H-pyrazol-3-yl)methyl]-3-piperidinecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,3,4,5,6-pentafluorobenzamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-2-methyl-4-nitro-3-pyrazolecarboxamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-3-(2,5-dioxo-1-pyrrolidinyl)benzamide	0
N-[4-(1H-benzimidazol-2-yl)phenyl]-4-ethoxy-3-nitrobenzamide	0
N-[4-(6-chloro-5-nitro-1H-benzimidazol-2-yl)phenyl]acetamide	0
N-[5-(1H-benzimidazol-2-yl)-2-methylphenyl]-2-(2-nitrophenoxy)acetamide	0
N-[6-(propan-2-ylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester	0
N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-2-[(1-ethyl-2-benzimidazolyl)thio]-N-methylacetamide	0
N-[[1-(2-phenoxyethyl)-2-benzimidazolyl]methyl]aniline	0
N-[[4-(diethylamino)phenyl]methyl]-1-[2-(1-piperidinyl)ethyl]-2-benzimidazolamine	0
N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-5-benzimidazolamine	0
N-[[5-(1H-benzimidazol-2-yl)-2-chloroanilino]-sulfanylidenemethyl]-2,6-dimethoxybenzamide	0
N-[[5-(1H-benzimidazol-2-yl)-2-methylanilino]-sulfanylidenemethyl]-5-chloro-2-methoxybenzamide	0
N-\{(1S)-2-\{4-[(5R)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl\}-2,2,2-trifluoroacetamide	0
N-\{2-[(4-benzylpiperidin-1-yl)methyl]benzimidazol-5-yl\}methanesulfonamide	0
N-butyl-1H-benzimidazol-2-amine	0
N-cycloheptyl-2-[(6-nitro-1H-benzimidazol-2-yl)thio]acetamide	0
N-methyl-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]amine	0
N-phenyl-1-propan-2-yl-2-benzimidazolamine	0
N2-(1H-benzimidazol-2-yl)benzene-1,2-diamine	0
NNC 55-0396 (free base) +	0
NS 1619	4
Omeprazole sodium	0
Omeprazole sulfide	2
Omeprazole sulfone	0
Ro 18-5364	0
ZSTK-474	0
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone	0
[1-[3-(4-methylphenoxy)propyl]-2-benzimidazolyl]methanol	0
[4-(2-benzimidazolylidene)-3-imino-2-phenyl-1H-pyridazin-6-yl]-thiophen-2-ylmethanone	0
albendazole +	48
astemizole	86
azilsartan medoxomil	0
bendamustine	0
bendazol	0
benomyl	56
benzimidazole +	372
benzimidazole fungicide +	424
benzimidazolecarbaldehyde +	0
benzimidazolecarboxylic acid +	78
benzimidazolequinone +	0
benzimidazolylcarbamate fungicide +	164
bibenzimidazole +	6
bilastine	0
binimetinib	1
carbendazim	86
chlormidazole	6
ciclobendazole	1
clemizole	15
crenolanib	0
dabigatran +	28
dabigatran etexilate	0
desmethylastemizole	2
dexlansoprazole	0
dexrabeprazole	0
dimethylbenzimidazole +	0
domperidone +	19
droperidol	2
emedastine +	1
ensulizole	0
fabomotizole	0
fenbendazole +	60
flibanserin	0
flubendazole	15
fuberidazole	0
glasdegib	0
hydroxyalbendazole	0
hydroxyfenbendazole	0
ilaprazole	0
lansoprazole	63
liarozole	1
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]benzimidazol-1-ide	0
mebendazole	51
methyl 4-oxo-4H-benzo[4,5]imidazo[2,1-b][1,3]thiazine-2-carboxylate	0
nocodazole	73
oxatomide	3
oxfendazole	18
pantoprazole	24
pantoprazole(1-) +	0
parbendazole	1
pimobendan	7
pimozide	6
procodazole	0
rabeprazole	17
selumetinib	26
tarocin B	0
tcmdc-123507	0
telmisartan	124
thiabendazole	310
veliparib	29

paths to the root